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Abstract 
Small vessel disease (SVD) is an important cause of stroke, cognitive decline, 
and age-related disability. The cause of SVD is unknown, increasing 
evidence from neuropathology and neuroimaging suggests that failure of the 
blood-brain barrier (BBB) precipitates or worsens cerebral SVD progression 
and its failure is associated with SVD features such as white matter 
hyperintensities (WMH), perivascular spaces (PVS) and lacunar infarcts. The 
BBB change mechanism may also contribute to other common disorders of 
ageing such as Alzheimer's disease (AD). 
Magnetic resonance imaging (MRI) has revolutionised our understanding of 
SVD features.  The MRI contributes to better understanding of the SVD 
pathophysiology and their clinical correlates. The purpose of this project was 
to better understand the pathogenesis of SVD, which involves improved 
understanding of BBB structures and pathophysiology and accurate 
measurement of cerebral SVD imaging characteristics on MRI scans. We 
aimed to assess (1) structures related to the BBB and factors that affect the 
BBB; (2) efficient and consistent WMH measurement method; (3) effect of 
stroke lesions on WMH and cerebral atrophy progression; (4) development 
and optimisation of computational PVS measurement method; (5) the 
relationships between PVS and SVD, blood markers, and BBB permeability. 
Section one describes structures and pathophysiology of the BBB.  I reviewed 
the BBB structural and functional components from the view of 
neurovascular unit, PVS, and junctional proteins. The PVS part was done in a 
systematic search. I also reviewed some common stimuli for BBB 
permeability including inflammation and ischemia. Ischemic triggers for the 
 
  vii 
BBB permeability were summarized systematically. Based on the literatures 
above, I summarized changes in junctional proteins in ischemia, 
inflammatory pain and AD models. 
Section two describes accurate measurement of WMH progression and 
atrophy. I used data from 100 patients who participated in a stroke study 
about BBB permeability changes in lacunar versus cortical stroke. To find a 
most efficient and consistent WMH measurement method, we tested several 
computational methods and effect of common processing steps including 
bias field correction and intensity adjustment. To avoid the effect of artefacts, 
I did a systematic search about artefacts and tested methods of image 
segmentation to avoid WMH artefacts as much as possible. To investigate the 
effect of stroke lesions on WMH and atrophy progression, I did the WMH, 
atrophy segmentation and stroke lesion measurements in a subgroup of 46 
patients with follow-up scans, and showed that stroke lesions distorted 
measurement of WMH and atrophy progression and should be excluded.  
Section three describes development and optimization of a computational 
PVS measurement method, which measures the count and volume for PVS 
based on a threshold method using AnalyzeTM software. We tested the 
observer variability and validated it by comparison with visual rating scores. 
We investigated the associations between PVS results with other SVD 
features (WMH, atrophy), risk factors (hypertension, smoking and diabetes), 
blood markers, and BBB permeability. 
In conclusion, MRI is a valuable tool for the investigation of cerebral SVD 
features and BBB permeability. Exclusions of artefacts and stroke lesions are 
important in accurate measurement of WMH. PVS are important features of 
 
  viii 
BBB abnormalities, and they correlate and share risk factors with other SVD 
features, and they should be considered as a marker of SVD and BBB 
permeability. Further systematic histological and ultrastructural studies of 
BBB are desirable in understanding the BBB regarding to the different parts 
of the cerebral vascular tree. 
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Chapter 1 Introduction 
1.1 The global burden of stroke 
Stroke is a most common life-threatening neurologic disease and is a leading 
cause of death and disability worldwide. Stroke is the second commonest 
cause of death after ischemic heart disease worldwide, and is the fifth cause 
of death in low-income countries, the first cause of death in middle-income 
countries and the second cause of death in high-income countries in 2004 
(Mathers et al., 2009).  In 2005, approximately 16 million first-ever strokes 
occurred and stroke caused 5.7 million deaths, 87% of which were in low and 
middle-income countries. Numbers of first-ever stroke are predicted to rise 
to 18 million in 2015 and 23 million in 2013. Numbers of deaths caused by 
stroke are expected to rise be 6.5 million in 2015 and to 7.8 million in 2030 
globally (Strong et al., 2007). Stroke is also a dominant cause of disability. 
The disability after stroke demands rehabilitation and long-term care. This 
huge economic burden is still increasing (Lopez et al., 2006; Strong et al., 
2007). 
The diagnosis of the pathological types and causes of stroke in clinical 
practice influences therapy efficiency and patient management. Population-
based stroke incidence studies showed ischemic stroke is the most prevalent 
stroke type, approximately four fifths of all strokes are due to cerebral 
ischemia (ranged from 67% to 81%), followed by parenchymal hemorrhage 
(7% to 20%) and subarachnoid hemorrhage (1% to 7%), and there is still 2% 
to 15% for undetermined type. Ischemic stroke was categorised into four 
groups: large vessel disease, small vessel disease (SVD), cardioembolic 





1.2 SVD imaging features  
Cerebral SVD account for approximately a quarter of ischemic stroke and a 
fifth of all stroke worldwide, and it is also the most common vascular 
contributor to dementia (Wardlaw et al., 2013c; Warlow et al., 2003).  The 
development of imaging techniques facilitates studies of the stroke and SVD 
mechanisms in humans and animals and helps the clinical diagnosis. X-ray 
computed tomography (CT) was first used as a pioneering imaging tool for 
clinical diagnosis and research in the early 1970s. Later in the 1980s, magnetic 
resonance imaging (MRI) was developed and used in clinics. CT remains 
widely used in stroke as it is quick and easy for routine imaging in patients 
presenting with possible stroke. It is very accurate in acute hemorrhagic 
stroke.  Though the scanning time of MRI is longer than CT, it generates 
superior image quality for the display of detailed brain anatomical structures 
and detection of tiny lesions such as ischemic stroke and SVD.  
The principle of MRI is based on the spin of atomic nuclei, which absorb and 
emit electromagnetic waves, and magnetic resonance (MR) scanners can 
therefore detect radio frequency signals emitted by excited atoms.  Hydrogen 
(1H) nuclei are commonly used in clinical MR imaging, due to their 
abundance that the human body is largely composed of water and each 
water molecule contain two hydrogen nuclei (Storey, 2006).  
A routine structural MR brain examination for stroke and SVD commonly 
consists of multiple sequences, including: a) T1- and T2-weighted imaging 
(T1W and T2W); b) T2*-weighted gradient-recalled echo imaging (GRE); c) 
fluid attenuated inversion recovery (FLAIR) imaging; d) diffusion-weighted 
imaging (DWI). T1W imaging is normally used to depict the anatomical 




detection such as fluid, gliosis and demyelination because higher water 
content in pathological tissues appears more hyperintensive than normal 
tissues on T2W imaging, and T2W imaging is used for PVS detection 
(Mantyla et al., 1999a). The GRE sequence can help hemorrhage detection, 
while FLAIR is used to null the cerebrospinal fluid (CSF) signal (which made 
the lesions near the fluid-containing spaces such as sulci or ventricles more 
distinguishable). DWI sequences aid the diagnosis of recent strokes (Bitar et 
al., 2006).   
Major SVD features on MRI (Wardlaw et al., 2013b; Wardlaw et al., 2013c) 
include (Figure 1.1) 
 White matter hyperintensities (WMH) 
 Perivascular spaces (PVS) 
 Lacunes 
 Recent small subcortical infarcts 







Figure 1.1 Inter-related SVD features.  
Abbreviations: 
SVD: small vessel diseases; WMH: white matter hyperintensities; PVS: perivascular spaces; 
FLAIR: fluid attenuated inversion recovery imaging; T2W: T2-weighted imaging; DWI: 
diffusion-weighted imaging; GRE: T2*-weighted gradient-recalled echo imaging. Because 
WMH are diffuse lesions, so an arrow points to a region with WMH intensity characteristics. 
Though PVS are focal lesions, there are too many of them, an arrow points to one PVS dot, 
all other dots having the same intensity, size and shape are also PVS. Other focal lesions 
such as infarct, lacune and microbleed features are highlighted within the circles. An arrow 




1.2.1 WMH  
WMH are signal abnormalities of variable size in the white matter that are of 
presumed vascular origin. They also occur in deep grey matter. WMH show 
low attenuated areas on CT (Mantyla et al., 1999b), appear as hyperintense 
on T2W, FLAIR (Gouw et al., 2008b; Haller et al., 2013; Jokinen et al., 2009; 
Wardlaw et al., 2004), and occasionally appear as hypointense on T1W MRI 




(Mantyla et al., 1999a). This radiological description helps to distinguish the 
white matter lesions of presumed vascular origin from other causes such as 
multiple sclerosis or leukodystrophies. WMH are generally distributed 
symmetrically in the white matter of cerebral hemispheres, and they coalesce 
together to become diffuse lesions when the number of lesions is large. 
Lesions in the deep grey matter and brainstem can be included in WMH 
category, but this should be explicitly stated and it may be better to use the 
term ‘subcortical hyperintensities’ (Wardlaw et al., 2013b; Wardlaw et al., 
2013c). Having more WMH at first presentation is also a predictor of worse 
WMH progression (Gouw et al., 2008a; Wardlaw et al., 2013a).  
WMH presence or progression are related to other SVD features such as PVS 
(Doubal et al., 2010b; Potter et al., 2013), lacunes (Gouw et al., 2008a), 
microleeds (Cordonnier et al., 2007) and atrophy (Aribisala et al., 2012; de 
Leeuw et al., 2006), and the WMH burden is more severe in patients with 
lacunar stroke (Rost et al., 2010).   
Presence and progression of WMH are also related to age-related vascular 
pathology, BBB permeability and ischemia (Brown et al., 2002; Pantoni and 
Garcia, 1997; Uh et al., 2010; Wardlaw et al., 2013a; Young et al., 2008). WMH 
on both T2W and FLAIR images correlate with myelin loss pathologically, 
though imaging overestimated periventricular and perivascular lesions but 
underestimated lesion in deep white matter (Haller et al., 2013). Increasing 
age is associated with WMH progression and is a risk factor for WMH 
(Longstreth et al., 2005; Wardlaw et al., 2013a). Hypertension is another risk 
factor for WMH, hypertension at baseline is significantly associated with 




Increased WMH are associated with structural and functional brain changes 
and cognitive and motor deficits, increased risk of stroke and death (Debette 
and Markus, 2010; Garde et al., 2005; Liou et al., 2010; Longstreth et al., 2005; 
Marquine et al., 2010; Silbert et al., 2008; van den Heuvel et al., 2006a).  
Currently, various visual rating scores and automatic or semi-automatic 
quantitative methods are available to measure presence and progression of 
WMH (Gouw et al., 2008b; Hernandez et al., 2010; Kapeller et al., 2003; Prins 
et al., 2004; van den Heuvel et al., 2006b). When using the automatic or semi-
automatic methods to measure WMH volume, observers should be aware of 
artefacts, focal infarcts and strokes which mimic the appearance of WMH, 
and the outputs need to be visually checked by an experienced rater. 
In order to investigate the mechanisms and clinical relevance of WMH in 
large population based studies, it is crucial to measure WMH accurately 
without including artefact and WMH mimics like stroke lesions. We will 
discuss about our work in achieving these aims in later chapters: the 
quantitative method we selected for WMH (Chapter 3), a summary of 
common WMH artefact on MR images (Chapter 4) and the influence of 
stroke lesions on WMH progression measurement (Chapter 5). 
1.2.2 PVS  
PVS are fluid filled spaces around the vessels (arteries, arterioles, veins, and 
venules) in both the deep and superficial areas of the brain (Pollock et al., 
1997; Zhang et al., 1990). PVS separate blood vessels from their surrounding 
brain parenchyma. Previously the presence of PVS was often dismissed as 




PVS are commonly microscopic. They are not visible on neuroimaging unless 
enlarged. The definition of PVS on MR images are structures with similar 
intensity as CSF on all MRI sequences. They appear as linear shape when 
imaged parallel to the course of the vessel they followed and they appear 
round (Di Costanzo et al., 2001; Rouhl et al., 2008), with a diameter less than 
3 mm when imaged perpendicular to the course of the vessel (Descombes et 
al., 2004; Hernandez et al., 2013; Wuerfel et al., 2008). PVS had been 
considered as a benign sign in the brain because PVS also appear on MRI in 
young and healthy people. However, increasing evidence showed that 
enlarged PVS might reflect the immune cells accumulation in the PVS and 
fluid drainage dysfunction (Polledo et al., 2012; Roher et al., 2003; Sagar et al., 
2012; Schley et al., 2006; Thal, 2009; Wuerfel et al., 2008). Increasing age and 
hypertension are two risk factors for PVS, and PVS are associated with SVD 
features WMH, lacunar infarct (Rouhl et al., 2008), lacune (Zhu et al., 2010), 
microbleeds (Martinez-Ramirez et al., 2013) and atrophy (Potter et al., 2013), 
inflammatory blood markers (Aribisala et al., 2014; Rouhl et al., 2011; Rouhl 
et al., 2010; Satizabal et al., 2013), increased BBB permeability (Wardlaw et 
al., 2009) and declining cognition (Maclullich et al., 2004; Roher et al., 2003). 
Increased PVS loads are considered as an important sign for active 
inflammatory disease such as MS (Wuerfel et al., 2008) and cognitive 
impairment such as AD (Thal, 2009).  
Currently most studies assess the PVS by visual rating scales, the lack of 
quantitative PVS measurement restrain the comparisons in the studies of 
evaluating the pathophysiological importance of PVS. We will describe more 
about PVS in later chapters. We will describe the PVS structure and function 




development and optimization process of a semi-automatic method we 
developed for PVS measurement (Chapter 6 and 7), and we also investigated 
the associations between PVS and SVD features (WMH and atrophy), blood 
markers, and blood-brain barrier permeability (Chapter 8). 
1.2.3 Lacunes  
Lacunes (derived from the French for ‘holes’) are subcortical CSF-filled 
cavities of presumed vascular origin with signal intensities the same as CSF 
on all MRI sequences, usually with a hyperintense rim when they appear 
hypointense on FLAIR (Potter et al., 2010b; Potter et al., 2011). They are 
larger than PVS, between 3 mm and about 15 mm in diameter in round or 
ovoid shape (Hernandez et al., 2013; Wardlaw, 2008). 
Asymptomatic lacunes are seen on imaging in middle aged and elderly 
patients frequently with no history of stroke-like symptoms. The prevalence 
of lacunes increases with aging in population-based studies (Vermeer et al., 
2007). Lacunes are associated with WMH and PVS (Choi et al., 2012; Zhu et 
al., 2010). Higher lacune scores are associated with an increased risk of post 
stroke depression (Santos et al., 2009), gait disorder, subsequent stroke and 
dementia (Snowdon et al., 1997; Vermeer et al., 2007) . 
Most lacunes are presumed to result from small subcortical infarcts although 
some might be the end result of small deep hemorrhages (Franke et al., 1991) 
and sometimes striatocapsular infarcts (which are atherothromboembolic or 
cardioembolic in origin) can resolve to leave a lacune (Wardlaw et al., 2013b).  
1.2.4 Recent small subcortical infarcts 
Recent small subcortical infarcts, commonly previously called lacunar 




territories of perforating small arteries or arterioles in the internal parts of the 
brain, ‘recent’ indicating that they have occurred in the previous few weeks 
(Wardlaw et al., 2013c).  On neuroimaging, recent small subcortical 
infarctions appear as low attenuation on CT scans, or increased signal on 
DWI, FLAIR and T2W images, and hypointense on T1W MRI compared with 
normal grey or white matter (Wardlaw et al., 2013b; Wardlaw et al., 2013c). 
However, for unknown reasons, a third of the patients with symptomatic 
lacunar stroke syndromes have negative DWI, which is an important alert for 
clinicians not to exclude the diagnosis of stroke even if DWI is negative 
(Doubal et al., 2010a).  
Subcortical infarcts were once considered as a benign ischemic stroke 
subtype because they rarely lead to death in the acute phase, were generally 
mild and not physically disabling and had a low recurrent stroke rate. 
However longer term studies have shown that long term there is an 
increased risk of death, disability, cognitive dysfunction, dementia and 
stroke recurrence (Norrving, 2008). Acute subcortical infarcts commonly 
shrink to lacunes, presence of cavitation range from 28% to 94% (Loos et al., 
2012; Moreau et al., 2012; Potter et al., 2010b) or smaller lesions of similar 
appearance of WMH or occasionally change to normal appearing tissues. 
Like other SVD features, the exact mechanisms underlying recent small 
subcortical infarcts are still debated (see later part 1.3 SVD pathological 
mechanisms). 
1.2.5 Cerebral microbleeds  
In the histopathology analysis, most cerebral microbleeds are believed to 
represent hemosiderin deposits in the perivascular tissues including in the 




hemosiderin (Shoamanesh et al., 2011). Microbleeds are generally not visible 
on CT, FLAIR, T1W and T2W MRI images, but are seen as small hypointense 
lesions on GRE images, are generally 2–5 mm in diameter and are up to 10 
mm (Cordonnier et al., 2007; Greenberg et al., 2009). 
Cerebral microbleeds are most commonly located in the deep grey or white 
matter in the cerebral hemispheres, brainstem, and cerebellum (Shoamanesh 
et al., 2011; Wardlaw et al., 2013c).  Microbleeds are associated with lacunar 
stroke and WMH (Wardlaw et al., 2006) and PVS (Martinez-Ramirez et al., 
2013). They were considered to be asymptomatic SVD markers, however, 
increasing evidence showed the microbleeds correlated with cerebral 
amyloid angiopathy and cognitive impairment in patients with dementia 
(Shoamanesh et al., 2011). 
1.2.6 Atrophy  
Brain atrophy is a reduction in brain volume and occurs in many disorders.  
As a feature of SVD, atrophy is defined as decreased total brain volume not 
caused by various macroscopic focal injuries such as trauma, inflammation 
or infarction (Wardlaw et al., 2013c). Generally, cerebral atrophy is 
manifested by decreased grey or white matter volume, increased ventricular 
volumes and enlarged superficial sulci or affecting only particular lobes or 
specific brain regions.  
On MRI of longitudinal studies, cerebral atrophy could be measured as 
decreased brain volume or increased CSF volume using serial registered MR 
imaging. It is a common accompaniment of ageing and is associated with 
SVD features such as WMH (Aribisala et al., 2012) and PVS (Chen et al., 2011; 




studies assessing the burden of vascular damage in the brain. Brain atrophy 
is also associated with cognitive decline and dementia. The global cerebral 
atrophy rate in Alzheimer's disease is higher than in healthy controls (Fox 
and Schott, 2004).  Focal tissue loss caused by stroke lesions and lacunes 
should not be considered as part of brain atrophy, and the influence of stroke 
lesions on atrophy measurement will be described in later chapter (Chapter 
5). 
1.2.7 Inter-related SVD features 
These main features of SVD visible on conventional MRI are now considered 
to be inter-related.  Acute lesions with different causes may have similar late 
appearance in their chronic stages (Wardlaw et al., 2013b; Wardlaw et al., 
2013c).  
Stroke symptoms with no visible lesions might change to normal appearing 
tissues or WMH in their chronic stage. Small subcortical infarcts change to 
normal appearing tissues, WMH, cavitate or disappear sometimes. Most 
lacunes are thought to arise from small subcortical infarcts, although some 
might be from hemorrhages or striatocapsular infarcts (Wardlaw et al., 
2013c). 
1.3 SVD pathological mechanisms 
There are few human SVD pathology studies because they rarely caused 
death in the acute phase. Increasing imaging evidence showed that all these 
SVD features are inter-linked, however, a common underlying mechanism 
explaining all these small vessel pathologies is not completely known.  
Occlusion of small vessels is one widely acknowledged mechanism of SVD 




perforating vessels from Fisher’s work (Fisher, 1968, 1979, 1982, 1998). The 
occlusion mechanism suggested that when a small arteriole occluded by 
fibrinoid necrosis which thicken the arteriolar wall and narrow the vascular 
lumen eventually lead to ischemia and tissue necrosis, which is called the 
lacunar hypothesis (Pantoni, 2010). Hypoperfusion was thought to be caused 
by vessel lumen restriction resulted in oligodendrocyte death and finally 
demyelination in the white matter (Pantoni, 2010; Pantoni et al., 1996; Petito 
et al., 1998). Vessel wall atheroma and vasospasm were two mechanisms 
thought to lead to narrowing of the arteriolar lumen and occlusion leading to 
reduced blood flow contributing to chronic and diffuse ischemia (Pantoni, 
2010). These three possible mechanisms of vascular ischemia in the brain 
were useful in explaining some of the pathological and imaging features of 
infarcts and WMH in the past.  However, they were poor for explaining the 
arteriolar wall changes and could not explain the PVS and microbleed 
features (Wardlaw et al., 2013b). 
Stimuli in the brain such as ischemia, inflammatory cytokines, seizures and 
oxidative stress may induce vascular endothelium wall property changes. 
The blood brain barrier (BBB) which is a single layer of endothelial cells 
joined by junction proteins limits substance transport into and out of the 
brain and may become permeable to some molecules or cells in response to 
stimuli (details in Chapter 2). The failure of BBB leads to leakage of 
components into and through the cerebral small vessels walls, fluid 
accumulation in the PVS, and edema in the perivascular tissues that affects 
the neuronal and glial cells and damages the brain parenchyma (Figure 1.2). 
This BBB permeability mechanism could explain SVD features such as small 




Many studies have found an association between failing BBB with normal 
ageing (Farrall and Wardlaw, 2007; Wardlaw et al., 2009) and worsening of 
BBB permeability in patients with lacunar stroke (Wardlaw et al., 2009; 
Wardlaw et al., 2008), increasing WMH (Rosenberg, 2009; Starr et al., 2003; 
Wardlaw et al., 2009), PVS (Wardlaw et al., 2009), cognitive impairment such 
as vascular cognitive impairment, dementia and Alzheimer’s disease (AD) 
(Farrall and Wardlaw, 2007; Starr et al., 2009; Taheri et al., 2011; Zipser et al., 
2007). Increased BBB permeability in normal appearing tissues at initial 
presentation with stroke also increased the risk of poor outcome and 
disability at long term follow-up after stroke (Wardlaw et al., 2009; Wardlaw 
et al., 2013a). 
1.4 Techniques for assessing BBB permeability  
Most of the studies previously used CSF:plasma albumin ratio to assess BBB 
permeability. Increase in CSF:plasma albumin ratio was used to assess 
increased BBB permeability which is based on the knowledge that albumin is 
a medium-sized protein of a molecular size of 67 kDa, with no specific active 
transport process related to its transport across the BBB. Although the brain 
could synthesis albumin, the majority of albumin is synthesised outside the 
brain, on the luminal side of the BBB (Farrall and Wardlaw, 2007; Wardlaw, 
2010). 
Increasing studies used MRI with intravenous contrast agent injection such 
as gadolinium contrast agents to examine BBB permeability. Signal 
enhancement data in different tissue types following contrast agent injection 
were used to estimate BBB failure (Armitage et al., 2011; Farrall and 





Figure 1.2 The SVD mechanism from the endothelium and BBB dysfunction hypothesis. 
*Based on the hypotheses by Wardlaw and Zlokovic (Wardlaw et al., 2003; Zlokovic, 2008). 
SVD: small vessel diseases; BBB: blood brain barrier; TJ: tight junctions; AJ: adhesion 
junctions; GJ: gap junctions; NVU: neurovascular unit; PVS: perivascular spaces; WMH: 





1.5 Unanswered questions  
A number of questions remain about the mechanism of SVD and how 
individual SVD features progress and are related to each other. In this thesis, 
I will address the following topics:  
(1) How does the BBB permeability influence SVD, is it the initiating 
mechanism of SVD? 
(2) What stimuli influence the endothelium and BBB changes in the early 
stages?  
(3) How should WMH volume, an SVD feature, be measured most accurately 
and efficiently on MRI using computational measures? 
(4) Can and how should PVS, another SVD feature, be measured 
computationally on MRI accurately and efficiently? 
(5) What are the associations between SVD features, blood markers of 
thrombosis, endothelial function and inflammation and BBB permeability? 
1.6 Outline and Aims of the thesis  
1.6.1 Section one: structure and pathophysiology of the BBB 
(1) What are the BBB structural and functional components, from the 
perspective of the neurovascular unit (NVU), PVS, and junctional proteins?  
(2) What are the stimuli for BBB permeability: where do ischemia and 
inflammation fit in?   





1.6.2 Section two: accurate measurement of WMH progression 
and atrophy 
(4) Testing of computational methods and effect of common processing steps. 
(5) Identification of common WMH artefacts. 
(6) Testing the effect of stroke lesions on measurement of WMH and atrophy.  
1.6.3 Section three: computational PVS measurement method 
and associations 
(7) Development and optimization of a computational PVS measurement. 
(8) Associations between PVS measures and other SVD features (WMH, 
atrophy), risk factors (hypertension, smoking and diabetes), blood markers, 





Chapter 2 Blood brain barrier structures and 
changes under pathological conditions 
2.1 Structures related to the blood brain barrier: from 
endothelium to neurons 
This chapter will describe major structural components of the blood brain 
barrier (BBB) and their functions from the view of neurovascular unit (NVU), 
perivascular spaces (PVS), and junctional proteins. This chapter also includes 
information on two important stimuli for BBB malfunction which are 
ischemia and inflammation. The structure and function of PVS and ischemia 
stimulus were reviewed in systematic searches. 
2.2 Neurovascular unit (NVU) 
Cerebral vessel endothelial cells, pericytes, smooth muscle cells (diminished 
in the capillary level (Zhang et al., 1990)), glial cells (astrocytes, microglia and 
oligodendrocytes), perivascular spaces between endothelial cells and endfeet 
of glia limitans, and neurons together form a functional unit, which are 
involved in regulating the cerebral blood flow, often referred as the NVU 
(Abbott et al., 2006) (see Figure 2.1). The cross-talk among neighbouring cells 
is important in maintaining the endothelium and the BBB integrity and 










2.2.1 Endothelium  
(1) Structures 
The BBB is formed by a single layer of brain capillary endothelial cells, 
inducing high electrical resistance (Rubin and Staddon, 1999). These 
endothelial cells adhere tightly to each other through different types of 
transmembrane junctional proteins. 
Two major categories of junctional proteins are called tight junctions (TJ) and 
adherens junctions (AJ) (Bazzoni and Dejana, 2004). They both function as a 
barrier which limits the paracellular permeability. TJ maintain cellular 
polarity and are formed by different types of TJ proteins, such as occludin, 
zonula occludens (ZO), claudins, and junctional adhesion molecules (JAM). 
AJ is involved in assisting leukocyte migration and intercellular signalling, 
and includes platelet endothelial cell adhesion molecule (PECAM), 
cadherins, catenins and actins. Detailed information about the structure and 
function for each TJ and AJ proteins, and their changes during pathological 
conditions, will be discussed in section ‘2.3 BBB junction proteins’. 
The third major type of cellular junction is called gap junctions (GJ). Gap 
junctional complexes are channels built by connexins, which allow 
intercellular communication such as exchanges of ions and small molecules 
(Bazzoni and Dejana, 2004; Cuevas et al., 1984; Dbouk et al., 2009). 
(2) Transport barrier 
O2 and CO2 diffuse freely through the BBB along concentration gradients, 
and molecules with a molecular weight of less than 400 Daltons (Da) and 
with less than 8 hydrogen bonds can also cross the BBB via lipid-mediated 
diffusion (Pardridge, 2007). Transport of most nutrients or metabolic wastes 




specialised transporters to facilitate the bidirectional transport through the 
barrier (Sa-Pereira et al., 2012; Zlokovic, 2011). 
(2-1) Transporters for nutrients  
Glucose is the main energy resource of the brain, and its transporter Glucose 
transporter-1 (GLUT-1, 55 kDa, kiloDaltons) mediates the glucose transport 
across the BBB (Cardoso et al., 2010). GLUT-1 is present on both the luminal 
and abluminal sides of the endothelium. The appearance of GLUT-1 is three 
times more on the abluminal side than on the luminal side (Simpson et al., 
2007a). This asymmetrical distribution might prevent excess glucose 
accumulation in the brain (Zlokovic, 2008). 
Monocarboxylate transporter-1 (MCT-1) is the transporter for lactate which is 
another important energy resource (Dienel, 2012; Wyss et al., 2011). MCT-1 is 
also present on both sides of the endothelium (Neuwelt et al., 2011; Zlokovic, 
2011). 
The amino acid (AA) transport systems L and y+ facilitate the bidirectional 
transport of essential amino acids, which are present on both the luminal and 
the abluminal sides of the endothelium (Hawkins et al., 2006; Omidi et al., 
2008). System L is a sodium-independent transporter, and mediates the 
transport of large essential neutral AA (i.e. histidine, threonine, methionine, 
valine, leucine, isoleucine, phenylalanine, and tyrosine). System y+ facilitates 
the transport of essential cationic AA in the brain which is sodium-
independent (i.e. lysine). With the presence of sodium, there is a weak 
interaction between system y+ and large essential neutral AA (i.e. histidine, 
threonine, cysteine, methionine, and valine). Both systems also mediate the 




There are five sodium-dependent transporters which exist only on the 
abluminal side of the endothelium and help to remove larger or small neutral 
AA, nitrogen rich AA, and acidic AA from the brain. They are system A, 
system ASC, system N, transporter for large neutral amino acids (LNAA), 
and transporter for excitatory amino-acid (EAAT) (Hawkins et al., 2006). 
There are two sodium-independent transporters present exclusively on the 
luminal side. They are system n and system xG- which mediate the transport 
of glutamine and acidic AA (Hawkins et al., 2006). 
(2-2) Transporters for metabolic waste 
Metabolic wastes are continuously generated in the brain and need to be 
eliminated otherwise they are neuron toxic. The rapid removal of toxic 
products is through high energy demanding active efflux though the 
transporters on the luminal side of the membrane, which facilitates the 
transport towards vessels.  Transporters assist this active efflux including:  
ATP-binding cassette (ABC); low-density lipoprotein receptor-related protein 
1 (LRP-1), and EAAT (ElAli and Hermann, 2011; Zlokovic, 2008). 
ABC subfamily B member 1 (ABCB1) is one of the ABC transporters, which is 
also known as P-glycoprotein (P-gp) and was previously called multidrug 
resistance-associated proteins (MRP). ABCB1 preferably locates on the 
luminal side of the endothelium and controls the removal of toxic lipophilic 
and amphipathic metabolites, prevents drug accumulation, and is involved 
in the amyloid-beta (Aβ)  efflux (ElAli and Hermann, 2011; Hermann and 
Bassetti, 2007; Zlokovic, 2011). 
The LRP-1 is a multiligand lipoprotein receptor. It is involved in the 
signalling pathways related to Aβ, apolipoprotein E (ApoE) and tissue 




clearing across the BBB. The receptor for advanced glycation end-products 
(RAGE) mediates the influx of Aβ (Deane et al., 2004). 
EAAT is one of the sodium-dependent transporters located on the abluminal 
side of the endothelium. It is responsible for clearing potentially neurotoxic 
amino acid glutamate (or glutamine) and keeping glutamate at low levels in 
the brain (Hawkins et al., 2006; Zlokovic, 2008). 
(2-3) Transporters for ions 
Levels of sodium and potassium could influence the neuronal and synaptic 
functions. They are mediated by the sodium pump also known as Na+-K+-
ATPase located in the plasma membrane of all animal cells. At the level of 
BBB, the sodium pump on the abluminal side of the endothelium facilitates 
the sodium influx and potassium efflux across the BBB (Zlokovic, 2008, 2011). 
(2-4) Transporters for large peptides and proteins 
Larger peptides and proteins have their own specific transporters, such as 
transferrin receptor and insulin receptor. They cross the BBB through 
receptor-mediated transport system (Zlokovic, 2008, 2011). Albumin is 
eliminated by receptors on the membranes of caveolae which controls 
transcellular permeability by regulating signaling, endocytosis, and 
transcytosis of the BBB (Zlokovic, 2008). 
(3) Transporter changes under pathological states 
Pathological factors trigger the expression or structural changes of the 
transporters, which can result in secondary neurodegenerative changes.  
(3-1) Ischemia 
Under ischemia-hypoxia conditions, the sodium pump stops working 




glucose also augments the GLUT-1 expression (Boado and Pardridge, 2002). 
In ischemic stroke, the P-gp transporter expression is upregulated (ElAli and 
Hermann, 2011). The effect of ischemia stimulus on BBB junctional proteins 
and its association with BBB will be described in detail in later section. 
(3-2) Neurodegeneration 
Both ABCB1 and LRP-1 are related to active efflux in the BBB, and their 
downregulation may play a role in neurodegeneration. Decreased P-gp 
function or deficiency was found in the progression of Parkinson’s disease, 
Alzheimer’s disease, and white matter degeneration of ageing subjects 
(Bartels et al., 2009; Bartels et al., 2008; Cirrito et al., 2005). Both decreased 
expression of LRP1 and oxidized LRP1 were found in the Alzheimer’s 
disease brains (Owen et al., 2010; Shibata et al., 2000).  Suppression of P-gp 
and LRP1 could aggravate the Alzheimer disease progression though the 
mechanism of excess Aβ deposition. 
2.2.2 Basement membrane  
Cells and their extracellular matrix support one another to maintain the 
structural integrity and function. The basement membranes are thin sheets of 
extracellular matrix and are comprised of two layers (lamina): basal lamina 
and reticular lamina.  
The basal lamina is derived from extracellular matrix and is a crucial 
component in the NVU. It supports the NVU structure and integrity by 
encircling the endothelium and pericyte. The adhesion receptors existing in 
the basal lamina establish the connections between endothelium and 




barrier function, which is partially explained by the existence of TJ and AJ in 
the endothelium (del Zoppo and Milner, 2006; Garden and Moller, 2006). 
(1) Structure and characters 
The endothelium and astrocyte cooperate together to generate the basal 
lamina. The basal lamina consists of collagen type IV, heparan sulfate 
proteoglycans (HSPG), laminins, other types of extracellular matrix and 
matrix adhesion receptors (i.e. integrin and dystroglycan) (del Zoppo and 
Milner, 2006; Farkas and Luiten, 2001). Mixed combinations of these basal 
lamina make up a three layered structure: an endothelial layer, an astrocytic 
layer and a fused layer between these two layers. Both endothelial and 
astrocytic layers are composed of collagen type IV, HSPG and laminins, with 
the middle layer mainly consisting of collagen type IV (Farkas and Luiten, 
2001). 
(2) Functions 
Besides potentiating the BBB barrier function, establishing the connections 
and providing the structural support for the NVU (del Zoppo and Milner, 
2006; Sa-Pereira et al., 2012), the basal lamina is involved in matrix-
endothelium signalling (Carvey et al., 2009) and a two steps leukocyte 
transport action through the BBB: (1) leukocytes migrate across endothelium 
and endothelial basal lamina into the perivascular spaces; (2) then pass 
across the astrocytic basal lamina into the brain (Bechmann et al., 2007). A 
detailed description of the leukocyte transmigration process and junction 





(3) Changes in ischemic stroke 
In ischemic stroke, the basal lamina rapidly loses integrin and dystroglycan 
matrix receptors. Matrix metalloproteinases (MMP) induces collagen IV 
degradation in the basal lamina and it is also associated with hemorrhagic 
transformation after stroke (del Zoppo, 2010a, b; Rosell et al., 2008). Tissue 
plasminogen activator (tPA) could exacerbate the outcome by activating 
MMPs (Adibhatla and Hatcher, 2008). Hyperbaric oxygen treatment reduces 
post ischemic damage by attenuating basal lamina degradation and 
decreasing MMP levels in a rat model (Veltkamp et al., 2006).  
2.2.3 Pericyte  
Pericytes are contractile cells encompassing the endothelial cells throughout 
the body and they have bidirectional contractile function in controlling 
capillary size and playing a major role in controlling cerebral blood flow 
(Peppiatt et al., 2006). They were first described as “contractile elements” by 
French scientist Rouget in 1874, and since then have been referred to as 
Rouget cells (Rouget, 1874). They were named as “pericyte” later to reflect 
their location: they are vascular mural cells embedded within the basal 
lamina layers on the abluminal side of capillaries.  They have close 
associations with the endothelium through intercellular signalling (Armulik 
et al., 2005; Dore-Duffy, 2008).  
(1) Structure and character 
Pericytes are normally star-shaped cells with an oval cell body surrounding 
the abluminal side of the microvascular endothelium, with elongated and a 
cigar shaped nucleus. They are embedded between the endothelial and 
astrocytic basal lamina extracellular matrix (Dore-Duffy and Cleary, 2010; 




Pericytes can synthesize and release a variety of factors which contribute to 
the BBB integrity, vessel stability and new vessel formation, hemostasis, 
contractile function and immune response (Dore-Duffy, 2008; Sa-Pereira et 
al., 2012). 
(2) Functions  
(2-1) Maintaining BBB integrity 
Pericytes may play an important role in maintaining BBB integrity, the 
influence of the pericyte on the BBB integrity being as important as that of 
the astrocyte, which will be discussed in later section ‘2.2.4 (1) Astrocyte (A)’. 
In cell co-culture conditions, pericytes increased higher transendothelial 
electrical resistance (TEER) and there was lower permeability for small 
molecular weight markers than with astrocytes in separate co-culture 
conditions. In the triple co-culture conditions, when a pericyte was 
positioned in the middle of endothelial cells and astrocytes, they induced the 
tightest barrier (Nakagawa et al., 2007). The pericyte densities may also 
contribute to the BBB integrity: they are positively related to vessel density 
and negatively related to vessel diameter (Armulik et al., 2010). Interactions 
between pericyte and endothelial cells are central processes in the regulation 
of vascular formation, stabilization, and remodelling.   
(2-2) Angiogenesis 
New vessel formation can be initiated after strong stimuli such as brain 
injury and hypoxia (Sa-Pereira et al., 2012). Vascular endothelial growth 
factor (VEGF), transforming growth factor β (TGF-β), angiopoietins (Ang-1, 
Ang-2), platelet-derived growth factor and its receptors (PDGF-B, PDGFR-β), 




are involved in regulating endothelial and pericyte cell function and vascular 
stability (Dore-Duffy, 2008; von Tell et al., 2006; Wolfle et al., 2005).  
VEGF is very important for initiating vessel formation and new vessel 
maturation (Jain, 2003). The expression of VEGF could increase production of 
PDGF-B which directs pericyte recruitment in the new vessels (Dore-Duffy, 
2008; Jain, 2003). In endothelium-restricted Pdgfb knockout-mutants, the loss 
of PDGF-B signalling leads to impaired pericyte recruitment to blood vessels 
(Bjarnegard et al., 2004). Another example is in the pericyte-specific PDGFRb 
deficient signalling mouse model: the pericyte loss in this model lead to 
vessel leakage in the brain and also leads to increased BBB permeability and 
hypoperfusion caused by reduced blood flow and reduced vessel reactivity 
(von Tell et al., 2006). In ageing mice, progressive pericyte loss preceded 
neurodegenerative changes with neuronal loss, reduced vessel reactivity and 
density, and impaired learning and memory function (Bell et al., 2010; 
Quaegebeur et al., 2010). 
(3) Immune potentials 
Pericytes have immune potential in modulating inflammatory events. They 
respond to inflammatory cytokines and express cell surface molecules which 
might facilitate T-cell recruitment (Balabanov et al., 1999). They also express 
macrophage surface markers and are involved in leakage of plasma proteins 
(Balabanov et al., 1996; Sims, 2000). 
(3) Changes in pathological states 
(3-1) Changes in ischemic stroke  
Under ischemic stimulus, pericytes become activated and degrade basal 
lamina to facilitate their migration into the central nervous system (CNS) 




(3-2) Changes during neurodegeneration 
Deficiency and dysfunction of pericytes influence neurodegeneration by two 
possible pathways: (1) pericyte loss reduces efficient microcirculation, and it 
induces perfusion stress to neurons and neuronal injury. (2) BBB breakdown 
induces serum protein transmigration and accumulation in the CNS, which 
also triggers neuronal injury.  Platelet-derived growth factor receptor beta 
(PDGFRβ) deficiency contributes to the pericyte loss (Bell et al., 2010).  In 
Alzheimer's disease (AD), pericyte loss leads to reduced vessel density and 
reactivity, reduced blood flow and increased BBB permeability (Quaegebeur 
et al., 2010).  
2.2.4 Glial Cells  
Besides neurons, and vascular cells such as endothelium and pericytes, there 
is another important type of cell in the CNS: glial cells, which include 
astrocytes, microglia and oligodendrocytes. ‘Glia’ is a Greek word meaning 
‘glue’ for its supporting function of surrounding neurons (Franklin and 
Bussey, 2013). The overall cerebral glia/neuron ratio is approximately 1.31 for 
female, 1.49 for male, and it varies across different brain structures (Azevedo 
et al., 2009; Pelvig et al., 2008). The cortical glial cells are comprised of 
approximately 75% oligodendrocytes, 20% astrocytes and 5% microglia. The 
number of oligodendrocytes decreases with age, and microglia increase with 
age in females, whereas the number of astrocytes is consistent through life 
(Pelvig et al., 2008).  
Glial cells provide direct effect or signalling in a variety of neuronal 
functions: forming myelin sheaths around axons (Mathis et al., 2003); 
controlling neuron maturation (Purkinje cell (Mathis et al., 2003)); mediating 




and function; associated with metabolic and lipid synthetic pathways (Chang 
et al., 2008) and mediating inflammatory response (Mrak and Griffin, 2005). 
These functions of glial cells contribute to neuron maturation and maintain 
CNS homeostasis (Hansson and Ronnback, 2003).  
Dysregulation of glial functions is involved in various injuries and diseases: 
ischemic stroke induces glial cell activation and inflammatory responses, 
which may contribute to neuron apoptosis (Stoll et al., 1998).  Increased 
microglia activation, astrocyte and oligodendrocyte apoptosis are found in 
cerebral white matter lesions (Simpson et al., 2007a; Simpson et al., 2007b).  
Glial activation and cytokine expression-mediated inflammation contributes 
to neurodegenerative diseases such as AD, and BBB permeability (Mrak and 
Griffin, 2005; Salmina, 2009; Tomimoto et al., 1996). 
(1) Astrocyte  
Astrocytes contribute to the BBB integrity, water transport and dynamic 
signalling involved in the microcirculation control, metabolic and 
inflammation pathways (Cahoy et al., 2008; Zonta et al., 2003). The astrocyte 
endfeet generate the astrocytic basal lamina which surrounds the outer 
surface of the endothelium. The dysfunction of astrocytes leads to BBB 
permeability and neurodegenerative diseases.   
(1-1) Functions of astrocytes 
(1-1-1) Regulating water transport  
Transmembrane proteins, located at the endfeet of astrocytes and which 
mediate cellular water movement, belong to the aquaporin (AQP) family. 
AQP4 is the primary water channel in the brain, highly expressed in 
astrocytic endfeet (Bloch and Manley, 2007). Another aquaporin, AQP1, 




breakdown of the BBB, the AQP4 water channel contributes to edema 
formation. The deletion of AQP4 can reduce brain edema accumulation 
when the BBB is broken, but also slows down the edema clearance when the 
BBB is restored (Bloch and Manley, 2007; Tomas-Camardiel et al., 2005). 
(1-1-2) Maintaining BBB integrity 
Astrocytes and their endfeet encircle the brain capillaries and provide 
signalling factors in the BBB development (Eugenin et al., 2011). The co-
culture of brain endothelium and astrocytes greatly enhances TJ expression 
and reduces the gap junctions when comparing with separately cultured 
endothelium. This co-culture also increases the astrocyte assembly and 
concentration, reduces the BBB permeability to sucrose and elevates the 
TEER (Cohen-Kashi Malina et al., 2009; Tao-Cheng and Brightman, 1988). 
Both agrin and AQP4 in the astrocytic endfeet help maintain the BBB 
integrity, and their loss is related to BBB permeability (Wolburg et al., 2009; 
Zhou et al., 2008). After the BBB is disrupted, astrocytes help to restore the 
BBB integrity by directing TJ proteins (Willis, 2010). 
(1-1-3) Signalling transduction 
Astrocytes can secrete a range of neurotransmitters or cytokines which 
modulate synaptic transmission, and signalling or metabolic pathways 
(Abbott et al., 2006; Cahoy et al., 2008; Hansson and Ronnback, 2003; 
Zlokovic, 2008). Neuron-astrocyte signalling also plays a role in cerebral 
blood flow regulation (Koehler et al., 2009; Zonta et al., 2003).  
(1-2) Changes under pathological conditions 
Astrocyte dysfunction triggered by pathological stress leads to BBB leakage. 
There is a decrease in astrocyte expression under hypoxic stress. Loss of 




2011). Under human immunodeficiency virus (HIV) infection stress, HIV-
infected astrocytes can trigger the signalling pathways to compromise BBB 
through a gap-junction-dependent manner (Eugenin et al., 2011). 
(2) Microglia  
Microglia were first described as a distinct glial cell type by del Rio Hortega 
in 1927 (del RÃ-o Hortega and Penfield, 1927). Microglia cells have surface 
antigens and are related to the phagocytic cell linage; they differentiate from 
circulating monocytes in the blood which enter the brain during embryonic 
development (Kim and de Vellis, 2005; Kreutzberg, 1996).  Microglia are 
classified into two groups according to their activation status and 
morphology: (1) highly ramified resting/surveying microglia and (2) 
amoeboid activated microglia (Kim and de Vellis, 2005). The shift from one 
state to another needs cytokine release and surface antigen expression 
(Hanisch and Kettenmann, 2007; Kim and de Vellis, 2005; Kreutzberg, 1996; 
Zlokovic, 2008). 
(2-1) Functions  
(2-1-1) Immune sensors 
Microglia cells are immune sensors in the brain. They continually screen the 
brain parenchyma tissue, and they are extremely sensitive guarders (Hanisch 
and Kettenmann, 2007; Hughes, 2012).  The surface antigen expression and 
cytokine synthesis increased after various stimulus (Kim and de Vellis, 2005). 
(2-1-2) Tissue repair 
Activated microglia cells initiate tissue repair and promote injured tissue to 
return to homeostasis by secreting growth factors (Hanisch and Kettenmann, 




(2-2) Changes under pathological conditions  
In white matter lesions (WML), there are an increased number of microglia 
cells. Microglia cells become highly activated and express more surface 
molecules such as major histocompatibility complex II (MHC class II). There 
are more MHC class II in the normal appearing white matters around WML 
than the normal appearing WM from no lesion brains (Simpson et al., 2007a; 
Simpson et al., 2007b).  
Activated microglia cells are involved in systemic inflammation and could 
contribute to chronic neurodegenerative disease, such as AD and PD (Perry 
et al., 2010). 
Activated microglia cells could also induce BBB dysfunction by releasing 
proinflammatory cytokines (Abbott et al., 2006). After the stimulus of 
lipopolysaccharide (LPS), the release of tumor necrosis factor-α (TNF- α) was 
elevated by release from activated microglia which induces BBB permeability 
(Nishioku et al., 2010). Similar to astrocytes, microglia cells could help restore 
the BBB integrity after the BBB is disrupted by directing TJ proteins (Willis, 
2010). 
(3) Oligodendrocytes  
Oligodendrocytes are responsible for synthesis of the myelin sheaths of 
axons (Aggarwal et al., 2011; Bradl and Lassmann, 2009; Mathis et al., 2003). 
The myelin and saltatory nerve conduction are the basis for fast information 
processing in a short distance (Aggarwal et al., 2011).  
Oligodendrocytes play a crucial role in NVU signalling. Oligodendrocytes 
express growth factors influencing the function of neighbouring neurons, 




2002; Hansson and Ronnback, 2003). Neuroligands could induce Ca2+ signal 
which mediates oligodendrocyte development, myelination in white matter, 
and demyelination. Ca2+ signal could be influenced by growth factors 
(Soliven, 2001). Oligodendrocytes are connected with astrocytes through gap 
junctions (Aggarwal et al., 2011). 
Deletion or dysfunction of oligodendrocytes can cause myelin loss and 
impair cerebellum development (Mathis et al., 2003; Watzlawik et al., 2010). 
Myelin attenuation and oligodendrocyte apoptosis are associated with WML 
(Simpson et al., 2007a). 
2.2.5 Perivascular space (PVS) 
The virtual spaces located between the endothelial basal lamina and the 
astrocytic basal laminas are called perivascular spaces (PVS) (Bechmann et 
al., 2007). PVS were firstly described and confirmed in detail by a German 
pathologist Rudolf Virchow and a French histologist Charles Philippe Robin 
more than a century ago, thus PVS are also known as Virchow-Robin spaces 
(VRS) (Hutchings and Weller, 1986).  
PVS are fundamental structures around vessels in a variety of species, and 
increasing evidence shows PVS function as an important site for immune cell 
accumulation and reaction in inflammatory disease, and are related to fluid 
drainage in the brain which is associated with brain edema and cognitive 
dysfunction. PVS are also associated with cerebral small vessel disease (SVD) 
and BBB permeability. We systematically searched the literatures for 
structure and functions related to PVS using Medline© up to June 2013. After 




We included 96 papers regarding PVS structure, PVS cell origin, immune cell 
accumulation within PVS, immune cell transmigration through PVS, and also 
pathological changes related to PVS under a variety of stimuli and 
associations with SVD and inflammatory diseases. We excluded case reports, 
comments, review papers, non-translatable (not English or Chinese), 
duplicates, and where the full text was unavailable. We also excluded topics 
about vet disease, gene-related diseases, method or treatment comparisons, 
neurotoxic effect, non-cerebral disease (such as in the spinal cord) and non-
vascular disease (such as cerebral metabolic disease). The number of 






Figure 2.2 Inclusion and exclusion list for PVS systematic search.  
(1) PVS Structures 
In both the superficial and the deep areas of the brain, PVS are extracellular 
fluid filled spaces located between the vascular endothelial basement 
membrane and the glial basement membrane, and they separate blood 
vessels from the surrounding brain parenchyma (Abbott, 2004). They follow 
the course of cerebral arteries, arterioles, venules and veins, and eventually 




membranes fuse together (Owens et al., 2008). However those spaces might 
become expanded under pathological conditions influenced by inflammation 
or fluid drainage dysfunction. When expanded, these spaces can be seen on 
magnetic resonance imaging (MRI) especially T2-weighted sequences which 
have signal intensity similar to cerebrospinal fluid (CSF) and generally less 
than 3 mm. They appear linear, round or ovoid depends on the imaged 
direction to the course of the vessels (Wardlaw et al., 2013c). 
PVS are fundamental structures located around vessels to maintain pressure, 
buoyancy and function as a drainage route in a variety of species such as 
avian, rodents, amphibians, reptiles and mammals (Table 2.1, all tables are in 
the last section of this chapter, 2.6 Tables).  
Three ultrastructural studies illustrated human cerebral PVS by light 
microscopy (LM), scanning electron microscopy (SEM) and transmission 
electron microscopy (TEM) (Esiri and Gay, 1990; Hutchings and Weller, 1986; 
Zhang et al., 1990). It is accepted that PVS are more likely to be extensions of 
subpial spaces (SPS) (Esiri and Gay, 1990; Hutchings and Weller, 1986; Zhang 
et al., 1990) rather than the subarachnoid spaces (SAS), which was proposed 
to have a free communication with PVS proven by tracer studies for a long 
time. Layers of leptomeningeal cells (pia mater) separate the SAS from the 
SPS and PVS, and those cells are joined by desomosomes or nexus junctions 
(Hutchings and Weller, 1986; Zhang et al., 1990). Based on the information 
from the literatures (Table 2.2), generally a blood vessel is separated from 
neuropil by three layers of basement membranes (BM), pericyte, and 
sometimes complete layers of smooth muscle cells (SMC, no SMC layers in 
capillaries), PVS and limitans from the endfeet of glial cells. On the side of 




BM layer is surrounded by a pericyte and the second layer of BM. On the 
side of glial limitans, the third BM surrounded the glial limitans. PVS are the 
spaces between the second and third layer of BM, filled with extracellular 
fluid, perivascular cells and collagens. So we hypothesize typical PVS cell 
types array from blood vessel to neurons as endothelial cells/1st 
BM/pericyte/2nd BM/PVS-cells/3rd BM/ limitans from the endfeet of glial 
cells (Figure 2.3). This PVS structure varies with vessel type and vessel 
location.  
 





In the basal ganglia regions, PVS around arteries are different from veins. 
PVS around arteries are like the typical PVS structure and location as 
described above (Figure 2.3), they are composed by two layers of 
leptomeningeal cells: arteries are firstly coated by 1st BM layer, pericyte, 
complete layers of SMC, 2nd BM and an inner layer of leptomeninges (L1), 
which forms the inner wall of the PVS; the outer layer of leptomeninges (L2) 
contact with basement membrane of glia limitans (3rd BM) in the brain. These 
two layers of leptomeningeal cells isolating the PVS from the arteries and 
glia limitans, and bundles of collagens fill the PVS. In comparison, PVS 
around veins are composed by one layer of leptomeninges and collagen 
sheets. Veins surrounded by 1st BM layer, pericyte, incomplete and atypical 
layer of SMC, 2nd BM layer and inner layer of leptomeninges (L1), but lack an 
outer layer of leptomeninges (L2), thus the PVS are encompassed by collagen 
sheets which are continuously overlying the basement membrane of the glia 
limitans (3rd BM layer) (Pollock et al., 1997). 
The structure of PVS also varies according to vessel location. Unfortunately, 
PVS have not been studied systematically in regard to the different parts of 
the cerebral vascular tree. We found three original studies about PVS 
ultrastructure and summarized their findings in Table 2.2.  In Zhang’s 
research (Zhang et al., 1990), they examined the arteries and veins in the SAS, 
arterioles, metarterioles, small and large veins, and small venules in the SPS, 
and arterioles, venules and capillaries in the cerebral cortex and white 
matter; in Pollock’s research (Pollock et al., 1997), they differentiate structural 
characteristics of the arteries in the basal ganglia and the arteries in the 




(Hutchings and Weller, 1986), they did not distinguish the arteries and veins 
or arterioles and venules, and used a general word ‘vessel’.  
There is a need of systematic research of PVS ultrastructure in the different 
parts of the cerebral vascular tree in human and animal models. This kind of 
research would help us understand PVS function and eliminate the 
apparently contradictory findings in current studies, such as whether PVS 
are continuous with SAS or SPS, whether fluids within PVS have exchanges 
with CSF and PVS differences between arteries and veins, arterioles and 
venules. 
(2) PVS cells 
Cells located within PVS are addressed as perivascular cells by their location. 
Perivascular cells differ from pericytes and microglia by their location, 
morphology and immune phenotype (Bechmann et al., 2001). This 
population contained dense lysosomal bodies and have active phagocytic 
activities; they function as scavengers in the PVS (Bechmann et al., 2001; Kida 
et al., 1993). Perivascular cells express ED2 antigens and MHC class II 
antigens (Kida et al., 1993), and are able to present antigens to naïve CD4+ T 
cells (Esiri and Gay, 1990; Walker, 1999). Perivascular cells share morphology 
and immune similarity with blood-borne macrophages, so they are also 
called perivascular macrophages (Bechmann et al., 2001; Guillemin and 
Brew, 2004).  
The question of whether perivascular macrophages were a population of 
resident histiocytes or a migratory population from the blood monocytes has 
been debated. Researchers using tracer injection, green-fluorescent-protein 
(GFP)-transfected cells and monoclonal antibodies immune staining (Table 




resident origin of perivascular macrophages (Bechmann et al., 2001). 
Macrophages have a short life span (Mercier et al., 2006). The carbon 
injection experiment demonstrated that carbon particles were still within 
macrophages for at least 2 years (Kida et al., 1993) suggests that at least some 
are resident macrophages but is conflict with short life time span of 
macrophages (Hickey, 2001). A possible explanation for this phenomenon is 
the carbon particles could possibly be re-ingested by new macrophages after 
the death of old ones. Currently it is accepted that macrophages could be 
replaced by circulating hematopoietic stem cells from blood approximately 
every three weeks (Hess et al., 2004; Mercier et al., 2006). This extravasation 
process was activated by macrophage chemo-attracting protein-1 (Hess et al., 
2004). After successful extravasation from vascular endothelium, the 
monocytes (or the stem cells) mature into perivascular macrophages (Mercier 
et al., 2006). 
Tracer experiments showed that though blood-borne macrophages could 
infiltrate into PVS and mature into perivascular cells, those cells did not 
further migrate into brain parenchyma at least in normal rats’ brain 
(Bechmann et al., 2001).  
(3) PVS Cell accumulation and transmigration 
CNS immune invasion is the entry of immune cells into the brain 
parenchyma in inflammatory conditions, and the invasion involves two 
steps: (1) immune cell accumulation within PVS; (2) after complete 
breakdown of BBB, immune cells transmigrated across the PVS and glia 
limitans and then invaded into the brain parenchyma (Owens et al., 2008). 
PVS functioned as an immune cell buffering site and reaction place 




(Table 2.5). In normal and in inflammatory conditions such as multiple 
sclerosis (MS), human immunodeficiency virus encephalitis (HIVE), 
encephalitis induced by other types of viruses and bacteria, and cerebral 
ischemia, a variety of immune cells such as macrophages, microglia, 
monocytes, T-lymphocytes, B-lymphocytes, and dendritic cells (DC) 
accumulated within PVS or infiltrated into the brain parenchyma through 
PVS. PVS were also involved in non-inflammatory pathological states, such 
as cerebral ischemia, traumatic brain injury (TBI), neurodegeneration and 
tumors (see Table 2.4 and 2.5).  
Under inflammatory condition of MS, accumulation of immune cells such as 
macrophages, DC and lymphocytes in PVS are prominent features of acute 
MS plaques (Bogie et al., 2011; Esiri and Gay, 1990). Transmigration of DC, 
macrophages, monocytes, neutrophils and other leukocytes across the BBB 
into the brain were found in MS or the MS rodent model Experimental 
autoimmune encephalomyelitis (EAE) (Ahn et al., 2009; McCandless et al., 
2008a; Sagar et al., 2012; Tsai et al., 1997). The very late activation antigen-4 
(VLA-4) assisted the entry of CD4+T cells into brain to cause EAE (Tsai et al., 
1997). Chemokine (C-X-C motif) ligand 12 (CXCL12) mediated leukocytes 
infiltrating to PVS, but not into parenchyma. CXCL12 redistributed to the 
luminal sides of venules in active MS lesions and this altered expression was 
specifically associated with MS (McCandless et al., 2008a). Nerve injury-
induced protein Ninjurin1 (Ninj1) facilitated the entry of myeloid cells, such 
as macrophages and monocytes across the BBB into the CNS in normal and 
EAE brains (Ahn et al., 2009). Chemokine ligand 2 (CCL2) facilitated 




Under the inflammatory condition of HIVE, mononuclear cells, CD3+ and 
CD8+ T cells accumulated in the PVS. The accumulation of immune cells was 
an important biomarker for HIVE and associated with BBB permeability 
(Hawkins et al., 1993; Petito et al., 2006). Lymphocyte infiltration to the PVS 
had been found in all three stages after HIV infection: asymptomatic HIV 
infection, early stage of Acquired Immune Deficiency Syndrome (AIDS) and 
fully developed AIDS. It was a characteristic finding in asymptomatic HIV 
infection (Kibayashi et al., 1996). Zonula occluden-1 (ZO-1) disruption and 
BBB permeability was found in the brain of patients with HIVE, 
cyclooxygenase 2 (COX-2) and CD68 positive macrophages, T and B 
lymphocytes infiltrated the PVS and migrated into the brain parenchyma 
through a damaged BBB (Fiala et al., 2002). Very low numbers of B 
lymphocytes entered all parts of the healthy human brain, and the 
transmigration into the PVS and brain was increased in some AIDS and pre-
AIDS brains (Anthony et al., 2003). In an animal model of HIV, researchers 
observed monocytes transmigrated from blood to CNS within 48 hours after 
simian immunodeficiency virus (SIV) infection. This monocyte infiltration 
was in the acute phase of SIV infection (Clay et al., 2007).  
Beside HIVE, immune cell accumulation within PVS and transmigration 
through PVS were also observed in other types of encephalitis induced by 
viruses or bacteria. In sheep infected with visna/maedi virus, macrophages, 
CD8+, CD4+ T cells and B cells accumulated within PVS (Polledo et al., 2012).  
When mice were infected by West Nile virus, specific CD8 T cells infiltrated 
the PVS and entered the CNS which was mediated by CXCL12 (McCandless 
et al., 2008b). When interferon gamma (IFN-γ) gene knockout mice were 




leukocyte transmigration into PVS and ventricles. Infiltrated leukocytes were 
positive to inducible nitric oxide synthases staining (Koustova et al., 2000). In 
humans infected with Venezuelan equine encephalitis virus, infiltration of 
lymphocytes, mononuclear cells and neutrophils was present in the PVS and 
leptomeninges (de la Monte et al., 1985). Accumulation of mononuclear cells 
in the PVS and infiltration into the meninges was observed in chicken 
infected with Marek's disease virus (Barrow et al., 2003). In rats infected by 
Trypanosoma brucei gambiense, which causes African trypanosomiasis in 
humans, transmigration of plasma and T cells was found in the PVS and 
leptomeninges (Anthoons et al., 1989). Leukocytes infiltrated into PVS, 
choroid plexus and leptomeninges was observed in cats infected with 
pneumoniae (Hochwald et al., 1984). In cerebral malaria, another cerebral 
inflammatory disease, leukocytes, macrophages and lymphocytes 
accumulation in PVS was a hallmark (Lackner et al., 2006). AQP4 located 
around capillary endothelium and astrocyte endfeet which facilitated the 
water movement also contributed to leukocyte accumulation (Ampawong et 
al., 2011). 
Under ischemic stimulus, infiltrating monocytes from the circulating blood, 
perivascular cells and parenchymal microglia increasingly expressed CD14, 
which functions as binding receptors for bacteria, viruses and apoptotic cells 
which activate monocytes and macrophages (Beschorner et al., 2002). CD14+ 
cells significantly contributed to the post-ischemic inflammatory response 
(Beschorner et al., 2002). 
Perivascular macrophages could produce cytokines and factors to enhance 
immune responses in collaboration with other immune cells and other 




through this space into brain parenchyma (Galea et al., 2005; Staines et al., 
2008).  
(4) Fluid drainage through PVS 
The PVS are filled with interstitial fluid (ISF) instead of CSF within brain 
parenchyma. ISF was derived from the fluid in the blood, grey matter and 
white matter presumably by diffusion through the extracellular spaces and 
bulk flow along PVS (Abbott, 2004; Schley et al., 2006; Zhang et al., 1992). 
Another kind of extracellular fluid CSF is produced by the choroid plexuses 
in the ventricles. CSF circulates in the ventricles and subarachnoid space 
(SAS) and drains into the blood via arachnoid granulations and villi in 
humans (Schley et al., 2006). There is a continuity between ISF and CSF 
(Tarnaris et al., 2011), both ISF and CSF systems function as supplements to 
the lymphatic circulation and protein clearance, and PVS is associated with 
ISF and CSF drainage in both physiological and pathological conditions 
(Table 2.6). 
Tracers such as albumin (Bradbury et al., 1981; Yamada et al., 1991), 
horseradish peroxidise (HRP) (Gregory et al., 1985; Rennels et al., 1985; 
Wagner et al., 1974) and immunoglobulin G Fc receptor (Siegelman et al., 
1987) entering the CNS were drained  by the PVS around blood vessels to the 
arachnoid granulations and finally enter the lymphatic circulation in 
physiological conditions. Soluble antigens, but not cells, drain from the brain 
by perivascular pathways (Schley et al., 2006). Such drainage pathways play 
a protective role in the clearance of proteins (Siegelman et al., 1987). 
The drainage efficiency of Aβ and tau proteins was associated with cerebral 




Schley et al., 2006). The structure of the PVS in the basal ganglia region may 
facilitate effective Aβ drainage in this region (Pollock et al., 1997). In ageing 
vessels, the reduced amplitude of pulse could prolong Aβ attachment time 
on vessel walls, and induce its accumulation (Schley et al., 2006). The 
accumulated Aβ deposition in drainage pathways would further impede 
clearance of Aβ and ISF from the brain in AD (Carare et al., 2008). The 
myelin particle clearance in MS may follow the same particles elimination 
mechanism (Kooi et al., 2009). Dilation of PVS was a sign of ineffective ISF 
drainage which correlated with total Aβ load, ApoE ε4 genotype and CAA 
severity in AD patients (Roher et al., 2003; Thal, 2009). 
In idiopathic normal pressure hydrocephalus (INPH), which is a condition of 
unknown causes that affects older people and results in enlarged ventricles, 
and problems of cognition, balance, gait and continence (Shprecher et al., 
2008), alterations in CSF dynamics may trigger the abnormal bulk flow of ISF 
along the PVS (Tarnaris et al., 2011). The altered CSF dynamics also impaired 
the Aβ clearance in an INPH rat model (Silverberg et al., 2010). The INPH 
also showed associations with ischemia (Corkill et al., 2003) and SVD, such as 
infarction (Bradley et al., 1991), and White Matter Hyperintensities (WMH) 
on MRI (Krauss et al., 1996; Krauss et al., 1997) in humans. 
In the rat model of intracerebral hemorrhage (ICH), spread of hematoma 
along perivascular spaces and perineural tracts was observed. The hematoma 
extension may involve lymphatic encephalopathy (He et al., 2012). PVS 
functioned as the route for edema fluid clearance in a tumor model in rats 




(5) PVS associate with inflammatory disease 
Besides the pathological evidence associated with immune cells in PVS 
described in earlier part’(3) PVS Cell accumulation and transmigration’, 
other studies (which did not describe from the direction of cells within PVS) 
also suggested the association between PVS and inflammatory disease such 
as MS (Gay, 2006), HIV (Gorantla et al., 2010), cryptococcosis in HIV 
infection (Klock et al., 2009) and trypanosomiasis (Rudin et al., 1984; 
Schmidt, 1983) within the CNS.   
In addition to histology, PVS on MRI have been investigated as a prognostic 
tool for inflammatory disease, especially in MS. For example, two studies 
show associations between PVS enlargement and inflammation in MS, with 
comparison to healthy controls, PVS number and volume was a marker for 
inflammation in MS patients (Wuerfel et al., 2008).  Another study  shows 
PVS in the supraventricular region was a marker for MS (Al-Saeed et al., 
2012).  PVS on MRI could possibly be a convenient tool in detecting 
inflammatory disease in other studies. 
(6) PVS associate with Small Vessel Disease (SVD)  
PVS are not visible on MRI unless enlarged. Enlarged PVS have been 
considered as normal structures in the brain for a long time since they also 
appear in small numbers in young and healthy control volunteers. However, 
increasing age and hypertension are two risk factors for PVS (Potter et al., 
2013). PVS rating score was independently associated with age, 
hypertension, WMH, and lacunar infarctions in basal ganglia regions 
(Martinez-Ramirez et al., 2013; Rouhl et al., 2008), and in both basal ganglia 
and white matters regions (Zhu et al., 2010). Also accumulating evidence 




vessel disease (SVD), inflammation, BBB permeability and cognitive 
dysfunction (Doubal et al., 2010b; Potter et al., 2013; Zhu et al., 2010). 
PVS associated with SVD: higher numbers of PVS in the basal ganglia region 
were associated with more severe silent lacunar infarcts and WMH (Rouhl et 
al., 2008). The severity of PVS was associated with the load of WMH and 
lacunes, as well as showing the association is stronger if the PVS are located 
in the basal ganglia rather than in the white matter (Zhu et al., 2010). The 
PVS in the white matter were associated with lobar microbleeds (Martinez-
Ramirez et al., 2013). PVS rating scores in the basal ganglia region were 
significantly associated with lacunar stroke and PVS scores in the centrum 
semiovale region after adjusting for vascular risk factors and WMH (Doubal 
et al., 2010b; Potter et al., 2013). Total PVS rating scores (basal ganglia and 
centrum semiovale) were correlated with deep WMH and previous stroke 
(Potter et al., 2013). 
PVS were also detected in the basal ganglia and temporal white matters in 
patients with cerebral autosomal dominant arteriopathy with subcortical 
infarcts and leukoencephalopathy (CADASIL), which is a single gene 
disorder form of SVD (Cumurciuc et al., 2006; Flossmann, 2006).  PVS in the 
basal ganglia region were potential markers for cerebral microvascular 
angiopathy before WMH become apparent in subjects at risk of stroke 
(Selvarajah et al., 2009). PVS also associated with myotonic dystrophy, as 
PVS near vertex were more frequent and severer in patients with myotonic 
dystrophy than in controls (Di Costanzo et al., 2001). The PVS rating score 
was related to BBB permeability in patients with lacunar stroke (Wardlaw et 
al., 2009). Increased BBB permeability in the white matter was also suggested 




were correlated with worse cognitive function in healthy older people. PVS 
were more common in older adults and more severe in patients with AD or 
mild cognitive impairment than in cognitively normal controls (Chen et al., 
2011).  
2.3 BBB junction proteins 
As mentioned in the earlier section describing the endothelium part of the 
NVU, tight junctions (TJ) and adherens junctions (AJ) are two major 
categories of junctional proteins in the BBB (Bazzoni and Dejana, 2004). The 
detailed description about the structure and function for each TJ and AJ 
proteins and their changes during pathological conditions will be discussed 





Figure 2.4 Junction proteins atlas of the BBB.  
2.3.1 Tight junctions (TJ) 
The TJs arrange as oligomeric proteins with transmembrane domains. In 
response to external stressors, such as hypoxia, inflammation and Aβ 
stresses, structure and phosphorylation states of TJ proteins alter rapidly. 
This may cause changes in BBB integrity and permeability (McCaffrey et al., 
2007; Sakakibara et al., 1997). 
(1) Occludin 
Occludin is the most studied TJ protein. Studies have found that occludin is 
located in the TJ in both epithelial and endothelial cells. It is an 




Occludin is composed of four transmembrane domains and a COOH-
terminal domain (domain E). The four transmembrane domains make up 
two extracellular loops which are rich in tyrosine and glycine residues. 
Domain E was found to be necessary to locate occludin at TJ (Furuse et al., 
1994). 
Occludin contributes to the electrical barrier function of TJ and probably the 
formation of aqueous pores. The increased expression of occludin was 
associated with the increase of transendothelial electrical resistance (TEER), 
which is an example of the occludin making the electrical paracellular barrier 
tighter (McCarthy et al., 1996). The TJ barrier function is also influenced by 
occludin phosphorylation status. Highly phosphorylated occludin is 
concentrated at TJ, and the use of protein tyrosine phosphatase inhibition 
induces occludin proteolysis and increases the paracellular permeability 
(Wachtel et al., 1999). Thus the phosphorylation is considered to be a key 
regulator of TJ assembly (Sakakibara et al., 1997). The occludin 
phosphorylation is regulated through RhoA-p160ROCK -dependent and -
independent manners (Hirase et al., 2001). The oligomeric form of occludin 
(homodimers) is critical in TJ assembly at the BBB which associates with ZO-
1 and caveolin-1 locate in plasma membrane (McCaffrey et al., 2007).  
The occludin expression and phosphorylated status is altered in a variety of 
pathological states. In studies of inflammatory pain models, expression of 
occludin significantly decreased in inflammatory pain groups induced by the 
λ-carrageenan and complete Freund’s adjuvant (CFA) (Huber et al., 2001). 
The total occludin expression was significantly decreased at 1h, 3h, 6h, 12h 
and 48h after the λ-carrageenan-induced inflammatory pain (Huber et al., 




significantly decreased by 60% (Brooks et al., 2005). Both stimuli increased 
BBB permeability. Studies have shown excessive occludin phosphorylation 
on tyrosine residuals increases transcellular permeability in epithelial and 
endothelial cells. Thus these studies suggested, using the inflammatory pain 
model, BBB permeability can be induced by decreased occludin expression 
secondary to inflammatory pain stimuli, which may be a consequence of 
increased tyrosine phosphorylation triggered by inflammation (Huber et al., 
2001). 
Hypoxic stress induced little change in occludin expression; however the 
expression increased significantly after hypoxia-reoxygenation (Mark and 
Davis, 2002). Further study of hypoxia stress has found that in the condition 
of hypoxia-reoxygenation there is more phosphorylated occludin (Witt et al., 
2003). In cerebral ischemia, expression of occludin decreases which leads to 
BBB integrity disruption, which might be caused by MMP (Rosenberg and 
Yang, 2007). During ischemia, tPA and age independently increase occludin 
phosphorylation, which triggers early BBB permeability following ischemic 
stroke (Kaur et al., 2011). 
In the experimental diabetic rats, occludin degradation was observed to 
coincide with increased MMP activity. This suggests that diabetes increases 
loss of TJ proteins which leads to BBB permeability, and MMP may 
contribute to this process (Hawkins et al., 2007). However, the combined 
stress of hypoxia and aglycemia, which is seen in ischemic stroke, induced 
increased occludin expression which was interpreted as a protection effect to 




In neurodegeneration disease, such as AD and vascular dementia (VaD), 
neurons overexpress occludin in frontal cortex and basal ganglia as 
compared to ageing controls (Romanitan et al., 2010; Romanitan et al., 2007). 
ApoE is a major apolipoprotein in the brain, and its isoform ApoE4 is a major 
risk factor for AD. The BBB and TJ integrities are regulated by apoE in an 
isoform-dependent manner. For example, BBB was reconstructed with 
primary astrocytes from human apoE4-knock-in mice (apoE4-BBB model). 
The effects of occludin phosphorylation at tyrosine residuals, and the 
activation of protein kinase C eta, were more enhanced in the apoE4-BBB 
model, when compared with those effects in the apoE3-BBB model 
(Nishitsuji et al., 2011). 
In EAE, an animal model of MS, the occludin dephosphorylation co-occurs 
with inflammation, which suggests occludin dephosphorylation could relate 
to immune cells migration and increased BBB permeability (Andrews et al., 
2007). 
In the human glioblastoma multiforme, occludin expression was significantly 
reduced in hyperplastic vessels, which may contribute to the microvascular 
permeability in human gliomas (Liebner et al., 2000). 
The altered expression of occludin is related to BBB permeability and 
leukocyte trafficking into the endothelium cells, which will be discussed in 
detail in a later section. 
In order to function properly and locate at TJ, occludin also needs 
cytoplasmic support from the family membrane-associated guanylate kinase 




(2) Zonula Occludens (ZO) 
Membrane-associated guanylate kinase (MAGUK) proteins are characterised 
by MAGUK domains: PDZ, Src homology 3 (SH3), and guanylate kinase-like 
domains. All of these domains can function as protein-protein interaction 
sites (Shin et al., 2000). Zonula occludens (ZO-1, ZO-2 and ZO-3) are 
members of the MAGUK protein family. 
(2-1) ZO-1 
ZO-1 is a protein with molecular mass of 220 kDa (Furuse et al., 1994; Itoh et 
al., 1993). It links transmembrane protein occludin with the cytoskeleton, 
which is directly required for occludin localization at TJ (Furuse et al., 1994). 
ZO-1-associated nucleic acid-binding protein binds to ZO-1 through SH3 
domain of ZO-1, which can regulate ErbB-2 expression and function in 
paracellular permeability (Balda and Matter, 2000). Gα12 can also bind to 
SH3 domain of ZO-1, which regulates barrier function of cultured Madin-
Darby canine kidney epithelial cells (Meyer et al., 2002). 
Altered expressions of ZO-1 are found in various pathological states. In the 
induced inflammatory pain model, ZO-1 expression is significantly increased 
in formalin, λ-carrageenan, and CFA pain models (Huber et al., 2001). It was 
confirmed in another λ-carrageenan induced inflammatory model that ZO-1 
expression significantly increased at 1h, 3h, and 6h compared with controls, 
and it returned to control level by 12h (Huber et al., 2002). However, in 
contrast with the previous two studies, there was no significant increase in 
ZO-1 protein expression in CFA induced chronic inflammatory pain model 




In the studies of MS, ZO-1 expression was found to be significantly different 
between different lesion types in MS, and also between MS lesions and 
normal appearing white matter. Further MS research found that ZO-1 is 
more frequent in active WML (Kirk et al., 2003; Leech et al., 2007).  In 
experimental diabetes rats, expression of ZO-1 decreased compared with 
controls (Hawkins et al., 2007). One study of human HIV found that loss of 
ZO-1 was highly associated with monocyte transmigration in HIV infection, 
and was also highly correlated with HIV-1-associated dementia (Boven et al., 
2000). 
(2-2) ZO-2 
Another protein from the MAGUK family is ZO-2, with a molecular mass of 
160 kDa (Furuse et al., 1994). ZO-2 and ZO-1 are not functionally identical: it 
aid the anchoring of occludin to the cytoskeletal architecture (actin) (Mitic 
and Anderson, 1998) which functions redundantly as ZO-1 (Umeda et al., 
2004). 
Similar to hypoxia stress induced change in occludin, the expression of ZO-1 
and ZO-2 are nearly the same after hypoxia, however, the expression of ZO-1 
and ZO-2 increases significantly after post hypoxia reoxygenation (Mark and 
Davis, 2002).  
(2-3) ZO-3  
Another MAGUK protein related to TJ is ZO-3. Similar as ZO-1 and ZO-2, 
ZO-3 also concentrates at TJ. However, it is expressed in many types of 
epithelial cells instead of the endothelium (Ekre et al., 2003). Except for the 
important TJ proteins like occludin, ZO-1, and ZO-2 mentioned above, there 
is another family of proteins which has higher cell adhesion activity than 




The claudin family is another important component in maintaining the BBB 
integrity. Occludins and claudins are both good adhesion molecules 
functioning at TJ to compose the tight “kissing point of TJ” which completely 
removes the space between neighbouring cells. The cell-adhesion activity of 
occludin is negligible when compared with that of claudins (Kubota et al., 
1999).  
(3) Claudins 
Claudins, named from the Latin claudere, means “to close” (Mitic et al., 
2000). Claudin-1 and claudin-2 were first isolated from chicken liver 
junctional fractions, from which occludin was first identified (Furuse et al., 
1998). They soon turned out to be a growing family of tight junction proteins 
(Mitic et al., 2000). Now, the claudin multigene family is composed of 16 
transmembrane proteins with molecular weight of 20–28 kDa (Kubota et al., 
1999; Romanitan et al., 2010). Claudins have high cell adhesion activity, 
concentrated at TJ and have an essential role in the formation of TJ strands. 
They appear to function as the primary seal at TJ in forming the TJ backbone 
(Romanitan et al., 2010). There are at least three types of claudin-claudin 
interactions: TJ type, disjunction type, and intracellular type; which can all be 
influenced by a single amino acid in the claudin extracellular loop 2 (Piontek 
et al., 2008). 
Claudins are responsible for TJ specific cell adhesion activity. Here are some 
descriptions of the claudin TJ function features. 
(3-1) Claudin-5 
Of all the claudin proteins expressed by brain endothelial cells, claudin-5 is 
considered to be the most critical component in keeping the BBB integrity 




expressed in all tissues, specifically localising in the endothelium of blood 
vessels, and functions importantly in regulating vascular and BBB 
permeability (Romanitan et al., 2010). 
A study of claudin-5 deficient mice found that the BBB barrier function 
against small molecules (<800 Da) was selectively dysfunctional. The brains 
of these mice had no bleeding or edema showing the main vessel structure 
was not altered. Also, the BBB barrier function against large molecules (>800 
Da) still remained. Therefore, the size-selective loosening of BBB in claudin-5 
deficient mice proved that claudin-5 plays a role in BBB size selecting 
passage function (Nitta et al., 2003). 
Similar to findings about occludin, the oligomeric form of claudin-5 is critical 
in TJ assembly at the BBB.  Claudin-5 homodimers also associate with plasma 
membrane protein ZO-1 and caveolin-1 (McCaffrey et al., 2007).  
Since occludin and claudin-5 were considered as two of the most important 
TJ proteins in keeping BBB integrity and barrier function, and increased 
phosphorylation states of both claudin 5 and occludin during ischemia were 
influenced by increased tPA level and age (Kaur et al., 2011). There is a 
hypothesis to distinguish their effects. It is hypothesised that the severity of 
BBB permeability relates to the disassembly of different TJ proteins, either 
occludin or claudin-5. In claudin-5 deficient mice, loss of claudin-5 leads to 
BBB dysfunction against small molecules (<800 Da) (Nitta et al., 2003) which 
was considered as a mild leakage,  whereas  decreased occludin expression 
was associated to albumin leakage (68 kDa) which was considered as a 
severe leakage and suggested that occludin disassembly predominates 




(3-2) Other proteins in the claudin family  
Similar to claudin-5, claudin-1 and claudin-3 also localize at the BBB and 
their expression levels were also altered in various pathological states 
(Romanitan et al., 2010). In addition, claudin-1, claudin-2, claudin-5 and 
claudin-11 were also found to localize at the choroid plexus where their 
expression is affected by protein kinase C activation (Romanitan et al., 2010; 
Wolburg and Lippoldt, 2002). Claudin-11 is concentrated in TJ and myelin, 
and it is also known as an oligodendrocyte-specific protein. It is proposed 
that claudin-11 plays a key role in the development and formation of 
oligodendrocytes and Schwann cells (Bronstein et al., 2000). 
Claudin-1, -2, and -3 function as cell adhesion molecules in a Ca2+ 
independent manner (Kubota et al., 1999). Claudin-2, claudin-4 and claudin-7 
regulate Na+ and Cl- ion transportation (Romanitan et al., 2010). In contrast to 
other BBB gatekeeper claudins, introducing claudin-2 markedly decreased 
the tightness of individual claudin-1/4-based TJ strands (Furuse et al., 2001).  
(3-3) Alterations of claudin proteins in pathological states 
In cerebral ischemia, decreased expression of claudin-5 impairs BBB 
integrity, and this process involves MMP (Rosenberg and Yang, 2007). 
During ischemia after stroke, tPA and age enhance claudin-5 
phosphorylation independently. The increase in claudin-5 phosphorylation 
triggers early BBB permeability following ischemic stroke (Kaur et al., 2011). 
In the CFA-treated inflammatory pain rats’ model, expression of claudin-3 
increased 450% and claudin-5 increased 615%. The changes in 
transmembrane claudin proteins contribute to alteration in BBB function 




expression in formalin, λ-carrageenan, and CFA pain models (Huber et al., 
2001). 
Claudin family proteins might respond to cellular stress, for example in AD 
and VaD brains there were altered expressions of claudin-2, claudin-5 and 
claudin-11 in neurons, astrocytes and oligodendrocytes. There was a 
significant increase of claudin-2, claudin-5 and claudin-11 in the neurons 
from both AD and VaD brains as compared to aged controls. Claudin-2 and 
claudin-11 expressed significantly higher in astrocytes from AD and VaD 
brains as compared to controls. For the oligodendrocytes, claudin-11 was 
significantly higher in AD and claudin-2 was significantly higher in VaD as 
compared to controls (Romanitan et al., 2010). 
In the human glioblastoma, expression of claudin-1 was totally lost in the 
majority of tumor microvessels and claudin-5 expression decreased 
significantly in hyperplastic vessels, which may contribute to the 
microvascular permeability and edema seen in human gliomas (Liebner et 
al., 2000). 
(4) Junctional adhesion molecule (JAM)  
Junctional adhesion molecule (JAM) proteins belong to the immunoglobulin 
superfamily (Del Maschio et al., 1999). JAM proteins facilitate leukocyte 
migration into the CSF and brain parenchyma, and also function in albumin 
influx into CSF. The monocyte and neutrophil infiltration, and albumin 
influx were strongly reduced after using JAM inhibitor (Del Maschio et al., 
1999). JAM has been found to colocalize with TJ molecules such as occludin, 




Sobocka et al., 2004). These data indicate that JAM may be a component in 
facilitating junction protein assembly.  
JAM-A, also known as platelet adhesion molecule 1 (PAM-1; F11 Receptor: 
F11R; a.k.a; JAM-1), is a protein with a molecular weight of 32-35 kDa 
(Sobocka et al., 2004). It is expressed in endothelial and epithelial cells and is 
also expressed on leukocytes, neutrophils, monocytes, erythrocytes and 
platelets (Bazzoni et al., 2000; Sobocka et al., 2004).  
Localization of JAM-A is thought to be initiated by homophilic interactions 
on adjacent cells. Leukocyte function associated antigen-1 (LFA-1) is a 
receptor for JAM-A. The binding of JAM-A to the β2-integrin LFA-1 
facilitates leukocyte migration.  Thus JAM-A is a counter-receptor for LFA-1 
for leukocyte migration and recruitment (Ostermann et al., 2002). 
Abnormal JAM-A expression was found frequently in active white matter 
lesions areas of MS and the JAM-A staining was less intense and more 
diffuse in these areas. The abnormal JAM-A expression was observed from 
small capillaries to large vessels and influenced leukocyte trafficking 
(Padden et al., 2007). 
2.3.2 Adherens junction (AJ) 
The key interaction in adherens junction (AJ) is between cadherin and 
catenin. The cadherin-catenin complex is essential for strengthening cell–cell 
adhesion and for transferring signals between neighbouring cells. The cell 
signaling can be transferred in three different ways: firstly, by localising 
signaling molecules directly; secondly, by controlling catenins in the 





(1) Platelet endothelial cell adhesion molecule (PECAM)  
Platelet endothelial cell adhesion molecule 1 (PECAM-1), which is also 
known as CD31, is a 130  kDa protein (DeLisser et al., 1994), which belongs to 
the immunoglobulin superfamily (Del Maschio et al., 1999), which is 
expressed on the surface of endothelial cells, leukocytes (e.g. monocytes and 
neutrophils), platelets, and selected T cell subsets (Newman, 1997).  
PECAM-1 promotes cell adhesion events involving endothelial cells, 
leukocytes and platelets (DeLisser et al., 1994). In some cell types, PECAM-1 
is also involved in signal transduction processes. It may function as an 
agonist receptor which initiates signal pathways leading to secondary 
adhesion by non–PECAM-1 receptors (Newman, 1997). 
PECAM-1 is a major participant in leukocyte recruitment and extravasation 
during inflammatory process and Aβ-related cerebrovascular disorders 
(DeLisser et al., 1994; Giri et al., 2000; Newman, 1997). In one EAE (animal 
model of MS) study, they fused PECAM-1 to human IgG-Fc. This fused 
sPECAM-Fc protein impaired leukocyte migration through the BBB and 
reduced autoimmunity (Reinke et al., 2007). Aβ mediates monocytes 
migration during cerebrovascular disorders like AD. Inhibitors of PECAM- 1 
and Aβ receptor RAGE decrease the migration of monocytes (Giri et al., 
2000). PECAM-1 inhibitors may bring a promising method in reducing 
leukocyte trafficking in both cerebral inflammatory and degenerative 
diseases with therapeutic benefits.  
(2) Cadherin 
Cadherin is a large family of single chain transmembrane adhesion proteins. 
Like other adhesion junction proteins, cadherin has adhesion functions of 




permeability.  Cadherin also contributes to scaffolding cellular morphology, 
signaling transduction, and angiogenesis (Dejana, 1996; Dejana et al., 2000). 
Vascular-endothelial-cadherin (VE-cadherin, also called 7B4, cadherin-5) is a 
major cadherin in mediating adhesion junctions, which mediates cell 
adhesion through homophilic and calcium-dependent manners (Breviario et 
al., 1995). VE-cadherin collocates with α-catenin (Breviario et al., 1995) and 
links to p120 and β-catenin (Dejana, 1996) and is highly phosphorylated in 
tyrosine when there are weak and unstabilized junctions (Dejana, 1996).  
VE-cadherin plays an important role in maintaining vessel endothelial 
integrity; it is required for both quiescent vessels and new vessels. VE-
cadherin regulates vessel integrity through three mechanisms: the first 
mechanism is directly activating signaling molecules; the second one is 
regulating gene transcription; and the third may be through forming 
complexes together with growth factor receptors, and modulating signaling 
properties (Lampugnani and Dejana, 2007). VE-cadherin functions as a 
scaffolding protein which is able to regulate gene transcriptions, associate 
vascular endothelial cell growth factor receptor and promote signaling 
(Dejana et al., 2000). 
(3) Catenin  
There are three types of catenins which function as junctional cytoplasmic 
plaque proteins: α-; β-; and γ-catenin. Cadherin-catenin interactions are 
necessary for strengthening adhesion between neighbouring cells and in 
transferring signals between cells (Dejana, 1996).  
Cadherin is bound to actin filaments, directly through interaction with α-




Anderson, 1998). The interactions between VE-cadherin and catenins are 
important in maintaining endothelial paracellular permeability (Dejana, 
1996).  Binding of catenins to ZO-1 weakens their interactions with VE-
cadherin, which may block the formation of tight junctions (Rajasekaran et 
al., 1996). 
(4) Actin  
Actin functions as cytoskeletal architecture, to which TJ complexes are all 
anchored (e.g. claudin-1, occludin, ZO-1 and ZO-2) (Mark and Davis, 2002). 
Actin is involved in regulating paracellular permeability, and it binds to 
cadherin indirectly (Mitic and Anderson, 1998). 
The expression of actin alters in response to extracellular stress. After the 
stress of hypoxia and reoxygenation, the expression of actin increased (Mark 
and Davis, 2002). However, in the condition of hypoxia and aglycemia, actin 
expression was dramatically reduced (Brown and Davis, 2005). Actin 
expression increased significantly in the inflammatory pain rat models 
induced by λ-carrageenan and CFA (Huber et al., 2001). 
2.3.3 Colocalization of junction proteins 
TJ and AJ proteins are highly colocalized (Figure 2.4, Table 2.7). From Table 
2.7 it can be seen that TJ protein ZO-1 appeared 7 times in colocalization with 
other junction proteins. Another TJ protein JAM occurred 5 times, whereas 
VE-cadherin, occludin and claudin-5 occurred 3 times.  These colocalizations 
suggest that ZO-1, JAM, occludin and claudin-5 are important junctional 
proteins in cytoskeleton structure, and may be involved in facilitating TJ and 





2.4 Stimuli for BBB compromise  
2.4.1 Leukocyte transmigration 
(1) Two steps of leukocyte transport across the BBB into brain parenchyma 
(1-1) Migration across endothelium and endothelial basal lamina into PVS.  
In this step, leukocytes have not entered the CNS yet. The PVS provides a 
buffering zone of pro-inflammatory cytokines and immune cells for further 
leukocyte trafficking.  
(2-2) Passage across the astrocytic basal lamina into the brain.  
Though both endothelial and astrocytic layers are built from collagen type 
IV, HSPG and laminin, the laminin isoforms are different. Endothelial basal 
lamina contains laminins 8 and 10, which are essential for T cell recruitment 
and adhesion. Laminins 1 and 2 are found in the astrocytic layer and are not 
capable of T cell adhesion (Sixt et al., 2001). The laminin isoform differences 
might explain why immune cells accumulate in the PVS: immune cells are 
able to migrate into the PVS but not out of the NVU: the second transport 
step out of the PVS needs assistance from MMP and their interactions with 
dystroglycan matrix receptors to digest the astrocytic basal lamina (Agrawal 










(2) General leukocyte transmigration steps  
Many studies have demonstrated that leukocytes extravagate from vessels 
via a transmigration mechanism through opening of interendothelial 
junctions. A four-step model for this transmigration of circulating leukocytes 
has been proposed (Figure 2.5):  
(2-1) Rolling: leukocyte rolling on endothelial cells 
Leukocyte rolling is generally mediated by interaction between selectins, 
which enables leukocytes to detect more signals from the endothelium. 
Leukocyte-selectin, platelet-selectin, and endothelial-selectin are three 
adhesion molecules belonging to the selectin superfamily. L-selectin is found 
only on non-activated leukocytes, whereas P-selectin and E-selectin are 
expressed on inflammatory endothelium.  
(2-2) Stimulation of the leukocytes 
The activation of leukocytes is stimulated by chemokines. 
(2-3) Tight adhesion to endothelial cells  
After leukocytes are stimulated by chemokines, the activity of integrin 
increases and the adhesion ability of leukocytes to endothelial surface 
proteins also increases. These proteins are present on the endothelial cell 
surface and belong to the immunoglobulin superfamily. This enhanced 
binding affinity increases leukocyte stability on the endothelial cell surface. 
(2-4) Transmigration 
The leukocyte transmigration through the endothelium induces opening 
between adjacent cells to facilitate its passage between them. PECAM-1 and 




(3) Junction proteins involved in the leukocyte transmigration 
Table 2.8 gives a summary of a variety of TJ and AJ proteins involved in 
leukocyte transmigration. Many TJ and AJ proteins are involved in leukocyte 
transendothelial migration, such as JAM, ZO-1, VE-cadherin and PECAM-1 
(Dejana et al., 2000; DeLisser et al., 1994; Muller, 2003; Ostermann et al., 2002) 
(Boven et al., 2000) (Figure 2.5). JAM-A and PECAM-1 are the most studied 
proteins in leukocyte diapedesis, functioning in leukocyte recruitment, 
adhesion and transmigration. Antibodies to JAM-1 and PECAM-1 inhibit 
their expression and are also efficient in inhibiting the leukocyte 
extravasation through endothelial junctions (Dejana et al., 2000; Del Maschio 
et al., 1999; Giri et al., 2000; Muller, 2003; Newman, 1997; Schenkel et al., 
2002). Moreover, JAM-1 is a counter-receptor for LFA-1. JAM-1 contributes to 
LFA-1-dependent transmigration of T cells and neutrophils; it supports arrest 
of T cells by LFA-1−mediation; and it guides and controls leukocytes during 
leukocyte recruitment and adhesion (Ostermann et al., 2002). 
Leukocyte transmigration can be triggered by inflammatory stress such as 
TNF-α, IFN-γ or HIV infection (Muller, 2003), which induces changes of 
junctional proteins’ expression and distribution. Increased Aβ deposition 
related to disorder such as AD is another stimulus for leukocyte migration 
through transendothelial junctions by increasing the presence of monocytes 
(Giri et al., 2000). 
2.4.2 Ischemic stimulus 
We undertook a systematic search for studies of the influence of ischemic 
stroke on changes in BBB permeability. We searched the published literature 




2013. We used exploded headings relating to Blood–brain barrier, 
Permeability, and Stroke with the Boolean operator AND.  
From 44 papers describing the associations between BBB permeability and 
stroke, 12 assessed the association between BBB permeability and ischemic 
stroke stress and were eligible for inclusion. We excluded duplicates, 
reviews, comments and papers without full text. We also excluded non-
stroke studies (renal hypertension; possible stroke; before ischemic stroke; 
vascular disruption model; relation with obesity) and excluded other types of 
strokes and combined ischemic and hemorrhage stroke (hemorrhage stroke 
or hemorrhage transformation; hyperglycemic stroke). Two studies focusing 
on the effect of ischemic stroke are not suitable for our study (edema and 
vascular density). Five studies describing permeability measurement 
methods were excluded. Figure 2.6 summarized the inclusion and exclusion 






Figure 2.6 Systematic searching of ischemic stress for the BBB permeability. 
From the 12 papers that appeared relevant for full assessment, we extracted 
data for animal type, ischemic stroke type, and permeability type and 
permeability markers used (details in Table 2.9). All 12 studies used animal 
models as the BBB permeability model induced by ischemia stimulus, five 
studies used mice and seven used rats (Sprague–Dawley rats are most 
frequently used animal model). Middle cerebral artery occlusion (MCAO) is 
the most common method in inducing experimental ischemia (8 of the 12 
studies). They used tracers or MRI to assess the BBB permeability, and 
several tracers were used such as Evan’s blue labelled albumin, horseradish 




From the information of these 12 papers, we generated the following figure 
(Figure 2.7) describing how the effect of cytokines, enzymes, drugs and other 
stimuli act individually or in combination to increase or decrease BBB 
permeability after the ischemic stimulus (information details used in 
generating Figure 2.7 figure is in Appendix A, Table A1).  
 
Figure 2.7 Summary of factors involved in the BBB permeability triggered by ischemia. 
Abbreviations: 
VEGF: Vascular endothelial growth factor; MMP: Matrix metalloproteinase; tPA: Tissue 
plasminogen activator; NOX2: NADPH oxidase; ROS: reactive oxygen species; TJ: tight 






Cytokines MMP-9, VEGF and tPA disrupt BBB under ischemic stimulus 
(Abu Fanne et al., 2010; Paul et al., 2001; Wang et al., 2009; Wang et al., 2005). 
Inhibition of cytokines VEGF and MMP-9, Rho-kinase, and surface protein P-
selectin are effective in reducing BBB permeability induced by ischemia (Jin 
et al., 2010; Paul et al., 2001; Satoh et al., 2010; Wang et al., 2009). However, 
inhibitor of NOX2 worsen ischemic stroke outcome and is not effective in 
reducing BBB permeability in ageing rats (Kelly et al., 2009). The NK1 
tachykinin receptor antagonist reduces BBB permeability and the 
combination treatment with it and tPA also decreases BBB permeability (Abu 
Fanne et al., 2010). The use of capsazepine reduces BBB permeability 
(Gauden et al., 2007). High does anti-cholesterol drug atorvastatin decreased 
BBB permeability may through may be through up-regulation of claudin-5, 







2.4.3 Contributions of junction proteins to the BBB permeability  
Pathological stresses influence the expression and phosphorylation status of 
TJ and AJ proteins which lead to BBB permeability. Here is an overview of TJ 
and AJ expression and phosphorylation changes in different pathological 
states. 
The BBB permeability can be detected by decreased transendothelial 
electrical resistance measurement and the increased passage of molecular 
tracers such as Evan’s blue labelled albumin, horseradish peroxidise and 
sodium fluorescein. The BBB permeability can also be determined by 
constant transfer for contrast agent (e.g. gadolinium compounds) on MRI. 
There are three well-developed disease models for the mechanism of BBB 
permeability and cerebral vascular diseases, which are the inflammatory 
pain model, the hypoxia model and the AD model (Romanitan et al., 2010; 
Romanitan et al., 2007). The AD model is included here because of vascular 
changes rather than the neurodegenerative effects. The junction proteins 
changes in these three models are summarized in Table 2.10. 
All inflammatory pain models (acute, short term and chronic) induced down 
regulation of occludin (Brooks et al., 2005; Huber et al., 2002; Huber et al., 
2001). The expression of claudin-1 did not change in any of these 
inflammatory pain models (Huber et al., 2001), and the expression of 
claudin-3 and claudin-5 increased in the chronic inflammatory pain model 
(Brooks et al., 2005). 
Hypoxia and reoxygenation stress triggered increased or decreased change 
expression of occludin (Brown and Davis, 2005; Kaur et al., 2011; Mark and 




difference might be caused by different hypoxic conditions used by the 
researchers when inducing hypoxia. The phosphorylation of occludin 
increased triggered by ischemic stimulus (Kaur et al., 2011; Witt et al., 2003). 
During hypoxia, expression of claudin-5 was reduced, together with an 
increasing phosphorylation pattern (Rosenberg and Yang, 2007). Expression 
of ZO-1 and claudin-3 stayed almost the same during hypoxia and 
reoxygenation (Witt et al., 2003). 
In AD and VaD brains, the expression of occludin, claudin-2, claudin-5 and 
claudin-11 increased significantly in neurons. However, most of the claudin-
expressing neurons were pyramidal type, which are involved in cognition 
and are typically affected by AD pathology (Romanitan et al., 2010; 
Romanitan et al., 2007).  The increased levels might reflect an autophagy of 
occludin and claudins proteins by neighbouring cells after the BBB 
breakdown (Zlokovic, 2008). 
Changes in occludin under inflammatory pain and hypoxia stress are similar, 
and changes in claudin-5 under inflammatory pain, AD and VaD stress are 
mostly the same. The similar changes of TJ proteins may reveal analogous 
pathological mechanisms under these pathological states. 
Apart from these three disease models, decreased expression, 
disorganisation or phosphorylation change of TJ proteins were also found in 
other disease such as  tumor, HIV related dementia, MS tissue and apoE-4 
knock-in mice model (Boven et al., 2000; Liebner et al., 2000; Nishitsuji et al., 





2.5 Conclusion  
The BBB is an important and complex structure which is involved in various 
cerebral diseases. Systematically reviewing the literature is useful to 
understand the structure and function of PVS, which are fundamental 
structures around vessels in a variety of species and important in immune 
function and fluid drainage in the brain. Changes in PVS are related to BBB 
permeability, and enlarged PVS are important imaging markers for cerebral 
small vessel disease.  
Various stimuli could trigger BBB permeability such as inflammatory pain, 
ischemia, cytokines, chemokines and infections by bacteria and viruses. The 
ischemia stimulus to BBB permeability was analysed and summarised 
systematically. We also systematically searched other important effects on 
BBB such as oxidative stress, nitric oxide levels and Apolipoprotein E 
phenotypes, however, we did not manage to analyse them all limited by time. 
A further literature review of these topics would be beneficial in 
understanding triggers for BBB permeability. 
Some results from the literature seem to contradict each other, maybe 
reflecting different models, methods and disease phase (such as acute and 






Table 2.1 PVS structures in different species. 
Spices Model Observation method  PVS place  PVS function  Study 
Human Normal MRI, histology whole cerebral hemispheres and connect the 
cerebral convexity, basal cistern, and ventricular 
system. 
drainage, buoyancy,  
pressure maintenance 
Tsutsumi, 2011  
Rats Normal electron-microscopy silver deposition, blood brain barrier barrier  Van Breemen, 1955  
Rat; Necturus Normal  particle injection Mammal: PVS is bounded by an inner arachnoid 
coat and an outer pia-glial, till arterioles and 
venules.  
Amphibian: PVS was found in intrapial vessels, 
capillary. 
fluid flow; continuity 
between SAS, intrapial 
PVS, intracerebral PVS 
and pericapillary space 
Brightman, 1953  
Duck Normal electron-microscopy Capillaries, wide PVS tracer flow from blood to 
the PVS 
Hirunagi, 1994  
Necturus; Ambystoma Normal electron-microscopy Necturus (capillaries): surrounded by a collagen-
containing space, delimited by an endothelial and a 
glial basement membrane. 
In Ambystoma (capillaries): PVS 
(some other capillaries: a single basement 
membrane shared by endothelium and glia). 
extracellular fluid Bodenheimer,1968  
Abbreviations:  






Table 2.2 The ultrastructure of PVS in relation to vessels in different regions of human brains. 
Observation 
method 
Vessel type Vessel location PVS location and related structures Study 
TEM vessel Enter the cortex SAS/pia/SPS                 SPS↔PVS 
Vessel/SPS-PVS(collagens)/BM (brain) 
Hutchings,1986  
LM vessel not described BM/artefactual space (brain)  
TEM Artery SAS Artery/lamina/SMC/space /pia (trabecula) Zhang,1990  
TEM Arteriole SPS Arteriole/SMC/pia (nexus junctions)  
TEM Vein SAS Vein/SMC/PVS(collagens)/pia (desmosomes)  
TEM Vein SPS Vein/thick collagens  
TEM Vein SAS Vein/collagen and flattened cells(SMC)/pia (desmosomes, nexus junctions)  
TEM Arteriole SPS Arteriole/SMC/SMC/pia (nexus junctions)/space /pia  
TEM Metarteriole SPS Metarteriole/incomplete SMC/collagens/pia(nexus junctions)/space/glia limitans 
(brain) 
 
TEM Venule SPS Venule/atypical SMC/collagens/space /pia or glia limitans  
TEM Venule leave SPS enter 
trabecula 
Venule/collagens/pial cells  
TEM Large Arteriole cerebral cortex  Artery/SMC/SMC/SMC/space/pia(nexus junctions/glia limitans   
TEM Venule WM Venule/atypical SMC/space (collagens)/BM of glia limitans  
SEM Artery BG (GP) Artery/cells/PVS/cells/space/BM (brain) Pollock,1997  
SEM Vein BG (GP) Vein/cells/PVS/BM (brain)  
SEM Artery BG Artery/cells/PVS/cells/collagens/BM (brain)  
TEM Artery BG Artery/SMC/cells/PVS/cells(direct contact)/collagens/BM (brain)  
SEM Vein BG Vein/cells/collagens (brain)  
TEM Vein BG Vein/cells/PVS/collagens/BM (brain)  
paraffin block  Artery SAS to brain SAS Artery/cells/PVS/cells-pia/(brain)  





PVS: perivascular spaces; SAS: subarachnoid spaces; SPS: subpial spaces; BM: basement membrane; SMC: smooth muscle cells; L: a layer of cells 
(leptomeningeal cell layer in  (Pollock et al., 1997)); SEM: Scanning electron microscopy; TEM: Transmission electron microscopy; LM: Light microscopy; 





Table 2.3 Studies about perivascular cells origins. 
Observation method Tissue type Origin Cell type Immune characters Study 
Carbon label Rats Two types: resident, 
emigrate 
Macrophages Not mentioned McKeever, 1978  
Ink injection Rats Resident (2 years) Phagocyte 
 
ED2+, ED1+, MHC class II+ Kida, 1993  
Monoclonal antibodies Mice separate macrophages 
and microglia 
Macrophages, microglia MHC class II+, CD 4+T 
Not for microglia 
Walker, 1999  
Tracer injection Rats 6% of blood-borne Macrophages ED-2 Bechmann, 2001a  
transplanted, GFP Mice migratory  Macrophages [GFP] Bechmann, 2001b  
Review Not mention migratory  Macrophages similar to blood-borne 
macrophages 
Guillemin, 2004  







Table 2.4 Immune cell accumulation within PVS. 
Human or 
Animal 
Disease Model Cell type related  Accumulation place Mechanisms Study 
Human Ischemia  Monocyte, 
macrophages, 
(microglia) 
PVS and brain 
parenchyma 
Effect of CD14 in the acute inflammatory response following 
stroke. Resting microglia lack CD14 
Beschorner, 
2001  
Rats MS macrophages, 
lymphocytes 
PVS and CNS-draining 
lymph nodes 
myelin phagocytosing macrophages inhibit TCR-triggered 
lymphocyte proliferation by producing NO 
Bogie, 2011  
Human  HIVE CD3+, CD8+ T cells, 
CTL 
PVS  and inflammatory 
nodules (PVS: CD3+, 
CD8+ T) 
parenchymal CD3+, CD8+T cells and CTLs are sensitive 
biomarkers for HIVE;  CD8+ T cells and CTLs could mediate 
brain injury in HIVE 
Petito, 2006  
Human HIV infection mononuclear 
cell 




Sheep VM encephalitis macrophages, 
CD8+, CD4+ T cells 
and B cells 
Perivascular cuffs and 
sleeves 
[Different stages of viral invasion]  
mild lymphocytic lesions:  CD8+ T cells  
severe lymphocytic lesions: CD8+, CD4+ T cells  
histiocytic lesions: macrophages, CD8+, CD4+ T cells and B cells 
Polledo, 
2012  
Mice cerebral malaria leukocytes, 
macrophages 
lymphocytes 





macrophages PVS; brain-CSF and 
CSF-blood interfaces 
Mannose receptor for macrophages Galea, 2005  
Rats TBI endostatin, collagen 
XVIII+ microglia, 
macrophages 
lesion parenchyma and 
PVS 
These cells as main cellular source of the antiangiogenic factor 





CSF: brain-cerebrospinal fluid; T, T-lymphocytes; B: B-lymphocytes; CTL: cytotoxic T lymphocyte; TCR: T cell receptor; MS: multiple sclerosis; HIVE: 
human immunodeficiency virus type 1 encephalitis; VM: visna/maedi; TBI: traumatic brain injury; SIDS: sudden infant death syndrome; NO: nitric 




Table 2.5 Immune cell transmigration through PVS. 
Human or 
Animal 
Disease Model Cell type related  Migration place Mechanisms Study 
Mice EAE (MS) dendritic cells recruitment in PVS; 
across BBB 
CCL2 facilitate CD11 labeled DC transmigration across the BBB in 
an ERK1/2-dependent manner; DC more efficient transmigration 
than T cell in BBB model 
Sagar, 2012  
Rats EAE (MS) macrophages/monocy
tes and neutrophils  
PVS, across BBB Ninj1 may mediate the entry of myeloid cells into the CNS across 
the BBB in normal and EAE brains 
Ahn, 2009  
Human MS leukocytes across PVS CXCL12 localize infiltrating leukocytes to PVS, preventing CNS 
parenchymal infiltration. Altered patterns of CXCL12 expression 
at the BBB were specifically associated with MS. 
McCandless, 
2008a  
Mice EAE (MBP 
injection) 
leukocytes PVS, across BBB leukocytes infiltration in PVS and cerebral cortex; 
VLA-4 important for CD4+T entry into brain; ICAM-1,VCAM-
1,LFA-1 expression in the brain after stimulation 
Tsai, 1997  
rhesus 
macaques  
SIV (HIV) monocytes blood to CNS  
(within 48h) 
proinflammatory cytokine IFN-r and the chemokine CXCL9 were 
rapidly induced in plasma in the SIV-infected group. IFN-
inducible chemokine CCL2 (monocyte CNS trafficking) 
Clay, 2007  
Human  HIV B, T cells PVS, enter brain B very low in normal brain Most AIDS brains lack B lymphocytes. 
Increased accumulation of B cells some AIDS and in pre-AIDS 
brains in the PVS and brain. 
Anthony, 
2003  
Human  HIV, AD Macrophages, T and 
B cells 
PVS and neuropil COX-2 and CD68 positive macrophages infiltrate AD and HIVE 
brains. ZO-1 disruption and fibrinogen leakage in AD and HIVE 
brains. Amyloid-β-containing macrophages infiltrate amyloid-β 
plaques and vessels in AD.T and B lymphocytes also infiltrate AD 
and HIVE. 
Fiala, 2002  
Human HIV lymphocyte leptomeninges and 
PVS 
Lymphocyte infiltration, found in all stages and characteristic 
finding in asymptomatic HIV infection.  
Kibayashi, 
1996  




encephalitis lymphocytes and mice with WNV. Inhibition of CXCR4 would promote T 
lymphocyte entry into the CNS parenchyma and increase viral 
clearance.  
2008b  
Chicken Marek's disease 
virus 
monocyte PVS, meninges blood monocytosis may be contributory factor in mononuclear 
infiltration into the meninges and PVS 
















PVS and adjacent 
tissue parenchyma 
CNS infection de la Monte, 
1985 
Rats T. b. gambiense IgM-producing 
plasma, morular, T  
PVS, leptomeninges T-dependent B-cell immune response with a chronic T. b. 






leukocytes infiltration of the 
PVS, choroid plexus, 
and leptomeninges  
hypoglycorrhachia of bacterial meningitis is the result of 







cells; T and B 
antibody-secreting 
cells: PVS &  
interstitial space; 
B and T cells: PVS 
antibody-secreting cells: intrathecal synthesis of antibodies Martinez-
Hernandez, 
2011 
Human TBI CD14+ macrophages, 
CD 14+ microglia 
PVS, brain 
parenchyma  
early CD14 expression: essential part of the acute inflammatory 
CNS response following trauma 
Beschorner, 
2002  




PVS efflux and influx of activated lymphocytes Kruse, 1994  
Abbreviations: 
PVS: perivascular spaces; BBB: blood brain barrier; T, T-lymphocytes; B: B-lymphocytes; DC: dendritic cells; MS: multiple sclerosis; EAE: Experimental 
autoimmune encephalomyelitis; SIV: simian immunodeficiency virus; HIV: human immunodeficiency virus; HIVE: human immunodeficiency virus 




brucei gambiense; TBI: traumatic brain injury; NO: nitric oxide; iNOS: inducible Nitric oxide synthases; MBP: myelin basic protein; LFA-1: lymphocyte 
function-associated antigen-1; VLA-4: very late activation antigen-4; ICAM-1: intercellular adhesion molecule-1; VCAM-1: vascular cell adhesion 
molecule-1; CD: cluster of differentiation; CCL2: Chemokine ligand 2; CXCL9: chemokine (C-X-C motif) ligand 9; CXCL12: chemokine (C-X-C motif) 
ligand 12; CXCR4: C-X-C chemokine receptor type 4; ERK: extracellular-signal-regulated kinases; Ninj1: Ninjurin1, nerve injury-induced proteinCOX-2: 






Table 2.6 Fluid drainage function involved PVS in normal and pathological conditions. 
Human or 
Animal 
Model related components 
of fluid  
drainage route Mechanisms Study 
Rats Normal ISF, CSF spread selectively along PVS outlining both 
arteries and veins and extending to surround 
capillaries 
through cerebral white matter, grey 
matter, SAS to the cribriform plate and 
nasal lymphatics 
Zhang, 1992  
Rats Normal [14C]sucrose  [14C]sucrose was retained longer within the 
walls and PVS of pial arteries and arterioles 
than in other subarachnoid tissues 
Rapid ventricle-to-cistern flow of CSF; CSF 
delivered factors and agents to these pial 
blood vessels. 
Ghersi-
Egea, 1996  
Rabbits Radioactive albumin 
injection 
Albumin CSF to deep cervical lymph draining by bulk flow via PVS and passage 
SAS  and to lymph 
Brandbury, 
1981  
Rabbits Albumin  Albumin drainage from brain via PVS Outflow through lymph  Yamada, 
1991  
Rats HRP injection HRP ventricles to PVS of blood vessels foreign protein removement Wagner, 
1974  
Cats HRP injection HRP HRP in the SAS enters the PVS around 
penetrating arterioles and rapidly permeates the 
gliovascular basal laminae surrounding 
capillaries 
PVS and capillary basal laminae offer 
preferential 'paravascular' routes for 




Cats, Dogs HRP injection HRP PVS around large vessels and in the BM around 
capillaries; over 4 min, in arterioles, venules and 
capillaries 
exchange of solutes between the CSF and 









CSF pathway from the PVS to the arachnoid 
granulations 
CSF outflow system has important 





IGF-1 IGF-1 was detected predominantly in the pia 
mater, PVS and subcortical white matter tracts 
The subcortical white matter tracts and 
perivascular pathways were the two major 
routes for IGF-1 movement  
Guan, 2000  
Rats ICH hematoma; 
blood 
PVS and the spaces around the nerve fibers; 
lymph sinuses in the bilateral deep cervical 
perivascular and perineural extension of 
hematomas widespread 







Human MS Myelin 
particles 
extracellular myelin: leptomeningeal tissue and 
PVS  
myelin debris was drained from sub-
cortical or cortical lesions to PVS, the 
meninges 
Kooi, 2009  
Mice CAA Tracers;  tracers drained out of the brain along BM of 
capillaries and arteries  
Soluble antigens, but not cells, drain from 
the brain by perivascular pathways.  
Carare, 2008  
mathematical 
model 
Aβ elimination in AD 
and CAA 
Aβ PVS drainage of ISF and solutes out of brain 
was driven by pulsations of the blood vessel 
walls, reverse direction to the flow 
Reduction in pulse amplitude prolonged 
attachment time, and impaired elimination 
of Aβ from the brain 
Schley, 2006  
Human INPH  CSF, ISF continuity of ISF and CSF  
 
Abnormal bulk flow of ISF along PVS may 
be a consequence of the underlying 
alteration of CSF dynamics in INPH 
Tarnaris, 
2011  
Rats NPH Aβ,Tau Aβ42 in CSF clearance pathways also increase 
in PVS and cortical parenchyma;  Aβ42 
retention: along ISF and CSF outflow pathways 
(SAS,PVS) and BBB 
Hydrocephalus in the elderly rat can 
induce Aβ and p-Tau accumulation. 
Altered CSF dynamics appears to impair 







HRP and MP: intercellular spaces and PVS, 
restricted by tight junctions.  
La3+ penetrated tight junctions 
the tight junctions may constitute for the 






lymph model: PVS dilation;  
loosen tissues around PVS 
partial ligation of cerebral superficial 
artery induced lymphatic encephalopathy 
Xiao, 2011  
Human, 
Rats 
Tumor edema PVS were fluid drainage pathway of edema PVS especially in grey matters Kida, 1994  
Rats Edema Albumin toward ventricles and cortical surface CSF pathway: protein-rich edema 
clearance 
Ohata, 1990  
Abbreviations: 
ICH: intracerebral hemorrhage; INPH: Idiopathic Normal Pressure Hydrocephalus; NPH: normal pressure hydrocephalus; CAA: cerebral amyloid 
angiopathy; AD: Alzheimer’s disease; CSF: cerebrospinal fluid; ISF: interstitial fluid; BM: basement membranes; SAS: subarachnoid space; Aβ: 




Table 2.7 Colocalization of junction proteins in the BBB. 
Junction type  Junction type  Interaction type Reference 
AJ VE-cadherin  AJ α-catenin Antibody immunostained Brevioria 1995  
AJ VE-cadherin AJ β-catenin Immunoprecipitation Rajasekaran 1996  
TJ ZO-1 AJ α-,β-, γ-catenin   
TJ JAM  TJ occludin Coprecipitation  Muraki 2000  
TJ JAM  TJ ZO-1   
TJ JAM  TJ cingulin   
TJ claudin-5  TJ ZO-1 Immunocytochemical double labeling Zaretski 2004  
TJ occludin TJ ZO-1   
TJ JAM-A TJ ZO-1   
TJ JAM-A AJ VE-cadherin   
TJ claudin-5 TJ ZO-1 Ultrastructural and  immunofluorescent localization McCaffrey 2007  
TJ claudin-5 AJ caveolin-1   
TJ occludin  TJ ZO-1   
TJ occludin AJ caveolin-1   
Abbreviations: 






Table 2.8 TJ and AJ involvement in leukocyte transmigration. 
Type of leukocyte TJ or AJ facilitate 
trafficking 
antibody or stress 
to TJ or AJ 
TJ or AJ 
Expression 
change 
Influence to leukocyte Ref 
leukocyte PECAM-1 - - Direct leukocyte recruitment; transendothelial migration DeLisser, 1994  
monocyte neutrophil PECAM-1 antibodies  ↓ inhibits transendothelial migration Newman, 1997  
monocyte JAM BV11 (mAb) ↓ inhibits monocyte transmigration Del Maschio, 
1999  
monocyte ZO-1  HIV ↓ monocyte infiltration Boven, 2000  
leukocyte JAM mAb ↓ inhibits leukocyte extravasation Dejana, 2000  
monocyte RAGE  antibody ↓ inhibits amyloid peptide deposition, inhibits Aβ-
mediated migration of monocytes 
Giri, 2000  
 PECAM-1 antibody ↓ inhibits Aβ-mediated migration of monocytes  
leukocyte JAM-A  - - contributes to LFA-1-dependent transendothelial 
migration of T cells and neutrophils 
Ostermann, 
2000  
monocyte CD99 hec2 (mAb) ↓ inhibits diapedesis of monocytes across endothelial cells 
by >90%; arrested monocytes where they were partially 
through the junction 
Schenkel, 2002  
 PECAM-1 mAb ↓ arrests leukocytes on the apical surface of endothelium  
leukocyte JAM-A TNF-α+IFN-γ redistribution redistributes to the endothelial apical surface Muller, 2003  
 PECAM-1 IFN-γ ↓; redistribution redistributes to the apical surface  
during migration VE-cadherin - ↓   
 JAM-A  - ↑   
 PECAM-1  - ↑   
 CD99  antibody ↓ Blockade of monocytes diapedesis.  
 “-“: not mentioned; “↓”: down-regulated; “↑”: upregulated   
Abbreviations:  





Table 2.9 BBB permeability triggered by ischemia. 
Animal Type of ischemia permeability type permeability marker Study 
Male C57Bl/6 mice Permanent MCAO vascular permeability  EB (Paul et al., 2001) 
SHRSP rats Transient forebrain ischemia BBB permeability sodium fluorescein;  
EB-labeled albumin 
(Abraham et al., 
2002) 
VEGF-overexpressing mice MCAO BBB permeability sodium fluorescein (Wang et al., 2005) 
Wistar rats microsphere injection vascular permeability HRP (Gauden et al., 2007) 
Female Sprague–Dawley rats MCAO-2h-reperfusion BBB permeability [14C] radioactivity (Kelly et al., 2009) 
Male 129S6/SvEvTac mice Filamentous MCAO BBB permeability EB (Wang et al., 2009) 
Male Sprague–Dawley rats Microthrombosis endothelial permeability bovine serum albumin (Satoh et al., 2010) 
Male NMRI mice hypoxia at 8% oxygen-48h vascular permeability sodium fluorescein (Bauer et al., 2010) 
Sprague-Dawley rats MCAO BBB permeability EB (Abu Fanne et al., 
2010) 
Male C57/BL 6 wild type mice/ 29 P-
selectin-deficient or knockout mice 
MCAO-30min BBB permeability Gd contrast injection (Jin et al., 2010) 
Male Sprague–Dawley rats MCAO BBB permeability IgG (Confocal microscope) (Cui et al., 2010) 
Male Sprague–Dawley rats MCAO-2h-reperfusion BBB permeability EB (Turner and Vink, 
2012) 
Abbreviations: 





Table 2.10 Expression and phosphorylation changes on TJ and AJ in pathological conditions. 
Pathological states Stimulus TJ or AJ expression change Phosphorylation 
change 
BBB change Study 
Inflammatory pain Acute; Short term; 
Long term 
occludin ↓ p↑ tyrosine [14C]sucrose Huber, 2001  
  Claudin-1 ↔ -   
  ZO-1 ↑ -   
  actin ↑ -   
 Short term occludin  ↓ - Evan’s blue Huber, 2002 
  ZO-1 ↑ -   
 Long term occludin ↓60% - Evan’s blue- Brooks, 2005  
  claudin-3 ↑450% - labelled   
  claudin-5 ↑615% - albumin  
  ZO-1 ↔ -   
  actin ↔ -   
Hypoxia 1% O2-99% N2 occludin ↔↑* - [14C]sucrose Mark, 2002  
 Hypoxic VS ZO-1 ↔↑* -   
 Post-hypoxic  ZO-2 ↔↑* -   
 reoxygenation claudin-1 ↔↔ -   
  actin ↑*↑* -   
 O2-controlled 
hypoxia 
occludin shift in bands p↑ [14C]sucrose Witt, 2003  
  claudin-3 ↔ -   




  actin ↔ -   
 ischemia-RP occludin ↓*RP - - Rosenberg, 2007  
 rt-PA; MMP claudin-5 ↓*RP -   
 ischemia-RP occludin ↓ p↑ Gd-DTPA Kaur, 2011  
 t-PA claudin-5 ↓ p↑ MRI  
Hypoxia and  SKF 96365 occludin ↑ localization TEER Brown, 2005  
aglycemia  actin ↓ -   
Diabetes insulin- occludin  ↓ - [14C]sucrose Hawkins, 2007  
 intervention ZO-1 ↓ - Evan’s blue  
 MMP-2,9 claudin-5 ↔ - albumin  
AD and VaD post-mortem 
human brains 
occludin ↑N;A;O - - Romanitan, 2007  
 post-mortem 
human brains 
claudin-2 ↑N;A;O (VaD) - - Romanitan, 2010  
  claudin-5 ↑N;A - -  
  claudin-11 ↑N;A;O (AD) - -  
Phosphorylation Rho-p ROCK160 
kinase 
occludin shift in bands p↑ horseradish 
peroxidase  
Hirase, 2001  
↑: upregulated; ↓: down regulated; ↔: unchanged; p: phosphorylation; -: not mentioned; * significant change. 
[Inflammatory pain]  
Acute: formalin; Short term: λ-carrageenan; Long term (chronic): complete Freund’s adjuvant (CFA)  
[Hypoxia] 
RP: reperfusion 
Gd-DTPA: gadolinium- diethylenetriaminepentaacetic acid, contrast agent for MRI 
[AD and VaD] 




Chapter 3 Patient Recruitment and Image 
Segmentation Main Methods 
This chapter describes the methods used for evaluating the best method for 
analysing white matter hyperintensities (WMH) and other tissue volumes 
(such as cerebral atrophy and stroke lesions) in cross-sectional and 
longitudinal studies and trials of patients with small vessel disease (SVD) – 
either lacunar stroke or silent SVD features. The analysis used data from a 
longitudinal study of lacunar stroke mechanisms, the Mild Stroke Study 
(MSS). A brief description of the patient recruitment and selection into the 
MSS is given here, followed by the image processing steps that were tested. 
3.1 Patient recruitment into MSS and subgroups 
The recruitment for the MSS was prospective and as consecutive as possible. 
We prospectively recruited 275 patients with clinical features of acute 
lacunar stroke and mild cortical stroke (as controls) in a large academic 
teaching hospital between January 2005 and July 2007 for a study of stroke 
mechanisms, the Mild Stroke Study. Cortical stroke patients were chosen as 
controls because they have a different stroke mechanism (mostly), and 
control for having a stroke, risk factor profiles, and secondary stroke 
prevention medications (Doubal et al., 2010b; Wardlaw et al., 2009).   
We included patients who had a definite diagnosis of lacunar or mild cortical 
stroke within three months of symptom onset. We classified the subtypes of 
lacunar and cortical strokes based on the clinical sympotoms and signs, then 
on the imaging findings, using risk factor free stroke subtyping (see below). 
All patients underwent usual investigations for stroke cause (carotid Doppler 




Diagnostic magnetic resonance imaging (MRI) at presentation was 
performed on a 1.5-Tesla magnetic resonance scanner (Signa LX; General 
Electric, Milwaukee, WI) with 22mTm-1 maximum-strength gradients. 
Sagittal T1-weighted (T1W) and axial T2-weighted (T2W), diffusion-
weighted imaging (DWI), fluid-attenuated inversion recovery (FLAIR), and 
gradient-recalled echo (GRE) sequences were performed (parameters shown 
in Table 3.1). 
Table 3.1 MRI scan parameters used in the Mild Stroke Study (baseline)  








T2W 102 6300 5 1.5 256 x 256 24 x 24 - 
T1W Min 450 5 1.5 256 x 224 24 x 24 - 
FLAIR 140 9000 5 1 256 x 224 24 x 24 - 
GRE 15 625 5 1.5 256 x 192 24 x 24 20o 
TE, time to echo; TR, time to repetition; T2W, T2-weighted imaging; T1W, T1-weighted 
imaging; FLAIR, fluid attenuated inversion recovery; GRE, gradient-recalled echo. 
 
A trained stroke physician assessed all patients and defined the clinical 
stroke subtypes according to the Oxfordshire Community Stroke Project 
classification (Bamford et al., 1991). Lacunar stroke was defined as pure 
motor disorder and/or sensory loss, or ataxic hemiparesis and mild cortical 
stroke was defined as being equivalent to a partial anterior circulation stroke, 
including cortical symptoms or signs. The definition did not take account of 
risk factors. Following initial clinical classification, radiological classification 
of stroke subtype was defined by location of the recent infarct using 
diagnostic MRI; primarily diffusion imaging than the other sequences. Both 
the clinical and radiological classifications were used to decide the final 
stroke subtype classification. When its clinical characteristics subtyped 




diagnosis was ‘cortical’, and vice versa. This misdiagnosis that about 20% of 
cortical infarcts are misdiagnosed clinically as lacunar infarcts and vice versa, 
probably accounts for ‘noise’ in previous clinical-imaging dissociation 
studies (Potter et al., 2010a). 
We recorded patients’ age, gender, weight, race, vascular risk factors (history 
of hypertension, smoking, diabetes, alcohol use and so forth), severity of 
stroke (National Institutes of Health Stroke Scale), ischemic heart disease, 
peripheral vascular disease, or transient ischemic attack and drug treatment 
before the stroke. All patients included in the study have stable blood 
pressure, hypertensive patients have their blood pressure well controlled 
with antihypertensive medication and patients with unstable or untreated 
hypertension were excluded. Patients with unstable medical conditions or 
contraindications to MRI, and severe stroke or hemorrhagic stroke were 
excluded. Further details of patients’ clinical characteristics related to each 
topic in Chapter 5 and 8 will be provided in these chapters. 
The study was approved by the Lothian Research Ethics Committee 
(2002/W/RA/03) (Wardlaw et al., 2013a) and all participants gave written 
informed consent. 
A subset of 100 patients without impaired renal function agreed to take part 
in a study using contrast enhanced MRI to assess blood brain barrier (BBB) 
permeability changes in lacunar versus cortical stroke. This second scan 
(permeability scan) was taken between at least one and three months after 
the diagnostic scans mentioned above to avoid any possible permeability 
alterations caused by the acute effects of the stroke. The T10 sequence with 




acquisition was repeated 26 times with acquisition time of 69s after injection 
sequentially after intravenous injection of 40 ml gadodiamide (Omniscan; GE 
Healthcare AS, Oslo, Norway) (Armitage et al., 2011; Wardlaw et al., 2009). 
For the 100 patients,  the acquisition  of permeability images failed for three 
patients for the following reasons: (1) Injector problem: injected 15ml of 
contrast agent rather than 40ml; (2) Contrast didn't enter blood stream for 
unknown reason; (3) Images missed the bottom of the brain due to 
radiographic error. 
From the 97 patients who had successful contrast enhanced MRI BBB 
sequences  (51 lacunar stroke and 46 with cortical stroke), 46 of them 
returned after a median of 39 months (IQR 30–45 months, between July and 
September 2009) for follow-up scanning (22 with the original diagnosis of 
lacunar stroke and 24 with the original diagnosis of cortical stroke). We 
performed MRI on the same 1.5-T Magnetic Resonance (MR) scanner with 
sagittal T1W and axial T2W, FLAIR and GRE sequences as obtained at 
baseline (parameters in the Table 3.2, slight differences were due to MR 
scanner upgrade that occurred in intervening period). 
Table 3.2 MRI scan parameters used in the Mild Stroke Study (follow-up)  








T2W 140 5000 5 1.5 384 x 384 24 x 24 - 
T1W Min 560 5 1 384 x 224 24 x 24 - 
FLAIR 140 9000 5 1 384 x 224 24 x 24 - 
GRE 15 625 5 1 384 x 224 24 x 24 20o 
TE, time to echo; TR, time to repetition; T2W, T2-weighted imaging; T1W, T1-weighted 





Eight of these 46 patients that had follow-up scans were selected to represent 
a full range of WMH and brain structural changes for a pilot study of image 
processing methods for this thesis (described in Chapter 5). In this pilot 
study, we explored seven different ways to find a reliable method that could 
measure the WMH at both time points consistently, and would be suitable to 
measure the longitudinal WMH change in the 46 patients with follow-up 
scans. By analysing and comparing the results, we were seeking the most 
accurate and least time-consuming method which could be applied to larger 
samples. 
The patient recruitment process and patient subgroups in image analysis 






Figure 3.1 Summary of MSS patient recruitment process and patient subgroups in 
imaging analysis.  
ICV: Intracranial volume, CSF: cerebrospinal fluid, WMH: white matter hyperintensities, 
PVS: perivascular spaces. 
 
3.2 Basic imaging processing steps 
All image processing was performed blind to all clinical and other imaging 
data. Baseline and follow-up images were analyzed separately and blind to 
each other’s results. The intracranial volume (ICV), index stroke lesions, any 
old infarcts including lacunes at baseline and new cortical or subcortical 
stroke lesions appearing at follow-up were manually outlined (masked) in 





3.2.1 ICV segmentation 
The ICV segmentation includes extracting the brain mask using the ‘Object 
Extractor’ module and modifying it using the ‘Region of Interest’ module in 
Analyze™ 9.0 software, based on GRE images (Figure 3.2).  
 





The ICV segmentation process includes: 
(1) Slice selection   
(2) Threshold selection  
(3) Brain mask extraction 
(4) Save brain mask object map  
(5) Load image and brain mask 
(6) Change the name and colour (name: ICV; colour: red)  
(7) Edit and save the ICV mask 
(8) Calculate the volume of the ICV mask 
(9) Save the ICV mask in the AnalyzeImage (7.5) format 
A detailed ICV segmentation manual is in the Appendix (B-1). 
3.2.2 Stroke Segmentation 
We manually outlined the stroke mask on the FLAIR image using the ‘Image 
Edit’ module, guided by DWI and T2W images based on the region-growing 
algorithm based in Analyze™ 9.0 software. The stroke segmentation 
included: 
(1) Slice selection   
(2) Adjust threshold in the ‘Auto Trace’ tool 
(3) Select ‘Delayed Flood Fill’ tool 





3.3 Testing seven MRI image processing methods for 
measuring WMH in eight patients 
We systematically searched and reviewed the literature seeking reliable 
methods for segmenting WMH. Most studies used multiple sequences and 
semi-automatic segmentation. Although the criteria for selecting the 
optimum threshold varied, in general, the use of descriptive statistics of the 
signal intensity in lesions as opposed to normal-appearing regions was a 
common approach. Semi-automatic methods used two or more sequences 
and a clusterisation algorithm. Some studies considered intensity adjustment 
and correction of inhomogeneities in the magnetic field as pre-processing 
steps before the actual segmentation while others did not. 
We grouped these alternatives into seven approaches using the method 
described in Ferguson’s paper (Ferguson et al., 2005) for thresholding  and 
the technique described in Hernandez’s paper (Hernandez Mdel et al., 2010) 
as the semi-automatic clustering method – as we had found it performed 
better than other clustering methods in previous analysis (Valdes Hernandez 
Mdel et al., 2011). We tested these seven methods (Figure 3.3) in eight 
representative patients to find the most accurate method visual inspection 
and least time-consuming alternative for measuring WMH volumes on the 
baseline and follow-up scans, and for determining the longitudinal WMH 
change. The stroke lesions (including the acute lacunar or cortical stroke 
lesions and any old stroke lesions) were excluded from the WMH lesion 
volume to avoid changes in stroke lesions distorting the WMH volume 
measurement at both time points and the WMH change (Results in chapter 5) 




The following section would describe the technical aspects of different 
approaches and imaging processing steps we compared. 
Thresholding Method  
The thresholding method was implemented using FLAIR images and 
Analyze™ 9.0 software (Mayo Clinic, Rochester, MN). Thresholds for WMH 
and stroke lesion masks were obtained separately using a region-growing 
algorithm based on the pixel intensity in the FLAIR images.  The threshold 
was achieved by placing four regions of interests (ROI) squares in the normal 
appearing white matters anterior to the frontal horn of the lateral ventricles 
on two consecutive slices (5mm X 5mm per each square; two squares 
bilaterally on one slice; the other two squares bilaterally on the consecutive 
slice). The mean intensity and standard deviations (SDs) of those four ROI 
squares was measured.  
Threshold= mean intensity + 6*SDs                                                     equation 1 
Previous studies of Framingham Offspring Cohort determined their effective 
thresholds in WMH measurements as 3.5 SDs in pixel intensity plus the 
mean intensity of brain parenchyma based on the summed images of first 
and second echo images from T2 sequences (Atwood et al., 2004; Jeerakathil 
et al., 2004). We modified it into 6 SD based on tests of WMH intensity on 
FLAIR images (equation 1). Thresholds obtained from this equation suited 
most cases. Because the threshold increased with severity of WMH loads, in 
cases with high WMH loads, signal heterogeneity increased in normal 
appearing white matter which we used to calculate the threshold. So in cases 




underestimation in lesion volumes, so for those cases we needed to adjust the 
threshold. 
MCMxxxVI Method  
The multispectral method  (MCMxxxVI), all the hyperintense lesions (WMH 
and any old or new stroke lesions) were selected in the combined FLAIR and 
GRE images based on colour fusion technique (Hernandez Mdel et al., 2010), 
and the stroke lesions and the false positive WMH (see Chapter 4, WMH 
artefacts) were manually removed from the total hyperintensive volume as a 
post-processing step. WMH masks were saved in the Analyze image format 
and the lesion volumes were saved in a spreadsheet. We segmented WMH at 
both time points using each of the seven methods. WMH volume differences 
were calculated by subtracting the baseline WMH volume from the follow-
up WMH volume. 
The seven tests of MRI image processing methods for measuring WMH was 
based on thresholding and MCMxxxVI method mentioned above. We tested 
the efficiency of thresholding and MCMxxxVI methods using original images 
(Experiment 1 and 4), bias field corrected images (Experiment 2 and 5) and 
intensity adjusted images after histogram equalization (Experiment 3 and 6). 
Intensity adjusted images after regression analysis was also tested using 
MCMxxxVI method (Experiment 7). We summarized images, methods and 
the name of the seven testing experiments in the figure below (Figure 3.3) 





Figure 3.3 Testing of seven WMH segmentation experiments.   
h: histogram equalization; r: regression analysis. 
 
Experiment 1: testing the original images (Thresholding 
method) 
We measured the WMH and stroke lesion volume at baseline and follow-up 
using Analyze 9.0 independently. The WMH segmentation steps in the 
threshold method include: 
(1) Load original FLAIR image in Analyze™ 9.0 software workspace 
(2) Place four ROI squares in the normal appearing white matters anterior to the 
frontal horn of the lateral ventricles on two consecutive slices (details were 
described in the ‘Thresholding Method’ above). 
(3) Calculate mean intensity and SDs of those four ROI squares. 
(4) Add seed in the WMH lesions and set the intensity of “Threshold= mean 




(5) Create a WMH object map and measure the WMH volume in all slices  
(6) Save the WMH object map 
Steps for stroke lesion segmentation are similar to the measurement of WMH 
segmentation, the only difference being to add the seeds in stroke lesion in 
step (4). 
Experiment 2: testing the bias field corrected images 
(Thresholding method) 
In order to test the effect of bias field correction algorithm in the threshold 
method, we used the method described in the paper (Guillemaud and Brady, 
1997) to remove the bias field influence on the original FLAIR images and 
saved the parameters. We then changed the original FLAIR images into the 
bias field corrected FLAIR images, and repeated WMH segmentation steps in 
the threshold method listed in Experiment 1. 
Experiment 3: testing the intensity adjusted images after 
histogram equalization (Thresholding method) 
We  adjusted the intensity of  the original FLAIR images using MATLAB 
‘histogram equalization’ algorithm script (Seul et al., 2000) by eliminating 1% 
data near the minimum intensity and 1% data near the maximum intensity, 
and stretching the rest of the intensity values of input image to new values. 
Therefore, we increased the output image contrast (Seul et al., 2000). We then 
repeated the WMH segmentation steps in the threshold method listed in the 
Experiment 1 using intensity adjusted images after histogram equalization.  
Experiment 4: testing original images (MCMxxxVI method) 
We need to register images, fuse FLAIR and GRE images, segment 




Analyze™ 9.0 software before the WMH segmentation using the MCMxxxVI 
method. 
Stage I-Image Registration 
We registered FLAIR and GRE images to the permeability image using the 
ANALYZE 9.0 ‘3-D Voxel Registration’ module, which allowed us to 
spatially register two volume images based on the Normalized Mutual 
Information algorithm. For the 3 cases which failed in the permeability scan, 
we registered FLAIR and GRE to T2W image (Figure 3.4). 
 





The volume registration process is as follows:  
(1) Intensity adjustment 
(2) 3D-voxel registration 
(3) Save transformed image 
(4) Manual registry for unsuccessful automated registration  
A detailed manual of image registration are in the Appendix (B-2).  
Stage II-Fuse images 
We fused FLAIR and GRE images using the ‘3-D Surface Registration’ 
module in Analyze™ 9.0 software, the image combination includes following 
steps: 
(1) Intensity adjustment 
(2) 3D-surface registration 
(3) Save the combined images of FLAIR and GRE as input images for 






Figure 3.5 Image combination of FLAIR and GRE images using Analyze™ 9.0 software.  
Base image: FLAIR image (Left), Match image: GRE image (Right), Combined image of 
FLAIR and GRE images (Middle). 
 
Stage III-ICV Segmentation  
Refer to the ICV segmentation steps in the previous section ‘3.2 Basic 
imaging processing steps-ICV segmentation’. 
Stage IV-Stroke Segmentation 
Refer to the ICV segmentation steps in the previous section ‘3.2 Basic 
imaging processing steps-Stroke segmantation’. 
Stage V-CSF Segmentation 
We segmented the CSF mask using the MCMxxxVI method, the 




(1) Load fused images saved and ICV mask generated from from previous steps 
(Figure 3.6 graphical interface of MCMxxxVI method) 
(2) Press ‘Load and Segment’ 
(3) Change the ‘Red’ from ‘1’ to ‘255’ and adjust the ‘Green’ from ‘1’ to ‘n’ (n is 
the threshold selected)  
(4) Press ‘Extract tissue’ 
(5) Remove false positive CSF in the brain tissue (Figure 3.7) 
(6) Save the final CSF and brain parenchyma binary masks and numerical 
results 
 






(A)                                         (B)                                         (C)                                          
 
(D)                                         (E)                                         (F)                                          
Figure 3.7 Removing of false CSF in MCMxxxVI method.  
Upper row: CSF mask before false CSF removement. (A) Fused image of FLAIR and GRE; (B) 
Binary mask of CSF mask; (C) CSF mask on fused image, white arrows point to false CSF 
regions. Lower row: after the removement. (D) Fused image of FLAIR and GRE; (E) Binary 
mask of CSF mask; (F) CSF mask on fused image.  
 
Stage VI-WMH Segmentation 
We segmented the WMH mask using the MCMxxxVI method, the 
segmentation process includes: 
(1) Load fused images saved from Stage II and brain parenchyma mask 
generated from Stage V 
(2) Press ‘Load and Segment’ 
(3) Adjust the ‘Red’ and ‘Green’ values 
(4) Press ‘Extract tissue’ 
(5) Remove false positive WMH and the stroke lesions 




The whole multi-stage image processing (Figure 3.8) was performed blind to 
all clinical data. Baseline and follow-up images were analyzed separately and 
blind to each other’s results.  
 
Figure 3.8 Flow process diagram of a multi-stage segmentation.  
Abbreviations: FLAIR, fluid attenuated inversion recovery image; GRE: gradient echo image; 
ICV: intracranial volume; CSF: cerebrospinal fluid; TL: total lesions; WMH, white matter 
hyperintensities. 
 
Experiment 5: testing the bias field corrected images 
(MCMxxxVI method) 
We fused the bias field corrected FLAIR and GRE images (described in 
Experiment 2) and repeated the WMH segmentation steps in the MCMxxxVI 
method listed in Experiment 4. 
Experiment 6: testing the intensity adjusted images after 
histogram equalization (MCMxxxVI method) 
We fused the FLAIR and GRE images after histogram equalization 
(described in Experiment 3) and repeated the WMH segmentation steps in 




Experiment 7: testing the intensity adjusted images after 
regression analysis (MCMxxxVI method) 
Colour fusion was thought to be dependent on the relative contrasts of the 
fused sequences rather than on the parameters of the acquisition protocols. 
We aimed to test this hypothesis in a pilot study of 100 scan sets randomly 
selected from the LBC1936 participants (Deary et al., 2007) in The 
Disconnected Mind Study (http://www.disconnectedmind.ed.ac.uk), we did 
a regression analysis to derive the relationship between the initial and final 
intensity ranges after visually adjusting the intensity range in the FLAIR and 
GRE images. As a result, we found that the final FLAIR intensity range 
(equation 2) depends on the initial GRE intensity range, and that the final 
GRE intensity range (equation 3) depends on the final FLAIR intensity range. 
The associations are expressed in the following equations: 
FLAIR final=545.3365+0.8158*GRE initial                                                              equation 2    
GRE final=674.5948+0.4061*FLAIR final                                                                 equation 3  
After automatically adjusting the intensities of the FLAIR and GRE images, 
we fused the intensity adjusted FLAIR and GRE images and repeated the 





3.4 Comparison of results from seven WMH 
measurement experiments 
We had two image analysts testing our seven experiments. Analyst 1 
performed all seven experiments, and analyst 2 repeated experiments 4 and 
6. Though eight patients were not powerful enough to do a statistical 
analysis, the aim of this pilot study using eight patients was to find a sensible 
and reasonable method for analysing WMH longitudinal change which was 
the most accurate and least time-consuming method. Since there was no gold 
standard method we could refer to, we mainly evaluated the efficiency of 
method by segmentation time and visual inspection of image and 
segmentation results.  
The WMH segmentation by the MCMxxxVI method (Experiment: E, E4 to 
E7) took 20 to 30 minutes per case, and this method used less time than the 
thresholding method (E1 to E3), which took approximately 40 to 90 minutes 
per case.  
By visual inspection, the overall image appearance after intensity adjustment 
(E6 and E7 ) did not show as good resolution and contrast as original image 
or image after bias field correction (E4 and E5) and brought more difficulties 
in the process of WMH segmentation.  
Moreover, by visual inspection, all of eight patients had obvious WMH 
longitudinal progression when comparing WMH loads between baseline and 
follow-up scans. However, after subtracted baseline WMH volume from 
follow-up volumes, some of results from the five experiments (expect E4 and 






Figure 3.9 WMH volume change results from seven experiments, by two analysts.   
E: experiment, A: analyst. Blue: experiments using original images; Green: experiments 
using bias field corrected images; Orange: experiments using intensity adjusted images after 
histogram equalization; Purple: after regression analysis. Both round dots and diamonds 
were the results from analyst 1, round dots presented the results of thresholding method 
(analyst 1, E1-E3), and diamonds were results from MCMxxxVI method (analyst 1, E4-E7). 
Triangles are the results from analyst 2 (analyst 2, E4 and E6).  
 
Based on the results shown in Figure 3.9 and considering time 
consummation for each experiment, we decided to take forward the methods 
used in E4 and E5 for further testing to explain more about measuring WMH 






3.5 Longitudinal image analysis of 46 cases with follow-
up scans 
The method testing experiments above (Figure 3.9) showed that the 
MCMxxxVI method was effective and consistent for WMH segmentation, 
using both original images (E4) and bias field corrected images (E5). Thus, 
we measured the CSF and WMH volume of the 46 patients who had follow-
up scans using the MCMxxxVI method (E4 and E5) at both time points. 
In order to assess the effect of stroke lesions on WMH and brain atrophy 
progression we also needed the intracranial volume (ICV) mask and stroke 
lesion mask (any old infarcts including lacunes at baseline and new stroke 
lesions appearing during follow-up). Both the ICV and stroke lesion masks 
were manually outlined based on the threshold method on FLAIR in 
Analyze 9.0 software, guided by FLAIR, diffusion-weighted and T2-
weighted images. The whole multi-stage image processing (Figure 3.8) was 
performed blind to all clinical data. Baseline and follow-up images were 
analyzed separately and blind to each other’s results. We segmented both 
baseline and follow-up scans for the 46 cases, using the MCMxxxVI method 
with both the original images (as in E4) and bias field corrected images (as in 
E5). We analyzed the effect of stroke on WMH and atrophy progression 
using the results from E5 (Results in Chapter 5). We also summarised the 
locations and frequencies of WMH artefacts appearing in the FLAIR images 







3.6 Image analysis of the 100 patients baseline scans  
The image preprocessing step of bias field correction (BFC) helped to 
compress noise and uniform tissue density which theoretically helps WMH 
segmentation. The old version of the BFC software did so (Figure 3.10 A); E5 
was easier than E4 when doing the WMH segmentation. However, when we 
planned to use E5 to do WMH segmentation in the rest 54 patients of the 100 
patients who participated in the BBB permeability study and had the baseline 
diagnostic and permeability scans only, we found the BFC software had been 
updated and the new version caused image display problems. The new 
version BFC software included a smoothing effect which explicitly 
eliminated hyperintensitive lesions, both WMH and focal infarcts, which 
distorted the essence of image characteristics. Because of this problem, we 
decided to avoid using bias field corrected images in our further studies for 
the present time. So we chose to use E4 (original image) to segment the 
remaining 54 cases. If better bias field correction software becomes available 






Figure 3.10 Comparison of old and new versions of bias field correction (BFC) software.  
A: old version BFC software compressed noise and “uniformed” tissue signal. B: new 






From prior experience of image segmentation (above), we found it was 
redundant to segment the stroke mask in Stage IV using the Analyze 
software and to remove the stroke lesion as false positive in Stage V. 
Moreover, the stroke lesion mask segmentation by threshold method in the 
Analyze software is very time consuming (o.5h~1.5h per case). Therefore we 
optimized the steps in the segmentation process (Figure 3.11).  
 
Figure 3.11 Flow process diagram of an optimized multi-stage segmentation developed in 
the MSS suitable for analysis of WMH and brain tissues in patients with stroke. 
Abbreviations: FLAIR, fluid attenuated inversion recovery image; GRE: gradient echo image; 
ICV: intracranial volume; CSF: cerebrospinal fluid; TL: total lesions; WMH, white matter 
hyperintensities. 
 
The first three steps (Image Registration; Fuse images; ICV segmentation) 
were the same, with the optimization occurring in the last three steps. 
Instead of obtaining stroke mask and WMH mask separately (as described 
above), in the MCMxxxVI method, we included all voxels with 




(new Stage V). We then separated and modified the TL mask to a stroke 
mask and a WMH mask in the Analyze software (new Stage VI). The changes 
are as follows: 
new Stage IV-CSF Segmentation 
The same as Stage V described above, which we segmented the CSF mask 
using the MCMxxxVI method. 
new Stage V-TL Segmentation 
We segmented all the hyperintense areas (TL mask) using the MCMxxxVI 
method. The TL segmentation process included: 
(1) Load fused images and parenchyma mask generated above 
(2) Press ‘Load and Segment’ 
(3) Adjust the ‘Red’ and ‘Green’ values 
(4) Press ‘Extract tissue’ 
(5) Save the TL mask 
new Stage VI-Separation of WMH and strokes 
We separated the TL mask into a WMH mask and a stroke mask using the 
‘Region of Interest’ and ‘Image Calculator’ modules in the Analyze 9.0 
software. We used the FLAIR, diffusion-weighted and T2-weighted images 
as references while doing the separation. The separation process included: 
(1) Load FLAIR image and TL mask 
(2) Remove the stroke lesions in the ‘Region of Interest’ module, edit and save 
the WMH mask 
(3) Subtract WMH mask from TL mask in the ‘Image Calculator’ module 




The results for the 100 patients in the BBB permeability study with baseline 





Chapter 4 White matter hyperintensities (WMH) 
artefacts 
4.1 Introduction 
The fluid attenuated inversion recovery (FLAIR) magnetic resonance image 
(MRI) is sensitive to subtle white matter hyperintensities (WMH), and is 
commonly used in WMH studies. However, the artefacts caused by 
cerebrospinal fluid (CSF) and blood flow, patient movement, inhomogeneity 
of magnetic field, and magnetic susceptibility sometimes mimic pathological 
conditions, could distort the accurate measurement of WMH and further 
misrepresent WMH progression, associations with risk factors and other 
cerebral small vessel disease features. 
The history of studying WMH artefacts on MRI images is not long, only since 
1992, when MRI started to be used more for studies in ageing, dementia and 
stroke. There is a need for a focused summary of the types of WMH artefacts 
and methods to avoid them in the WMH segmentation process, which would 
be a useful guide in the future training of WMH segmentation and facilitate 
accurate WMH measurements.  
We aimed to summarize guidance in differentiating the white matter (WM) 
artefacts from WMH based on the published literature, especially on the 
FLAIR sequence which is commonly used to identify WMH. We also 
summarized the locations and frequencies of WMH artefacts in a cohort of 46 
patients with stroke and WMH, and we compared them with artefacts based 
on the literature. The summary of location and frequency of WMH artefacts 
in the literature and stroke patients would be a useful guidance for future 





4.2.1 Search strategy and study selection 
We searched the published literature from PubMed© and Medline© up to 
23rd January 2013. We searched the terms “Artefact FLAIR” and “Artefact 
FLAIR” using PubMed©; and we used exploded headings relating to WMH 
and Artefact using Medline©. We used a two-part search strategy: initially 
for artefacts seen on FLAIR images; then for artefacts specifically related to 
WMH. We also checked paper reference lists and comments for these papers. 
4.2.2 Inclusion and exclusion criteria 
We included full papers in English about human brain studies which 
assessed a variety of MRI artefacts (mainly on the FLAIR images) in various 
cerebral disease models, with high image qualities.  
We excluded studies published only in abstract, not published in English and 
duplicates. We excluded studies that only included animals as well as non-
cerebral disease studies because we wished to focus on studies of artefacts 
related to pathological changes in human brains. We excluded studies which 
used FLAIR image as a control evaluate a novel sequence, algorithm, 
diagnostic or measurement protocols which might mention artefact but not 
on FLAIR sequence. We also excluded studies used MRI images having low 
resolution, because their conclusions might be compromised by the poor 
image quality. 
4.2.3 Data extraction  
Firstly, I screened all papers’ titles and abstracts, and extracted data into an 




sequences used in studies, whether the study was about cerebrovascular 
disease, the main results and conclusion of the study.  
Based on the main results and conclusion, studies focusing on the 
appearance of image artefacts were included for further full paper 
assessment. Artefacts types and locations, study aim, disease type and 
patients number of were extracted after reading through full papers. For 
those studies evaluating a specific sequence to reduce the image artefacts, 
whether the sequence was successful in reducing specific type of artefact, or 
contrarily increased the extent of artefacts was noted. We summarized 
artefact frequencies in the included literature. 
4.2.4 Summary of common artefacts in a cohort of stroke 
patients with WMH 
Independent of the literature searching described above, we summarized 
types and frequencies of WMH artefacts seen on the baseline scans of 46 
stroke patients   who returned for follow-up scans in the Mild Stroke Study 
permeability study (recruitment details in Chapter 3). We used baseline and 
follow-up images from these 46 patients to assess the effect of stroke lesions 
on WMH progression in the following chapter (Chapter 5). 
All slices on FLAIR sequences in each patient were reviewed, and images of 
tissues with doubtful artefacts were saved into several categories (such as 
hyperintensities near ventricles, bilateral corticospinal tract hyperintensities, 
and patient movement) mainly based on their location.  These WMH 
artefacts categories were reviewed and advised by an experienced 





We compared types, locations and frequencies WMH artefacts in the 46 
stroke patients with the results from our literature searching, and 
summarized types of artefacts mentioned in the previously published 
literature which also appeared in our study into a training guide for WMH 
segmentations. 
4.2.5 Feedback from WMH segmentation training 
Two image analysts have been trained with aid from our WMH artefacts 
guide in their WMH segmentation training (see Appendix C: WMH artifacts 
training guide). They provided feedback on the usability and 






4.3.1 Artefact characteristics from the included literature 
In addition to the 26 studies fitting our criteria, we included two more 
studies found from searching the reference lists of the literature, thus in total 
we included 28 studies (Figure 4.1) exploring the FLAIR artefacts in a variety 
of brain diseases, such as white matter lesions in multiple sclerosis 
(Bachmann et al., 2006; Sled et al., 1998), stroke (Willinek et al., 2003), 
subarachnoid hemorrhage (Wiesmann et al., 2002), epilepsy (Phal et al., 2008) 
and tumors (Oatridge et al., 2001; Von Kalle et al., 2010), as well as healthy 
and normal brains. In the 28 studies, four studies did not specify their patient 
characters such as number or disease type; the other 24 studies in total 
included 1044 participants, with a minimum sample size of four patients, a 






Figure 4.1 Flowchart of artefact searching strategy.   
Grey lines and boxes indicate excluded studies and primary reasons. Black lines and boxes 




Table 4.1 Descriptions of 28 included studies arranged by published date.  
In the results column “↓” means artefacts decreased, “↑” means increased, and “↔” means no change. 
Author, year  Artefacts mentioned Sequence detail Effect on artefacts Patient type Patient 
Number 
Gawne-Cain, 1997 CSF flow FLAIR: normal and disease appearance normal brain  40 
Sled, 1998 Inhomogeneity N3:bias field correction ↓ MS (WML) 12 
Bakshi, 2000 CSF flow Ventricles artefacts appearance normal brain 100 
Tanaka, 2000 CSF flow FAIS ↓ posterior fossa disease 20 
Hajnal, 2001 CSF flow adiabatic inversion ↓ Not mentioned 4 
Oatridge, 2001 Patient movement KRISP ↔ gliomas 14 
 CSF flow & Blood flow KRISP ↓   
Herlihy, 2001 CSF flow & Blood flow KRISP ↓ a variety of brain disease 20 
 Patient movement KRISP ↑   
Curati, 2001 CSF flow & Blood flow KRISP & adiabatic KRISP  ↓ established disease 10 
Herlihy, 2001 CSF flow & Blood flow KRISP ↓ suspected disease 10 
Kallmes, 2001 CSF flow 3D ↓ healthy 7 
Wu, 2002 CSF flow Fast ↓ Not mentioned 377 
Wiesmann, 2002 CSF flow PD-weighted ↓ SAH 13 
Willinek, 2003 Patient movement SENSE ↓ cerebral ischemia (stroke) 62 
 Inhomogeneity SENSE ↓   
Aprile, 2003 CSF flow  MTC ↓ a variety of brain disease 50 
Naganawa, 2004a CSF flow  3D ↓ healthy; MS; tumor 11 
Naganawa, 2004b CSF flow 3D-TSE-VFL  ↓ a variety of brain disease Not 
mentioned 
 Metal 3D-TSE-VFL  ↓   
Bachmann, 2006 CSF flow 3T ↑ MS (WML) 22 
Cianfoni, 2006 Patient movement SS-FSE-FLAIR ↓ free healthy; SAH patients 32 





      
Lisanti, 2007(Lisanti 
et al., 2007)(Lisanti et 
al., 2007)(Lisanti et 
al., 2007) 
CSF flow CSF artefact mechanism  Not mention a variety of brain disease Not 
mentioned 
Stuckey, 2007 CSF flow & Blood flow subarachnoid space Not mention a variety of brain disease Not 
mentioned 
 Metal     
 Patient movement     
Phal 2008 Patient movement 3T ↔ epilepsy 25 
Neema, 2009 CSF flow normal findings 3T  appearance healthy 22 
Alkan, 2009 Patient movement BLADE ↓ tumor 50 
 CSF flow BLADE ↓ free   
Von Kalle, 2010 Patient movement BLADE ↓ white matter abnormalities 
in tumor 
26 
 CSF flow BLADE  ↓   
Lummel, 2011 CSF flow 3D-Cube ↓ healthy; epilepsy; SAH 25 
Nyberg, 2012 Patient movement BLADE ↓ Not mentioned 25 
Lavdas, 2012 Patient movement BLADE ↓ uncooperative; 67 
 CSF flow  T2 FLAIR BLADE ↓ cooperative  
Abbreviations 
CSF: cerebrospinal fluid; SAH: Subarachnoid hemorrhage; MS: multiple sclerosis; WML: white matter lesions. FLAIR: fluid attenuated inversion 
recovery; N3: as nonparametric nonuniform intensity normalization; FAIS: flow artefact–insensitive; KRISP: k-space reordered by inversion time at 
each slice position; 3D: three-dimensional; PD: proton-density; SENSE: sensitivity encoding; MTC: magnetisation-transfer contrast; 3D-TSE-VFL: 3D 
imaging with a turbo spin-echo sequence with variable flip-angle echo trains; BLADE: a PROPELLER equivalent implementation of the Siemens 




The terms for describing the same type of artefact varied substantially 
between studies. For example, the CSF flow artefact used in Table 4.1 is also 
named as artefact caused by CSF inflow (Naganawa et al., 2004b), CSF 
motion (Aprile et al., 2003), CSF pulsation (Bakshi et al., 2000), pulsatile CSF 
flow (Cianfoni et al., 2006), pulsative flow (Lavdas et al., 2012) and motion-
related phenomena of CSF (Lisanti et al., 2007) in the studies. And the patient 
movement artefact used in Table 4.1 is also named as motion artefact (Lavdas 
et al., 2012), artefact caused by patient motion (Cianfoni et al., 2006; Curati et 
al., 2001; Herlihy et al., 2001a), head movement (Cianfoni et al., 2006) and eye 
movement (Stuckey et al., 2007). This amount of variation inhibits cross-
study comparisons, so we unified terms after as terms we used in Table 4.1. 
We avoided using the word ‘motion’ alone to describe artefact, because this 
word causes confusion, it could either be the artefact caused by patient 
movement and by CSF or blood movement, so we specify these different 
types of artefacts as ‘Patient movement’, ‘CSF flow’ and ‘CSF and blood 
flow’. 
There is a high interest (23/38) in studying the methods to reduce the 
artefacts. Twenty-two studies tried different imaging techniques to reduce 
flow artefacts, movement artefacts, inhomogeneity of magnetic field and 
metal artefacts. And one study improved the image processing algorithm to 
reduce the inhomogeneity artefacts. 
Sequences such as flow artefact–insensitive (FAIS) (Tanaka et al., 2000), 
adiabatic inversion (Hajnal et al., 2001), k-space reordered by inversion time 
at each slice position (KRISP) (Curati et al., 2001; Herlihy et al., 2001a; 
Herlihy et al., 2001b; Oatridge et al., 2001), three-dimensional (3D), Fast, 




imaging with a turbo spin-echo sequence with variable flip-angle echo trains 
(3D-TSE-VFL) (Naganawa et al., 2004a), a PROPELLER equivalent 
implementation of the Siemens Medical System (BLADE) and 3D-Cube 
techniques have all shown the benefits in reducing CSF/blood flow artefacts. 
When the magnetic field is increased to three teslas (3T), the flow artefacts 
increased as well. SENSE, BLADE and SS-FSE-FLAIR techniques reduce 
patient movement artefact, whereas the movement artefact remains the same 
or even get worse with the KRISP technique. Increasing the magnetic field to 
3T instead of 1.5T did not influence patient movement artefacts. 3D-TSE-VFL 
technique is useful in reducing the magnetic susceptibility caused by metal, 
and SENSE technique is useful in reducing the inhomogeneity of magnetic 
field. The N3 (nonparametric nonuniform intensity normalization) method is 
useful to eliminate the bias field. 
The most frequent artefact was CSF flow artefacts, in 23 of the total 28 
studies, and the second most frequent artefact is caused by patient 
movement (details in Table 4.2). Blood flow artefact, inhomogeneity artefact, 
and metal artefact are also included. 
Table 4.2 Artefact frequency in the included literature.  
Artefact Type Number of studies (frequency) 
CSF flow 23/28 (82.14%) 
Blood flow 5/28 (17.86%) 
Patient movement 10/28 (35.71%) 
Metal 3/28 (10.71%) 
Inhomogeneity 2/28 (7.14%) 
 
4.3.2 Frequencies of artefacts in the 46 patients 
As we found in Table 4.1 and 4.2, most literature described WMH artefact by 




artefact type during WMH segmentations, but we feel it is generally harder 
to distinguish the WMH from normal appearing white matter tissues near 
ventricles, insular cortex and white matter tracts, so we summarized WMH 
artefacts by their locations in the 46 stroke patients following the sequence 
from the bottom to the vertex of the brain.  
In order to describe each artefact type without confusion, we combined the 
information of both the type and location of artefact, and number them 
separately for convenience of artefact frequency analysis (Table 4.3). For 
example, CSF flow artefacts are numbered as N1 to N4 according to their 
locations in the fourth ventricle, bilateral sylvian fissures, third ventricle and 
lateral ventricles. And patient movement have been divided into head 
movement (N7) and eye movement (N8). The artefact in the white matter 
tracts only appeared in one article (Neema et al., 2009), but it is quite 
frequent in our analysis, so we number it as N5.  
Table 4.3 WMH artefact number used in 46 patients. 





fourth ventricle; aqueduct;  
cistern ventral to 
mesencephalon 
N1 (Alkan et al., 2009; Bailey, 2007; 
Bakshi et al., 2000; Kallmes et 
al., 2001; Lummel et al., 2011; 
Stuckey et al., 2007) 
CSF flow  
 
bilateral sylvian fissures and 
insular cortex 
N2 (Naganawa et al., 2004b; Neema 
et al., 2009) 
CSF flow  
 
third ventricle N3 (Bakshi et al., 2000; Lummel et 
al., 2011; Neema et al., 2009) 
CSF flow  
 
lateral ventricles N4 (Bakshi et al., 2000; Lummel et 




white matter tracts N5 (Neema et al., 2009) 
Inhomogeneity inhomogeneity of magnetic 
field 
N6 (Willinek et al., 2003) 
Patient movement  eye movement N7 (Stuckey et al., 2007) 
Patient movement  head movement N8 (Alkan et al., 2009; Nyberg et 




Within the 46 patients, artefacts N1 to N5, which are located in ventricles, 
cisterns, sylvian fissures and white matter tracts appeared frequently, in 
more than half of the patients. The artefacts in third ventricle and lateral 
ventricles showed in all 46 patients. The artefacts N6 and N7, which were 
caused by inhomogeneity of magnetic fields and eye movement occurred in 
less than two patients, so were infrequent artefacts. The artefact caused by 
patient head movement (N8) did not appear frequently, but could have large 
influence of all MR slices. A whole group and individual patient artefact 
frequency summary, for the artefacts with high frequency or high influence 
in the 46 patients are summarized below (Table 4.4). 
Table 4.4 Frequencies of highly frequent or influential artefacts in the cohort of 46 
patients and in individual patient, and the frequencies of real lesions in common place of 
artefacts. 
TYPE Frequency in 46 
patients (pts) 
Frequency in individual 
patient (number of slices) 

























hard to distinguish: need 







hard to distinguish: need 
















hard to distinguish, 
limited by image quality 
 
Ventricles, fissures and white matter tracts are frequent places for artefacts, 
but real lesions also occur in these places, and need to be distinguished from 
artefact by reference to DWI, other sequences, and going through each 









Real lesions appeared in the cisterns, sylvian fissures and white matter tracts. 
For the third ventricle and lateral ventricles, there is no standard to 
distinguish artefacts from real lesions; we kept excluding the hyperintensities 
in those two places consistently (Table 4.4). 
4.3.3 Three kinds of artefact-linked image features not 
mentioned in previous studies 
There were three kinds of artefact-linked image features (Figure 4.3): Q1, 
hyperintensive circle around the whole skull; Q2, ‘dirty white matter’, are 
diffuse white matter lesions which are highly influenced by subtle changes in 
threshold applied; Q3, hyperintensive dots above the lateral ventricles. Q2 
appeared frequently in more than half of the patients, and Q1 could influence 
more than half of the slices, details summarized in Table 4.5. 
 
Figure 4.3 Three kinds of artefact-linked image features (Q1-Q3) showing in the 46 




Table 4.5 Frequencies of three kinds of artefact-linked image features in the cohort of 46 
patients and in individual patient. 
TYPE Frequency in 46 patients Frequency in individual 
patient (number of slices) 
Q1 
bright skull circle 
4/46 (pts) 
8.70% 
3/30~ 15/30 (slices) 
10.00%~50.00% 
Q2 












4.3.4 Feedback of WMH segmentation training guide 
Two image analysts found this WMH artifacts training guide (Appendix C) 
very illuminating and helpful to decide about the WMH and artefacts 
especially when they found similar cases as the examples we gave in the 
guide. They also found it quite hard to decide about what to include when 






In the systematic searching and literature summary, I found it hard to extract 
information when different research group used slightly different terms to 
describe what appeared to be the same artefact, as there were at least seven 
different terms in describing the CSF flow artefacts and five for patient 
movement. We need to be consistent in the WMH artefact terminology and 
definitions. The term ‘motion’ should be avoided if used alone, because it 
could be either be artefacts caused by CSF or blood flow or patient 
movement, and people should make which of these they meant clear when 
using ‘motion’. The term ‘ghosting effect’ also appeared quite often in the 
published literature and (while in common use to mean for example an 
image of the eyes outside the skull due to eye movement) should be avoided 
in the future since it lacks specificity of artefact origins or characteristics.  
One literature by Gawne-Cain (Gawne-Cain et al., 1997) suggested standards 
to differentiate WMH from artefacts in the posterior internal capsule and 
posterior cerebral peduncles; pons and posterior centrum semiovale; anterior 
caps; periventricular lines; posterior caps and occipital white matter. 
However, we still need to investigate more in order to set a gold standard in 
excluding artefacts, for example in Gawne-Cain’s paper, they considered 
hyperintensities less than 5 mm in anterior ventricular caps as artefacts even 
when they are asymmetrical. It was doubtful that in Bailey et al. (Bailey, 
2007) considered WMH in the posterior horns of the lateral ventricles as 
‘shine through’ artefact, which seemed to be real lesions from the example 
figure they provided in the paper. In the literature, Erasmus et al. (Erasmus 




not include it since it is one of the common scenario on MRI and could not be 
avoided, and we need to stay as consistent as possible in tissue decision. 
A variety of sequences and algorithms had been developed to deal with CSF 
and blood flow artefacts, movement artefacts, inhomogeneity of magnetic 
field and metal artefacts, and not all of them were successful. For example, 
though high magnetic field was successful in increasing image quality and 
improving some details on MRI, the acquisition time was longer and the 
artefacts were more pronounced which lead to little net benefit on diagnosis 
(Bachmann et al., 2006; Wardlaw et al., 2012).  
Our WMH artefact results are consistent with the published literatures; CSF 
flow artefacts were the most frequent artefacts, which influenced large areas 
in the brain such as ventricles, cisterns, sylvian fissures and white matter 
tracts. Patient movement is another huge influencing factor in image quality 
and further distinguishing WMH. 
We had a fairly large sample size, larger than the median of the sample size 
in the literature. It is a representative cohort of stroke patients with WMH, 
which would be useful in identifying the WMH artefacts in the studies of 
SVD.   
Based on our WMH artefacts imaging summary generated in the 46 stroke 
patients, we selected examples of typical artefacts referring to previous 
published literatures (N1 to N8) and we added examples of real lesions 
which appeared in the same locations as typical artefacts. We also 
summarized three types of artefacts which had not been mentioned in 
previous publications (Q1 to Q3). We combined those image examples into a 




the WMH segmentation training. We suggested that new image analysts 
should use a reference image (e.g. the same FLAIR slice) when doing the 
segmentation, and they should check ‘tissue’ through slices and compare 
with the common artefacts in the guide when they were doubtful about the 
artefacts. We had generally positive feedbacks from analysts who used this 
WMH artefact guide, they found very it helpful. They also found the same 
experience that “hyperintensities on the edges of the brain” and “dirty WM” 
were hard to decide. 
Our literature review and artefact guide still has limitations and still needs 
improvements, because we only included the literature from the systematic 
search; other papers which describe WMH segmentation methods may also 
include some descriptions of artefacts, but were not included due to 
restricted time. However we think that we found the main artefacts and 





Chapter 5 Effect of stroke lesions on WMH and 
cerebral atrophy measurement 
5.1 Introduction 
White matter hyperintensities (WMH), lacunar strokes, lacunes and atrophy 
are all features of cerebral small vessel disease (SVD). They are related to 
cognitive impairment and dementia. Accurate volumetric measurement is 
essential when using these SVD features as outcome measures in clinical 
trials and observational studies relating to SVD mechanisms and clinical 
consequences such as cognition.  
As described in Chapter 1, 3 and 4, WMH have increased signal on T2-
weighted (T2W) and fluid attenuated inversion recovery (FLAIR) magnetic 
resonance imaging (MRI), and decreased signal on T1-weighted (T1W) 
relative to normal white and grey matter (Wardlaw et al., 2013c). Stroke 
lesions may have similar signal characteristics to WMH on several MR 
sequences. The similar signal characteristics of WMH and stroke lesions 
mean that the latter may accidentally be included when measuring the 
burden of SVD in the form of WMH volume using image processing 
algorithms, resulting in distortion of the WMH volume. 
Brain atrophy is associated with cognitive decline and dementia. Cerebral 
atrophy rates could be used as a surrogate marker to predict cognitive 
decline or monitor disease progression, and can be measured as brain 
volume decrease, or cerebrospinal fluid (CSF) increase, using serial 
registered MRI. Lacunes are subcortical rounded or ovoid cavities between 3 
and 15 mm in diameter with the same intensity as CSF on all brain scan 




distorted by tissue loss caused by focal tissue loss following stroke, either 
cortical or subcortical, by formation of, where replacement of damaged tissue 
by CSF, if included in the global brain volume measurement, would 
artificially inflate the brain atrophy measurement. 
In this study, we measured WMH, CSF, stroke lesions and lacunes separately 
and evaluated the effect of stroke lesions on baseline measurement of WMH 
volume and CSF, and the influence of stroke lesions on longitudinal 






We used imaging data from 100 patients described in Chapter 3, who were 
recruited prospectively in a study of stroke mechanisms with clinical features 
of a lacunar or mild cortical stroke and also participated in blood brain 
barrier (BBB) permeability study (Wardlaw et al., 2009). From the 100 
patients (51 lacunar stroke and 49 cortical stroke) who were recruited into the 
original study soon after presenting to hospital with an acute stroke, 46 
patients (22 with the original diagnosis of lacunar stroke and 24 with the 
original diagnosis of cortical stroke) returned after a median of 39 months 
(IQR 30 to 45 months) for follow-up scanning. All patients were assessed by a 
trained stroke physician and underwent diagnostic MRI with T1W, T2W, 
FLAIR, gradient recalled echo (GRE), and diffusion weighted imaging (DWI) 
as described in Chapter 3. About three years later, we repeated MRI on the 
same 1.5 T MR scanner.  
5.2.1 Image Processing and rating 
All image processing was performed blind to all clinical and other imaging 
data. Baseline and follow-up images were analysed separately. The 
intracranial volume (ICV), stroke lesions, old infarcts including lacunes at 
baseline and new cortical or subcortical stroke lesions appearing at follow-up 
were manually outlined (masked) on FLAIR, guided by DWI and T2W 
images using a region-growing algorithm in Analyze 9.0 software, and CSF 
and WMH volumes (millilitre: ml) were measured using an image processing 
algorithm (MCMxxxVI) (Hernandez et al., 2010) (detailed segmentation steps 
were described in the segmentation section of Chapter 3).  
Brain volume was obtained by subtracting CSF from ICV and cerebral 




two time points. WMH progression is the volume difference between follow-
up and baseline scans. The tissue loss due to stroke lesions was calculated by 
combining the baseline stroke lesion mask with the follow-up CSF mask, the 
overlapping tissue between those two masks was considered as tissue 
change due to stroke. 
A neuroradiologist coded WMH using Fazekas score, for periventricular 
(PWMH) and deep lesions (DWMH) separately in the left and right 
hemispheres (Wardlaw et al., 2011). Brain atrophy were coded using a 
validated template (Farrell et al., 2009), with superficial and deep atrophy 
coded separately.  
5.2.2 Statistical Analysis  
In the baseline 100 patients, the distribution of ICV and brain tissue volume 
expressed as a percentage of ICV were normal, and the distribution of CSF, 
WMH, stroke lesion volumes and lacunes were not normal. All the volumes 
in the 46 patients with follow-up were not normal for both time points (from 
inspection of histograms). We expressed absolute lesion volumes in ml and 
also adjusted for inter-subject differences in head size using the ICV.  
Numeric variables were expressed as mean (Standard deviation: SD) and 
median (interquartile range: IQR). For baseline 100 patients, we adjusted 
measures of WMH, atrophy and stroke lesions for factors such as stroke type, 
age, sex, hypertension, smoking and diabetes using multivariable regression. 
We compared WMH volume excluding stroke lesions with including stroke 
lesion using non-parametric tests (Wilcoxon Signed Rank Test), and 
considered P<0.05 as statistically significant. For the 46 patients with follow-




lesions/lacunes with WMH including stroke /lacunes (to test if the lacunes, a 
part of SVD, made a material difference to the WMH volume), and cerebral 
atrophy excluding versus including tissue loss due to stroke lesions/lacunes, 
using Wilcoxon Signed Rank Test. We also tested the effect of stroke lesions 
on sample size estimation for a clinical drug trial using WMH as an outcome 
measure using G power test.  
Multivariable linear regression was performed with Minitab (Minitab Inc, 
version 16). Wilcoxon Signed Rank Test was performed with the Statistical 
Package for the Social Sciences, Version 16.0 (SPSS, Chicago, Illinois). The G 
power test was used for sample size calculations (Erdfelder et al., 1996) done 






5.3.1 Cross-sectional results of baseline 100 patients 
In the 100 patients with stroke, the mean age was 66.81 years (SD, 11.3 years; 
range, 37 to 92 years), median National Institutes of Health Stroke Scale 
(NIHSS) score was 1 (interquartile range, 0 to 1), 77% were male, and there 
were 51 patients with lacunar stroke and 49 patients with cortical stroke.  
The patients with cortical stroke were older (70 versus 64 years) and had a 
higher prevalence of hypertension and lower prevalence of smoking and 
diabetes than the patients with lacunar stroke (Table 5.1). Seventy-one 
patients (71%) had index stroke lesions visible on MRI. A third of the patients 
with symptomatic lacunar stroke syndromes did not show any lacunar 
infarct on DWI image and a quarter of the patients with cortical stroke also 
showed negative DWI. The result was consistent with a larger study of 246 
patients that included these 100 patients (Doubal et al., 2010a).   
At baseline (Table 5.2), the median WMH volume was 11.0 ml (IQR: 4.5 to 
26.4), periventricular WMH rating was 1 (IQR: 1 to 2) and deep WMH rating 
was 1 (IQR: 1 to 1). Patients with cortical stroke had slightly higher WMH 
volume. The mean brain tissue volume was 79.7 ml (SD= 4.2), the median of 
deep atrophy rating was 1 (IQR: 0 to 2) and superficial atrophy rating 1 (IQR: 
0 to 1). Patients with cortical stroke had less brain tissue volume. For 71 
patients with index stroke lesion, the median of stroke lesion volume was 2.3 
ml (IQR: 1.1 to 12.1), cortical stroke patients had larger stroke lesion volume 











Difference (95% CI) and P 
Value Between Lacunar and 
Cortical Groups 
Age 66.8 (SD=11.3) 64.1 (SD=11.7) 69.6 (SD=10.3) mean difference=-5.5, (95% CI -
9.9 to -1.1, p=0.014*) 
Gender (Male) 77 (77.0%) 32 (62.7%) 45 (91.8%) Chi-Square=11.9, df=1, p=0.001* 
History of hypertension 62 (62.0%) 30 (58.8%) 32 (65.3%) Chi-Square=0.4, df=1, p=0.504 
History of smoking (n=99) 53 (53.5%) 28 (54.9%) 25 (51.0%) Chi-Square=0.2, df=1, p=0.619 
History of diabetes 15 (15.0%) 10 (19.6%) 5 (10.2%) Chi-Square=1.7, df=1, p=0.188 
Visible stroke on MRI  29 (29.0%) 17 (33.3%) 12 (24.5%) Chi-Square=0.9, df=1, p=0.330 




Table 5.2 Volumetric and rating results of WMH, atrophy and stroke lesions of baseline 100 patients (unadjusted). 
Measures Total (n=100) Lacunar (n=51) Cortical (n=49) Difference (95% CI) and P Value Between 
Lacunar and Cortical Groups 
WMH     
WMH volume (ml) 11.0 (IQR: 4.5 to 26.4) 10.8 (IQR: 3.9 to 25.9) 11.5 (IQR: 4.7 to 27.8) mean difference=-3.6, (95% CI -14.2 to -6.9, 
p=0.497) 
PWMH rating 1 (IQR: 1 to 2) 1 (IQR: 1 to 2) 1 (IQR: 1 to 2.5) Chi-Square=5.8, df=3, p=0.121 
DWMH rating 1 (IQR: 1 to 1) 1 (IQR: 1 to 1) 1 (IQR: 1 to 1) Chi-Square=0.7, df=3, p=0.879 
Atrophy     
ICV (ml) 1428.4 (SD= 122.5) 1394.5 (SD=121.0) 1463.6 (SD=115.0) mean difference=-69.1, (95% CI -115.9 to -22.2, 
p=0.004*) 
CSF (ml) 279.4 (IQR: 231.5 to 343.1) 264.1 (IQR: 228.1 to 314.1) 321.9 (IQR: 256.5 to 356.7) mean difference=-39.7, (95% CI -65.8 to -13.5, 
p=0.003*) 
Brain tissue volume (%) 79.7 (SD= 4.2) 80.5 (SD=3.4) 78.7 (SD=4.8) mean difference=1.8, (95% CI 0.2 to 3.4, 
p=0.032*) 
Deep rating 1 (IQR: 0 to 2) 1 (IQR: 0 to 2) 1 (IQR: 0 to 2) Chi-Square=4.1, df=3, p=0.249 
Superficial rating 1 (IQR: 0 to 1) 1 (IQR: 0 to 2) 1 (IQR: 0 to 1) Chi-Square=4.9, df=3, p=0.179 
Stroke     
Stroke volume (ml) 2.3 (IQR: 1.1 to 12.1, 
n=71) 
1.3 (IQR 0.7 to 2.0, n=34) 8.9 (IQR: 2.8 to 27.5, n=37) mean difference=-11.7, (95% CI -17.1 to -6.4, 
p<0.001*) 
Median NIHSS score 1 (IQR: 0 to 2) 1 (IQR: 0 to 2) 1 (IQR: 0 to 2) Chi-Square=2.7, df=6, p=0.841 
SD: standard deviation; IQR: interquartile range; NIHSS indicates National Institutes of Health Stroke Scale; brain tissue volume (%): brain tissue volume expressed as a 




We adjusted for stroke type, age, sex, hypertension, smoking and diabetes 
(Table 5.3), increasing age significantly associated with worse WMH, atrophy 
and stroke volume. Smoking correlated with higher PWMH rating scores 
(p=0.018) and male gender had worse deep atrophy (p=0.003). Patients with 
lacunar stroke had significant smaller stroke lesions than patients with 




Table 5.3 Influence of stroke type, age, sex, hypertension, smoking and diabetes on WMH, atrophy and stroke lesions (adjusted for stroke type, 
















WMH       
WMH volume 1.154 (-10.247 to 
12.555, p=0.841) 
0.777 (0.283 to 1.272, 
p=0.002*) 
2.390 (-10.906 to 
15.685, p=0.722) 
6.964 (-4.144 to 
18.072, p=0.216) 
7.441 (-3.150 to 
18.032, p=0.166) 
2.279 (-12.634 to 
17.192, p=0.762) 
PWMH rating 1.754 (0.719 to 4.167, 
p=0.219) 
1.099 (1.053 to 1.149, 
p<0.001*) 
1.205 (0.431 to 3.333, 
p=0.727) 
1.587 (0.676 to 3.704, 
p=0.288) 
2.778 (1.190 to 6.250, 
p=0.018*) 
1.724 (0.535 to 5.556, 
p=0.365) 
DWMH rating 1.613 (0.658 to 4.000, 
p=0.295) 
1.099 (1.042 to 1.136, 
p<0.001*) 
1.754 (0.602 to 5.000, 
p=0.304) 
2.174 (0.885 to 5.263, 
p=0.090) 
1.639 (0.709 to 3.704, 
p=0.250) 
1.667 (0.524 to 5.263, 
p=0.386) 
Atrophy       
Brain tissue (%) 0.556 (-0.915 to 2.028, 
p=0.455) 
-0.253 (-0.317 to -
0.189, p<0.001*) 
0.248 (-1.468 to 1.964, 
p=0.775) 
0.983 (-0.450 to 2.417, 
p=0.176) 
-0.417 (-1.784 to 0.950, 
p=0.546) 
-1.092 (-3.017 to 0.833, 
p=0.263) 
Deep rating 1.818 (0.787 to 4.348, 
p=0.159) 
1.124 (1.075 to 1.176, 
p<0.001*) 
5.000 (1.754 to 14.286, 
p=0.003*) 
1.389 (0.606 to 3.226, 
p=0.435) 
0.943 (0.431 to 2.083, 
p=0.887) 
1.563 (0.505 to 4.762, 
p=0.442) 
Superficial rating 1.124 (0.474 to 2.703, 
p=0.788) 
1.099 (1.053 to 1.149, 
p<0.001*) 
2.174 (0.763 to 6.250, 
p=0.144) 
1.389 (0.592 to 3.226, 
p=0.446) 
1.282 (0.571 to 2.857, 
p=0.547) 
0.746 (0.230 to 2.439, 
p=0.628) 
Stroke       
Stroke volume -10.581 (-16.342 to -
4.820, p<0.001*) 
0.291 (0.042 to 0.541, 
p=0.023*) 
-1.230 (-7.948 to 5.488, 
p=0.717) 
-2.274 (-7.887 to 3.339, 
p=0.423) 
4.717 (-0.635 to 
10.069, p=0.083) 
-2.199 (-9.734 to 5.337, 
p=0.564) 
NIHSS 1.020 (0.459 to 2.273, 
p=0.965) 
0.971 (0.935 to 1.000, 
p=0.073) 
1.010 (0.398 to 2.564, 
p=0.991) 
0.935 (0.433 to 2.041, 
p=0.866) 
0.901 (0.429 to 1.887, 
p=0.777) 
0.448 (0.154 to 1.299, 
p=0.140) 
PWMH: periventricular white matter hyperintensities; DWMH: deep white matter hyperintensities; brain tissue (%): brain tissue volume expressed as a percentage of 




We assessed the effect of stroke lesion volumes on baseline WMH volume by 
comparing volumes of WMH with and without stroke lesion volumes (Table 
5.4). In all 100 patients, the median baseline WMH volume was 10.97 ml (IQR 
4.48 to 26.38) excluding, and 17.96 ml (IQR 5.23 to 39.35) including stroke 
lesions (Z=-7.323, p<0.001). Restricting the analysis to just the 71 patients with 
visible stroke lesions on MRI, the median WMH volume was also smaller 
when excluding stroke lesion volumes (16.16 ml, IQR 6.29 to 33.19) than 
including stroke lesions (26.47 ml, IQR 12.23 to 53.21) (Z=-7.323, p<0.001). The 
results showed that failure to exclude stroke lesion volumes from WMH 
volume measurement in these patients resulted in both larger apparent 
WMH volumes and larger IQRs which added substantial noise to WMH 
baseline measurements, meaning that WMH volume would be significantly 
distorted. 
Table 5.4 The effect of the stroke lesions on WMH volume (ml) interquartile range (IQR) 
at baseline in all 100 patients and 71 patients with visible stroke lesions on MRI. 
 WMH  WMH + stroke Significance level 
100 patients    
Median (ml) 10.97 17.96 Z=-7.323, p<0.001 
IQR 4.48 to 26.38 5.23 to 39.35  
Length of IQR 21.90 34.14  
71 patients with visible stroke lesion on MRI 
Median (ml) 16.16 26.47 Z=-7.323, p<0.001 
IQR 6.29 to 33.19 12.23 to 53.21  





5.3.2 Longitudinal changes of 46 patients with follow-up  
Amongst the 46 patients with follow-up scans, their baseline mean age was 
68 (standard deviation: SD+/-11) years, 30 (66%) had hypertension, 4 (13%) 
had diabetes, 23 (50%) were lacunar subtype, median baseline National 
Institutes of Health Stroke Scale (NIHSS) was 2 (IQR 1-3). The median time to 
follow-up MR was 39 months (IQR 30 to 45 months). 
Stroke lesions 
At baseline, 33 (72%) had stroke lesions visible on MRI, median volume was 
2.05 ml (IQR 0.88 to 8.88). Three patients had new stroke lesions on follow-up 
imaging. The stroke lesion volume decreased in 11 and increased in 22 
patients between baseline and follow-up to give a median follow-up total 
stroke lesion volume of 2.43 ml (IQR 0.66 to 13.42). However the volume 
change ranged from 39.14 ml smaller to 79.97 ml larger than the baseline 
stroke lesion volume (Figure 5.1, Table 5.5).  
Seven of the 33 patients (15% of total patients) had stroke lesions plus one or 
more lacunes at baseline. The median baseline lacune volume was 0.30 ml 
(IQR 0.17 to 0.47). Lacune volume decreased in 2 patients and increased in 5 
patients during follow-up to give a median follow-up lacune volume of 0.43 






Figure 5.1 Variation in WMH volume at baseline, follow-up and progression due to 






Table 5.5 In all 46 patients with follow-ups, the results of median, minimum, maximum and IQR of stroke lesions (SL) volume (ml). SL progression 
is the volume difference between follow-up and baseline scans.  
Patient Group Median Minimum Maximum IQR 
SL at baseline     
All patients (n=46) 1.08 0.00 76.02 0.00 to 6.22 
SL (n=33) 2.05 0.20 76.02 0.88 to 8.88 
SL no lacunes (n=26) 2.23 0.20 76.02 0.93 to 10.09 
SL and lacunes (n=7) 1.33 0.33 64.18 0.76 to 8.88 
SL at follow-up     
All patients (n=46) 0.85 0.00 112.52 0.00 to 6.49 
SL (n=33) 2.43 0.00 112.52 0.66 to 13.42 
SL no lacunes (n=26) 2.26 0.00 112.52 0.70 to 14.79 
SL and lacunes (n=7) 4.14 0.33 25.04 0.38 to 12.18 
SL progression     
All patients (n=46) 0.00 -39.14 79.97 -0.01 to 1.29 
SL (n=33) 0.12 -39.14 79.97 -0.32 to 2.75 
SL no lacunes (n=26) 0.16 -6.11 79.97 -0.27 to 2.50 
SL and lacunes (n=7) 0.05 -39.14 3.30 -0.43 to 3.17 
SL relative change (%)     
All patients (n=46) 0.00 -100.00 356.11 -2.51 to 39.16 
SL (n=33) 19.89 -100.00 356.11 -22.44 to 49.19 
SL no lacunes (n=26) 20.58 -100.00 356.11 -18.43 to 51.81 




Effect of stroke lesions on WMH volume 
Among all 46 patients with follow-ups, the median baseline WMH volume 
was 8.54 ml (IQR 5.86 to 15.80) excluding, and 10.98 ml (IQR 6.91 to 24.86) 
including stroke lesions (difference Z=-5.012, p<0.001). At follow-up, the 
median WMH volume was 12.17 ml (IQR 8.54 to 19.86) excluding and 14.87 
ml (IQR 10.02 to 38.03) including the baseline and any new stroke lesions 
(difference Z=-4.937, p<0.001). Including/excluding just lacunes alone at 
baseline or follow-up also made small but significant differences (Table 5.6). 
Restricting the analysis to just the 33 patients with stroke lesions at either 
time point, or the 26 patients with a stroke lesion but no lacunes, or the 7 
patients with lacunes (who all also had stroke lesions) gave similar results for 
the proportional difference in WMH volume between including and 
excluding stroke lesions and lacunes as for all 46 patients (Table 5.7-5.9). 
However, the absolute true WMH volumes were larger in patients with a 
stroke lesion (e.g. baseline WMH volume 10.15 ml, IQR 6.51 to 18.13, Table 
5.7) than in those without (e.g. baseline WMH volume 6.63 ml, IQR 4.62 to 
9.47, Table 5.10). When we adjusted for inter-subject differences in 
intracranial volume, the pattern of results was the same.  
Amongst all 46 patients, WMH volume increased in 43 and decreased in 3 
patients between baseline and follow-up (range -1.94 ml to 33.16 ml) when 
stroke lesions were excluded. When stroke lesions were included, 40/46 
patients had an increase and 6 had a decrease in WMH volume although the 
median WMH volume progression excluding stroke lesions did not differ 
significantly from that including stroke lesions (difference Z=-1.831, p=0.067, 
Table 5.6). However, the WMH progression was considerably different from 




potential difference in WMH volume progression being huge, ranging from -
35.78 ml to 78.79 ml (Figure 5.1, 5.2) or between -208.75% to 163.83% of the 
baseline WMH volume, as shown in the increasing length of the IQRs, from 
WMH volume excluding stroke lesions (e.g. 11.77, Table 5.7) to including 
stroke lesions in the WMH volume (e.g. 23.47, Table 5.7). Thus including the 
stroke lesions adds substantial noise to the measurement of baseline, follow-
up and progression of WMH volume. 
 
 
Figure 5.2 Three slices from the same patient showing the influence of stroke lesions (SL) 
at baseline and new stroke lesions appearing during follow-up on WMH volume 




Table 5.6 In all patients with follow-ups (n=46), the results from non parametric tests (Wilcoxon Signed Rank Test) for differences in WMH volume (ml) 
according to inclusion/exclusion of lacunes or stroke lesions (SL). 
Measurement 
(n=46) 
Median IQR Length of IQR Signed Rank for difference 
with WMH only 
p-value 
WMH only      
Baseline 8.54 5.86 to 15.80 9.94 - - 
Follow-up 12.17 8.54 to 19.86 11.32 - - 
Progression 3.25 1.22 to 7.59 6.37 - - 
WMH + lacunes      
Baseline 8.54 5.86 to 15.80 9.94 -2.371 0.018 
Follow-up 12.19 8.54 to 19.86 11.32 -2.366 0.018 
Progression 3.27 1.22 to 7.69 6.47 -1.690 0.091 
WMH + SL      
Baseline 10.98 6.91 to 24.86 17.95 -5.012 <0.001 
Follow-up 14.79 10.02 to 38.03 28.01 -4.937 <0.001 
Progression 4.71 1.17 to 10.86 9.69 -1.831 0.067 
WMH + lacunes + SL      
Baseline 10.98 6.91 to 25.00 18.09 -5.012 <0.001 
Follow-up 14.87 10.02 to 38.67 28.65 -4.937 <0.001 






Table 5.7 In 33 patients with visible stroke lesions (SL) on MRI, the results of non parametric tests (Wilcoxon Signed Rank Test) for differences in WMH 
volume (ml) according to inclusion/exclusion of lacunes or SL. 
Measurement 
(n=33) 
Median IQR Length of IQR Signed Rank for difference 
with WMH only 
p-value 
WMH only      
Baseline 10.15 6.51 to 18.13 11.62 - - 
Follow-up 13.93 9.93 to 24.74 14.81 - - 
Progression 3.36 1.35 to 7.64 6.29 - - 
WMH + lacunes      
Baseline 10.61 6.51 to 18.28 11.77 -2.371 0.018 
Follow-up 14.04 9.93 to 24.83 14.9 -2.366 0.018 
Progression 3.43 1.35 to 7.70 6.35 -1.690 0.091 
WMH + SL      
Baseline 18.46 8.30 to 31.77 23.47 -5.012 <0.001 
Follow-up 24.87 12.49 to 39.25 26.76 -4.937 <0.001 
Progression 5.13 1.71 to 12.18 10.47 -1.831 0.067 
WMH + lacunes + SL      
Baseline 18.46 8.31 to 31.77 23.46 -5.012 <0.001 
Follow-up 24.87 12.51 to 39.52 27.01 -4.937 <0.001 




Table 5.8 In 26 patients with no lacunes but with visible stroke lesions (SL) on MRI, the results of non parametric tests (Wilcoxon Signed Rank Test) for 
differences in WMH volume (ml) according to inclusion/exclusion of SL. 
Measurement 
(n=26) 
Median IQR Length of IQR Signed Rank for difference with 
WMH only 
p-value 
WMH only      
Baseline 9.06 6.02 to 15.80 9.78 - - 
Follow-up 12.30 8.54 to 19.86 11.32 - - 
Progression 2.74 1.30 to 7.45 6.15 - - 
WMH + SL      
Baseline 15.77 7.82 to 25.34 17.52 -4.557 <0.001 
Follow-up 21.56 12.06 to 37.16 25.1 -4.373 <0.001 




Table 5.9 In seven patients with lacunes (who all also had stroke lesions: SL), the results of non parametric tests (Wilcoxon Signed Rank Test) for 
differences in WMH volume (ml) according to inclusion/exclusion of lacunes or SL. 
Measurement 
(n=7) 
Median IQR Length of IQR Signed Rank for difference with 
WMH only 
p-value 
WMH only      
Baseline 18.14 10.15 to 37.39 27.24 - - 
Follow-up 25.67 13.51 to 49.18 35.67 - - 
Progression 5.93 3.36 to 11.80 8.44 - - 
WMH + lacunes      
Baseline 18.70 10.61 to 37.68 27.07 -2.371 0.018 
Follow-up 26.35 14.04 to 49.61 35.57 -2.366 0.018 
Progression 5.94 3.43 to 11.93 8.50 -1.690 0.091 
WMH + SL      
Baseline 27.01 13.57 to 73.88 60.31 -2.366 0.018 
Follow-up 38.55 14.61 to 50.14 35.53 -2.366 0.018 
Progression 9.10 1.04 to 11.60 10.56 -0.338 0.735 
WMH + lacunes + SL      
Baseline 27.57 13.74 to 74.05 60.31 -2.366 0.018 
Follow-up 39.08 14.77 to 50.57 35.8 -2.366 0.018 




Table 5.10 In the 13 patients without visible stroke lesions (SL) on MRI, who all did not have lacunes, the results of Median, Minimum (Min) 
Maximum and IQR of WMH volume (ml).  
WMH only (n=13) Median Minimum Maximum IQR 
Baseline 6.63 3.10 36.22 4.62 to 9.47 
Follow-up 9.19 4.00 69.38 6.35 to 12.57 
Progression 3.13 -1.94 33.16 0.16 to 6.46 





Effect of stroke lesions on atrophy 
Among 46 patients, median brain tissue volume excluding the stroke lesions 
was 1155.16 ml (IQR 1069.97 to 1250.78) at baseline and 1127.66 ml (IQR 
1054.82 to 1204.77) at follow-up; including the stroke lesions was 1154.35 ml 
(IQR 1069.97 to 1250.63) at baseline and 1127.66 ml (IQR 1052.26 to 1204.76) 
at follow-up. Expressed in terms of brain atrophy, the median brain atrophy 
volume was 24.49 ml (IQR 12.87 to 54.01) excluding and 24.61 ml (IQR 15.54 
to 54.04) including the stroke lesions (Wilcoxon Signed Rank test, Z=-3.915, 
p<0.001).  
When expressed as a percentage of ICV, the median percentage of brain 
tissue volume in the ICV excluding the stroke lesions was 81.04% (IQR 
79.16% to 83.25%) at baseline and 78.45% (IQR 76.04% to 81.87%) at follow-
up; including the stroke lesions was 81.03% (IQR 79.15% to 83.25%) at 
baseline (Wilcoxon Signed Rank test, Z=-3.724, p<0.001) and 78.32% (IQR 
75.63% to 81.83%) at follow-up (Wilcoxon Signed Rank test, Z=-4.372, 
p<0.001). 
For 46 patients, the median stroke lesions volume change between baseline 
and follow-up was 0.00 ml (IQR 0.00 to 0.81). Twenty-two patients had tissue 
loss due to stroke lesions, the median baseline tissue loss due to stroke 
lesions was 0.011 ml (IQR 0.00 to 0.24), and this decreased in 3 patients and 
increased in 19 patients during follow-up to give a median follow-up volume 
of 0.96 ml (IQR 0.07 to 2.95). For the 22 patients, the median stroke lesions 
volume change was 0.90 ml (IQR 0.05 to 2.89), with volume differences 
between true brain atrophy volume (excluding effect of stroke lesions) and 
apparent brain atrophy volume (including effect of stroke lesions) ranging 




represents up to 1.65% of the baseline brain tissue volume, or up to 4-fold 
more than true brain atrophy (Figure 5.3). 
For all 46 patients, the median progression of brain atrophy as a percentage 
of ICV was 1.73% (IQR 0.92% to 3.55%) excluding versus 1.77% (IQR 1.03% to 
3.56%) including the stroke lesions. For the 22 patients with tissue loss due to 
the stroke lesions, the median brain atrophy as a percentage of ICV was 
2.03% (IQR 1.35% to 4.50%) excluding versus 2.03% (IQR 1.44% to 4.94%) 
including the ISL.  
 
Figure 5.3 Estimation of absolute and relative brain atrophy excluding and including the 





Effect of stroke lesions on sample size in studies of WMH as an outcome 
measure 
We estimated sample size for a trial of the effect of a drug on WMH 
progression, assuming a 20% reduction in WMH progression with active 
drug, from 30% in the control group to 24% in the treated group. At 80% 
power and alpha of 0.05, the trial would require 1730 patients based on 
WMH volume excluding stroke lesions and 3623 patients if the stroke lesions 
were included in the WMH volume, this difference being largely driven by 






WMH and brain atrophy are of increasing interest in studies of ageing, stroke 
and dementia. In this fairly typical cohort of patients who had originally 
presented with an acute lacunar or cortical mild stroke, we demonstrated 
that failure to account for stroke lesions when measuring WMH volume 
could increase significantly both median baseline and follow-up WMH 
volume by about 20% and added substantial noise to the measurement of 
WMH progression. Similarly, for individual patients, failing to consider the 
stroke lesions when measuring brain atrophy could increase apparent brain 
volume loss by up to 21.25 ml more than true brain atrophy volume, 
representing 1.65% of baseline brain volume, or up to 4 times more than true 
brain atrophy.  
As WMH and atrophy are commonly present together in brains of older 
people (Appelman et al., 2009) as are clinically apparent and silent infarcts 
(Liou et al., 2010), so failure to exclude stroke lesions from measures of both 
WMH and atrophy could confound substantially any studies assessing any 
correlation between risk factors for or treatments to prevent stroke, WMH 
and delay atrophy. For example, one might think that a drug to prevent 
cardioembolic stroke was reducing WMH progression when in fact it was 
preventing recurrent ischaemic stroke but not influencing WMH progression 
at all. 
We demonstrate an important consideration for both cross-sectional and 
longitudinal studies of WMH, longitudinal studies of brain atrophy and 
randomised trials of treatments to prevent WMH progression or brain 
atrophy, by showing that failure to exclude the stroke lesions, even though 




2.43 ml at follow-up), could lead to very misleading estimates of WMH 
volumes and brain atrophy. Including the stroke lesions in the WMH 
volumes adds noise to the WMH data at baseline, follow-up and estimates of 
progression, resulting in loss of statistical power. Acute or old stroke lesions 
may be present at entry to a study, may shrink in size or increase and new 
stroke lesions may appear during follow-up. Thus, for the individual patient, 
the effect of stroke lesions on WMH volume progression is huge and 
impossible to predict on an individual basis if stroke lesions are included 
because of the large negative or positive effects of the stroke lesions change. 
Reassuringly, the specific effect of lacunes alone on the longitudinal WMH 
measurements was small and can probably be ignored unless present in large 
numbers. Including the stroke lesions in measurement of atrophy also adds 
noise to the brain tissue volume at baseline, follow-up and estimation of 
progression. 
This has important implications for design and in particular for sample size 
calculations for observational studies and randomised trials using WMH 
volume, WMH volume progression or brain atrophy as an outcome measure. 
Statistical power is driven by the IQR, a measure of “noise” in the system, as 
well as by the absolute difference between groups that one is trying to detect. 
The added noise from stroke lesions and consequent more than doubling of 
the sample size would substantially increase trial duration and costs. Failing 
to exclude stroke lesions from WMH volume measurement could obscure the 
effect of treatment on WMH progression and mean that potentially effective 
treatments would be missed in error or make ineffective treatments look as if 
they were beneficial. Visual WMH rating scales avoid the problem of infarcts 




changes in WMH burden than are WMH volume measures, assuming that 
the latter are accurate. Use of both WMH visual scores and volumes in a 
study would help identify discordant volume values that might help avoid 
confounding of WMH volume by stroke lesions.  
The strengths of this study include the use of a representative cohort of 
patients with a wide range of severities of WMH. The analyst was blinded to 
all clinical information. We used a carefully tested WMH and CSF volume 
measurement method (MCMxxxVI) (Hernandez et al., 2010) that combines 
information from two sequences to reduce errors in WMH and CSF 
detection. A neuroradiologist identified the infarcts, lacunes and 
distinguished them from WMH for image processing.  
The study limitations include the results may not apply to patients with 
multiple lacunes as only seven patients had a few lacunes. Our population 
had more stroke lesions than in similarly-aged subjects without history of 
stroke, although silent cortical and subcortical stroke lesions and lacunes 
occur in up to 75% of otherwise asymptomatic older volunteers (Gorelick et 
al., 2011; Morris et al., 2009). It was difficult sometimes to distinguish the 
edge of the stroke lesions from the WMH but we performed the analysis 
blind to all other factors so any bias is likely to be minimal.  
Further studies are needed to determine the full magnitude of the effect that 
stroke lesions and lacunes could have on WMH and cerebral atrophy 
measurement, find better ways of discriminating between stroke lesions and 





Chapter 6 Development and optimization of a 
Perivascular spaces measurement method 
Perivascular spaces (PVS), or Virchow-Robin spaces are pial extensions of the 
subarachnoid space that surround the walls of arteries, arterioles, veins and 
venules as they course into the brain parenchyma (Etemadifar et al., 2010; 
Kwee and Kwee, 2007). PVS function as drainage and fluid circulation 
pathways for soluble and insoluble material through the central nervous 
system (Rennels et al., 1985). Many inflammatory processes take place in the 
PVS, for example they are specific sites for immune cell accumulation, 
reaction and transmigration into the brain parenchyma (e.g. leukocytes, 
dendritic cells, T-cells, B-cells and macrophages (Polledo et al., 2012; Sagar et 
al., 2012; Wuerfel et al., 2008)). We had described the PVS ultrastructure, 
fluid drainage through PVS, immune cells accumulation and transmigration 
in the PVS, and inflammatory diseases or small vessel diseases (SVD) related 
to PVS in detail in Chapter 2 (2.1.5 perivascular space). 
The appearances of PVS on imaging may provide evidence of vascular or 
inflammatory changes in the brain. PVS are round or linear delineated 
structures seen on magnetic resonance imaging with intensities close to 
cerebrospinal fluid (CSF) and less than 3mm (Kwee and Kwee, 2007) 
diameter in cross section (Wardlaw et al., 2013c). PVS on MRI are associated 
with increasing age, cognitive impairment, cerebral SVD (lacunar stroke and 
white matter hyperintensities: WMH), multiple sclerosis (MS), and may be 
related to altered blood brain barrier (BBB) permeability (Doubal et al., 
2010b; Maclullich et al., 2004; Potter et al., 2013; Wardlaw, 2010; Zhu et al., 
2010). We mentioned the definition of PVS on MRI and their associations 




In following three chapters, we will present the development and 
optimization processes of a computational method applied to quantify PVS 
count and volume using 16 test cases (Chapter 6). In Chapter 7, we validated 
the computational method in 100 mild stroke study cases (the patients’ 
information in given Chapter 3) and compared PVS count/volume generated 
in the PVS computational method with the visual rating results from a 
validated visual rating scale (Maclullich et al., 2004). In Chapter 8 we will 
explore the associations between PVS and other SVD features (e.g. WMH and 
atrophy), blood markers, and BBB permeability.   
6.1 Introduction 
Perivascular spaces (PVS) on magnetic resonance imaging (MRI) are 
commonly assessed using visual rating scales, and several different rating 
scales have been proposed (Chen et al., 2011; Doubal et al., 2010b; Maclullich 
et al., 2004; Patankar et al., 2005; Potter, 2011; Rouhl et al., 2008; Zhu et al., 
2010). These scales differ in how they score the anatomical location or range 
of PVS, as summarized in Table 6.1 (all tables in this chapter are in section 6.6 
Tables). Potter (Potter, 2011) reviewed and evaluated the ambiguities and 
advantages in these existing PVS visual rating scales and combined their 
strengths to develop a more comprehensive visual rating scale (available at 
http://www.bric.ed.ac.uk/documents/epvs-rating-scale-user-guide.pdf). This 
new scale used standard T2-weighted (T2W) structural brain MRI to assess 
the severity of the PVS located in three major anatomical regions (midbrain: 
MB, basal ganglia: BG and centrum semiovale: CS) and tested its observer 
variability (Potter, 2011).  
All existing rating scales have similar limitations: limited range of PVS, 




inter-observer differences. These limitations could be overcome by the use of 
computational methods, which may provide more precise PVS number and 
also allow their size/volume to be measured. Such methods could be useful 
for more subtle measurements and analyses, for example calculating the 
percentage of PVS volume in the total brain volume and investigating an 
association between PVS volume and white matter hyperintensities (WMH) 
volume. 
To our knowledge, few studies have described any computational methods 
suitable for PVS quantification (Descombes et al., 2004; Uchiyama et al., 2008; 
Wuerfel et al., 2008). Our systematic review found six studies that used 
computational methods to assess PVS and four studies that presented 
approaches with potentials for quantifying PVS (Hernandez et al., 2013). 
Though these computational methods were promising, they have not been 
widely used in the target population of patients with small vessel disease, 
and maybe computational intense and time consuming for large clinical 
studies.  
In this chapter, we present a user-friendly computational method for 
counting the number and measuring the volume of PVS useful in large 
clinical research studies. This method was based on the best knowledge from 
a validated visual rating scale regarding standard slice selection in the BG 
and the CS regions (Potter, 2011). We developed the method and tested the 
intra- and inter-observer agreement of this computational method. We 
describe thresholds that work in most cases, and describe refinements for 





6.2 Methods  
6.2.1 Sample selection 
For developing and testing the computational approach, the imaging 
datasets for 16 subjects were randomly chosen from The Lothian Birth 
Cohort 1936 (LBC1936) Study (http://www.lothianbirthcohort.ed.ac.uk/) to 
represent a full range of PVS, WMH, lacunes, and brain atrophy based on 
previous analyses (Deary et al., 2007).  
6.2.2 Brain MRI acquisition 
All MRI acquisition was conducted in the Brain Research Imaging Centre, 
University of Edinburgh (http://www.bric.ed.ac.uk). A GE Signa Horizon 
HDx 1.5T clinical scanner (General Electric, Milwaukee, WI), equipped with 
a self-shielding gradient set and manufacturer-supplied eight-channel 
phased-array head coil, was used to acquire T2W, T1-weighted (T1W), 
gradient echo (GRE) and fluid attenuation inversion recovery (FLAIR) 
datasets amongst other sequences. Full details of the MRI protocol for this 
study had been published previously (Wardlaw et al., 2011). The 
characteristics of the sequences relevant for assessing PVS in this chapter are 
summarised in Table 6.2. 
6.2.3 Standard image preprocessing steps 
Registration  
PVS on MRI are defined as ‘sharply delineated round or linear structures of 
intensity similar to that of cerebrospinal fluid (CSF) and less than 3mm in 
axial diameter’ (Kwee and Kwee, 2007; Wardlaw et al., 2013c). The main 
sequence used to identify PVS was T2W images (Kwee and Kwee, 2007). 




from other lesions such as WMH, infarcts and lacunes (Groeschel et al., 
2006). The base sequence for our technique was the T2W sequence. T1W and 
FLAIR, were rigidly registered to the corresponding T2W volumes using 
FLIRT software (FMRIB Linear Registration Tool) (Jenkinson et al., 2002) 
from the FMRIB Software Library (FSL, University of Oxford, UK), available 
at http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/.  
Generation of intracranial volume (ICV) mask 
In order to reduce the intensity difference between non-brain tissue and 
brain tissue, the ICV was manually masked out from the skull on the GRE 
images using the Object Extraction Tool based on a region-growing 
algorithm in AnalyzeTM 10.0 (Analyze Direct, Inc. Overland Park, KS, USA). 
False positives were removed manually. The steps in the ICV segmentation 
had been described in Chapter 3 and a detailed ICV segmentation manual is 
in the appendix (see Appendix B1 Intracranial volume segmentation 
Manual). 
6.2.4 Development and optimization of the multi-stage PVS 
segmentation method 
We used ‘Object Counter’ function in the AnalyzeTM 10.0 software to develop 
our segmentation technique. Figure 6.1 (all figures in this chapter are all in 
section 6.5 Figures) schematically represented all the steps that we applied in 
the method development and optimizations: the steps with solid outline 
were ultimately included in the final procedure for general PVS 
segmentation and full details of each step in Figure 6.1 are in the Appendix 
E1 (Detailed perivascular spaces segmentation steps in Figure 6.1).  
PVS are commonly seen in the BG and CS (Kwee and Kwee, 2007) as these 




evaluated clinical PVS visual rating scale (Potter, 2011), we selected a 
representative slice in the BG and CS. In the BG, we chose the slice that 
contains at least one characteristic BG structure (i.e. caudate nucleus, internal 
capsule, thalamus, lentiform nucleus, external capsule and insular cortex) 
and also usually shows the most PVS. In the CS, we chose a slice between the 
superior aspect of the bodies of the lateral ventricles and the subcortical 
white matter near the vertex (see Figure 6.2). Tests of intra- and inter-
observer reliability (both visual rating and computational identification) 
showed high variability in the identification of the elongated PVS that are 
common in the CS and outer regions of the BG slice (Figure 6.3). Therefore, 
we restricted our assessment to bilateral ovoid regions on the BG slice, one in 
each hemisphere, delineated by the vertical ramus of the lateral fissures and 
the posterior segment of the lateral fissures as shown in Figure 6.2.  
Analysis of the intensity distribution in the T2W images revealed that PVS 
have intensity levels ranging from 0.3 to 0.9 that vary even within the same 
subject, presumably due to factors such as partial volume averaging 
(Hernandez et al., 2013), making it unfeasible to assess PVS using a single 
threshold without any intensity adjustment. Therefore we performed a linear 
intensity adjustment in 3 stages: normalisation, gamma correction and linear 


























where Imax and Imin are the maximum and minimum intensity levels and ' ),,( zyxi  
and ),,( zyxi  are the resultant and initial intensity levels for a voxel identified 
by the coordinates (x,y,z). Initially we used a linear intensity transformation 




minimum and maximum values respectively. However, it was necessary to 
transform the intensity levels quadratically to successfully apply one 
threshold on each of the test cases. This was achieved doing a voxelwise 
product of the intensity-adjusted-T2W image with itself, or, as Imin was zero, 
using a gamma correction factor of 2.  
We performed additional tests to try to improve PVS segmentation such as 
combining T1W and T2W images and manually excluding lacunes (steps 
outlined by dotted lines in Figure 6.1). 
6.2.5 Observers and analysis 
Two observers (Ob1, Ob2) measured the PVS count and volume using 
AnalyzeTM 10.0 software.  I’m the Ob1 had worked with clinical brain 
imaging for more than 2 years and designed and tested each step in this 
method , and Ob2 is an undergraduate medical student worked with brain 
imaging for 6 weeks and helped to test Step 2, 3 and 5 in this method (Figure 
6.1). We both did the PVS measurement twice but on two separate occasions. 
I used the same standard slices both times. Ob2 was blinded to the standard 
slice number chosen by me for the first measurement, and was unblinded for 
the second measurement. Ob1 was a more experienced analyst; Ob2 did not 
have long time image analysis training. Bland-Altman plots (Bland and 
Altman, 1986) were used to estimate the agreement within or between 





6.3 Results  
In the results section, we will show how we managed to increase method 
consistency and reduce numbers of thresholds. We summarized the work 
flow for the final optimized method. 
6.3.1 Observer variability and optimization 
Observer variability  
After we applied multiple thresholds in step 2, we visualized the locations 
for intra- and inter- observer variability in the Figure 6.3. Three different PVS 
masks were selected as an example. This method was helpful in picking up 
the dots in the two ovoid regions of the BG, but was not effective in picking 
up the linear-shaped PVS in the CS.  
For comparing the observer variability, we also calculated the mean and 
standard deviation (SD) of the PVS results and generated the Bland-Altman 
plots. Both observers had higher intra- and inter-observer variability on the 
PVS volume and count measurements in the BG regions than in the CS 
regions (large SD). Ob2 tended to measure less than Ob1 in the BG region, 
and more in the CS region for PVS volume and count measurements, tables 
of observer variability, Bland-Altman plots and locations for observer 
variability are in the Appendix F (Observer agreement in the PVS method 
development and validation).  
In order to diminish the observer variability and increase the consistency, we 
restricted the regions of interest (ROI) to the bilateral ovoid regions in the BG 





Efficiency of restricting ROI into BG regions 
For the PVS count measurements, after restricting the regions of interests 
specifically to the two BG ovoid regions (BG ROI), both intra- and inter-
observer variability were less (smaller SD, Table 6.3) and the discrepancy 
range were smaller compared with measuring the whole BG slice (Appendix 
F).  
6.3.2 Threshold optimization 
We used intensity adjusted T2W image (T2W-ia) in the optimization step. We 
aimed to use only one threshold rather than multiple thresholds for each 
patient in the PVS segmentation and find a pattern of thresholds. 
Tests such as combining T1W-ia and T2W-ia images and manually excluding 
lacunes were not successful in reducing numbers of thresholds (steps 
outlined by dotted lines in Figure 6.1, results in the Appendix G: Results 
from unsuccessful steps in the PVS method development and optimization). 
A voxelwise product of the T2W-ia image with itself was able to reduce 
number of threshold into one. We also identified a general pattern that 
involved the use of three optimum thresholds, each one to be applied 
according to the T2W image characteristics of the individual patient as 
follows: 
(1) Low Threshold (7.5% of maximum intensity) was suitable for a patient that 
had scattered PVS, a uniform, visually normal intensity background, and 
few focal lesions such as WMH or lacunes (1/16 case). 
(2) High Threshold (15% or above of maximum intensity) was suitable for 




other lesions (WMH, lacunes, mineral deposits), or with poor scan quality, 
for example from patient movement (8/16 cases).  
(3) Medium Threshold (11.25% of maximum intensity) was suitable for patients 
that did not have the characteristics requiring use of either low or high 
thresholds (7/16 cases). 
6.3.3 Final optimized PVS segmentation method 
The final procedure for general PVS segmentation was determined to be:  
1. Chose the standard slice in the BG region. 
2. Apply intensity adjustment to the T2W image. 
3. Combine two T2W intensity adjusted images. 
4. Set the region of interests into two BG ovoid regions (BG ROI). 
5. Apply one threshold (Low, Medium or High) according to the image 
characters. T1W and FLAIR images would be used as reference image. 
6. For difficult and complicated cases, another threshold or the same threshold 
plus manual editing should be applied.  
For most of the cases, the final PVS segmentation would take 8 to 13 minutes 
per case in total, and for complicated cases, it might need 5 to 20 more 
minutes including the application of multiple thresholds or further manual 




6.4 Discussion  
This semi-automatic threshold-based method was promising for measuring 
BG PVS volume, and could be a complementary method to existing visual 
rating scales. The method also showed promises for counting PVS number 
automatically rather than manually, decreasing the amount of counting time 
and reducing counting errors. We also provided ways of dealing with 
difficult and complicated cases, by increasing the number of threshold or by 
manual editing.  
This method has limitations. The final optimized method only focused on the 
PVS in the BG region. It was harder to choose the CS standard slice at the 
first stage. Moreover, the shapes of the PVS in the CS region were not 
consistent, either linear or round shape, influenced by the vessels running in 
various directions. Finally, it was more frequent to have a high background 
signal caused by the diffuse hyperintensive lesions in the CS region than in 
the BG region which influenced the PVS detection. CS volume and count 
were deemed to be too variable to develop further at this point. This method 
requires manual editing and the efficiency in picking up the PVS largely 
depends on the skills of observers and the quality of the images. There is the 
potential for developing fully automated software based on the object-
approach mechanism described by (Descombes et al., 2004).  
A further comparison is needed to prove the efficiency of this method, by 
comparing results from this method with validated PVS visual rating scores 
(in Chapter 7). A study of the associations between PVS and WMH, cerebral 
atrophy, blood markers, and the BBB permeability would be useful to 
provide critical evidence in the study of small vessel disease mechanisms (in 






Figure 6.1 Steps in a multi-stage PVS segmentation approach.  
Abbreviations: BG, basal ganglia; T2W, T2-weighted image; T1W, T1-weighted image; ia, image after intensity adjustment. The solid lines are the steps 






Figure 6.2 Standard slices for the BG and CS regions, and regions of interest (ROI) 




   
Figure 6.3 Location of intra- and inter-observer variability in the BG (Left) and CS (Right) 
regions.  
On the left side, the first row demonstrates the intra-observer variability; the second row 
demonstrates the inter-observer variability of the PVS in the BG region. The images on the 
right show the intra- and inter-observer variability in the CS region. Dots in red indicate the 
PVS selected by Ob1 only for the first time but not for the second time. Dots in blue indicate 
the PVS selected by Ob 1 for the second time only. Dots in violet (the merged colour of red 
and blue) show the PVS selected by Ob1 for both time points, which represent the 
consistency of measurements within Ob1. Therefore the red and blue dots indicate the 
locations of intra-observer variability. The dots in green indicate the PVS selected only by 
Ob2 when unblinded to the standard slice number chosen by Ob1. The dots in yellow are the 
overlapping PVS selected by both observers, showing the consistency between observers. 





Figure 6.4 Illustration of final optimized PVS segmentation method. 
Abbreviations: BG, basal ganglia; T2W, T2-weighted image; T2W ia, T2-weighted image 






Table 6.1 Anatomical location and range of PVS in commonly used rating scales.  
The table was extracted from Potter’s work of developing and validating a comprehensive 
visual rating scale (Potter, 2011).  
Author-Year Anatomical location Scale and Range of PVS 
Heier et al. , 1989  Lenticulostriate;  
High convexity 
1-3 Mild; Moderate; Marked 
<2mm 1 Mild 
2-3mm 2 Moderate 
>3mm 3 Marked 
>4mm upgrade to next level 
Elster and 
Richardson, 1991  
MB Absent 
Present (1)Unilateral; (2)Bilateral 
























Patankar et al. , 2005  CS; 
MB; 
Subinsular; 
BG scheme 1;2 
0-5 
Groeschel et al. , 
2006  




Rouhl et al. , 2008  BG; 
CS round/oval; 
CS linear 









Table 6.2 Characteristics of the MRI sequences used in this study. 
Study  LBC1936 Study (Wardlaw et al., 2011) 
TR/TE/TI (ms)   9.7/3.984/500 (T1W) 
TR/TE (ms)   940/15 (T2W) 
TR/TE/ TI (ms)   9000/140/2200 (FLAIR) 
Pixel bandwidth (KHz) 15.63 (T1W) 
12.5 (GRE) 
15.63 (FLAIR) 
Matrix 192 x 192 (T1W) 
256 x 192(T2W) 
256 x 256(FLAIR) 
Number of slices   160 (T1W) 
80 (T2W) 
40 (FLAIR) 
Slice thickness (mm) 1.3 (T1W) 
2 (T2W) 
4 (FLAIR) 
Inter-slice gap (mm) 0 
Voxel size (mm3) 1.3 x 1.3 x 1(T1W) 
1 x 1 x 2 (T2W) 
1 x 1 x 4 (FLAIR) 
ms: millisecond; KHz: kilohertz; mm: millimetre; mm3: cubic millimetre. 
Table 6.3 The effect of BG ROI mask in increasing PVS measurement consistency. 
PVS count Without BG ROI mask With BG ROI mask 
Mean SD Mean SD 
Intra (Ob1) 72.50 28.65 49.88 15.88 
Intra (Ob2) 56.69 10.55 51.06 10.27 
Inter (blinded) -15.88 24.47 1.12 13.12 
 -18.12 25.89 -0.50 13.36 
Inter (unblinded) -13.50 24.58 2.87 12.55 
 -15.75 25.26 1.25 12.15 






Chapter 7 Validation of Perivascular spaces 
measurement method 
7.1 Introduction 
In chapter 6, we developed a computational perivascular spaces (PVS) 
method based on a validated PVS visual rating scale (Potter, 2011) and tested 
intra- and inter-observer variability. We included two regions for method 
development: basal ganglia (BG) and centrum semiovale (CS), and we found 
CS PVS were harder to quantify and had higher observer variability than in 
the PVS in the BG ovoid regions. Therefore, our final computational PVS 
method only included the BG ovoid regions which take about 10 minutes on 
average per case, and more time for further manual editing or multiple 
thresholds application for complicated cases. In this chapter, we will test the 
accuracy of this method in a larger sample by comparing its results (PVS 
count and volume) with the PVS visual rating scores (Maclullich et al., 2004; 
Potter, 2011). 
7.2 Method 
7.2.1 Patient information 
We used the imaging data from 100 patients who participated in the BBB 
permeability study, the information about patients’ recruitment and brain 
imaging procedure is given in Chapter 3. We applied the PVS final 
segmentation method (Figure 6.4 in Chapter 6) to measure PVS count and 
volume in the baseline scans of these 100 patients and in 46 of whom had 
follow-up scanning about three years later. The PVS count is the number of 
PVS dots appeared in the BG regions, and the PVS volume is the total 
volume of all these PVS dots, not the averaged volume for each dot which we 




7.2.2 PVS visual rating  
A neuroradiologist rated the PVS in the BG regions as follows: 0=no PVS, 
1=<10 PVS, 2=10–20 PVS, 3=21–40 PVS, and 4>=40 PVS, separately in the left 
and right hemispheres, and an ‘overall’ score using a scale previously 
developed by our group (Maclullich et al., 2004; Potter, 2011). PVS visual 
rating scales were available for all of these cases.  
7.2.3 Statistical Analysis 
In these 100 patients, we used linear regression to investigate the associations 
between BG PVS count/volume and BG PVS rating scales. All linear 
regression analyses were performed in R program version 2.15.2 
(http://www.r-project.org/). 
We also investigated the agreement of PVS computational results and visual 
rating results using marginal homogeneity (MH) analysis (MH program, v. 
1.2, http://www.john-uebersax.com/stat/margin.htm). PVS computational 
count was condensed into a ‘score’ using the same standard as the PVS 
visual rating scores rating based on (no PVS was 0, less than 10 PVS was 1, 11 
to 20 PVS was 2; 21 to 40 PVS was 3, and more than 40 PVS was 4).  
7.3 Results 
7.3.1 Association between BG PVS volume and BG count 
In the 100 cases, BG PVS count increased significantly with BG PVS volume 
(coefficient of linear regression: 67.266; 95% confident intervals (95%CI): 
57.927 to 76.604, Figure 7.1, all figures in this chapter are in section 7.5 
Figures).  
An increase of one millilitre (ml) in PVS volume leaded to an increase of 67 




patients who had follow-up scans, the results are similar and positive 
relationship still exists (93, 95% confident interval is 74 to 112). Follow-up 
linear regression results also indicated a high regression trend of PVS count 
and PVS volume (77, 95% confident interval is 61 to 92).  
There was no association between the average size of PVS (here expressed as 
average PVS volume per count) and the PVS count (Figure 7.1), which is 
consistent with the visual observation that most PVS on MRI have similar 
sizes, no matter how few or many there are.  
7.3.2 BG PVS count and BG PVS visual rating scores 
For baseline 100 patients, BG PVS count increased with overall BG PVS 
visual score (2.114, 95%CI 1.364 to 2.864). The positive associations remained 
for comparing BG PVS computational count and left/right BG PVS visual 
rating scores.  The subgroup of 46 patients who had both baseline and 
follow-up scans showed similar associations at both time points (Figure 7.2 
Table 7.1, all tables in this chapter are in section 7.6 Tables).  
7.3.3 BG PVS count and BG PVS visual rating scores (MH) 
We then investigated the agreement of PVS computational measures and 
visual rating scores by comparing the BG PVS count and BG PVS visual score 
using MH analysis, and displayed the frequencies of the condensed PVS 
score from PVS computational method and PVS visual rating score in 
histograms. We condensed the raw PVS computational count to match the 
same scale range as for the PVS visual rating scale: from 0 to 4 (score 0=none 
PVS dots; 1=1~10 PVS dots; 2=11-20 PVS dots; 3=21-40 PVS dots; 4=>40 PVS 




We found a similar spread of values for PVS computational and visual count 
scores. Histograms from both scoring systems showed two high frequency 
peaks. The highest peak at baseline was score 1, and it changed from 1 to 2 
during follow-ups suggested the patients had worse PVS rating for follow-up 
(Figure 7.3).  
The visual rating score tended to measure less than the PVS count rating 
when the number of PVS dots was low and more when the number was 
high. For example, for baseline BG PVS measurement, the smallest difference 
between both rating systems was in score 1, and the difference increased as 
the score increased (score 2 and 3), showed that it was hard to quantify PVS 
when the numbers of PVS dots increased.  
The interval range of visual rating scores was from 0 to 4 but the PVS count 
scores was from 1 to 3, which suggested the visual rating scores spread better 
than the condensed scores from the PVS count. The PVS visual rating score 
showed a wider range implying that the visual rating detects smaller or more 
subtle PVS change than the PVS computational count score. Alternatively, 
the visual rating score was an estimate of PVS number not a precise count. 
In sum, the histograms (Figure 7.3) show several points: a) for baseline, the 
computational and visual counts had a very similar distribution with the 
median score being 1 and second commonest score being 2; b) the difference 
between the rating systems increased as the score increased indicating that it 
was harder to quantify larger numbers of PVS;  c) the visual rating score 
tended to measure less than the PVS computational count when there were 




more PVS on the follow-up scans (median score 2  Indicating that agreement 
continued as the PVS count worsened with progressive SVD. 
7.3.4 BG PVS volume and BG PVS visual rating scores 
Similar as comparison between BG PVS count and BG PVS visual rating 
scores in the BG region, there were positive associations between PVS 
computational volume and visual rating scores (overall BG region, left and 
right part in the BG regions), for both time points scans (Figure 7.4, Table 
7.2).  
7.4 Discussion 
The present study validated the PVS method we described in Chapter 6 in 
100 patients with mild stroke, 46 of whom had follow up scans. We 
evaluated the associations between PVS count and volume, and PVS visual 
rating scores. There was significant associations between PVS volume and 
PVS count in the BG region. However, the average PVS size (PVS volume per 
count) was not associated with the PVS count, consistent with visual 
observations that PVS size in general does not vary with number. The PVS 
computational results (PVS count and volume) also agreed well with a 
widely used PVS visual rating score.  
When the PVS count was converted into the same categories as used in the 
visual rating score and compared with the PVS visual rating scores, the 
results showed a similar pattern with a similar spread of curves, interval 
range and peaks but visual rating scores showed wider dynamic range than 
computational count converted to scores. The BG PVS count ‘scores’ 
(condensed from PVS count) and PVS visual rating scores have very good 




number of PVS, a similar problem found with inter-observer agreement for 
PVS visual rating. Therefore the cases with high background signal or many 
diffuse WMH being assigned the highest score (score 4) when visually rating 
PVS to overcome this problem. 
Though the current study quantified the PVS in the patients with lacunar or 
cortical strokes, PVS also appear in MRI scans from young and healthy 
volunteers who participate as controls for studying the mechanisms of 
ageing and brain diseases, and so this method should also be tested in 
normal subjects in further studies. 
In the following chapter, I will use the BG PVS results obtained from this 
chapter to assess the associations between BG PVS count/volume and white 
matter hyperintensities, cerebral atrophy, CS PVS, blood markers and blood 








Figure 7.1 Associations between PVS volume (ml) and count in baseline 100 patients.  
Left: Positive association between total PVS volume (ml) and count. The x axis represents the 
PVS count, which means the number of PVS dots obtained from the PVS computational 
method. The y axis is the total PVS volume expressed in millilitres which also obtained from 
the PVS computational method. The blue squares are results from baseline 100 patients. The 
red dots results from 46 of the 100 patients who had follow-up scans. Right: No association 
between averaged PVS volume and count in both baseline and follow-up. The y axis is the 








Figure 7.2 Associations between PVS count and PVS visual rating scores in BG region at 






Figure 7.3 Comparison of PVS computational count condensed into a ‘score’ of similar 
range to the visual rating categories and PVS visual rating score at baseline and follow-
up.  
The x-axis in the histograms represents the values of the score intervals. The y-axis 
represents the frequency of two variables’ occurrence. The results of the condensed score 
from PVS computational count are labelled in dark blue and the results from the PVS visual 





Figure 7.4 Associations between PVS count and PVS visual rating scores in BG region at 





Table 7.1 Associations between PVS count and PVS visual rating scores for baseline and 
follow-ups. 




Baseline 100 patients    
BG Overall 2.114 1.364 to 2.864 36.291 
BG Left 2.179 1.427 to 2.930 36.038 
BG Right 2.130 1.372 to 2.887 36.310 
Baseline 46 patients    
BG Overall 2.175 0.849 to 3.502 38.042 
BG Left 2.372 1.031 to 3.713 37.444 
BG Right 2.175 0.849 to 3.502 38.042 
Follow-up 46 patients    
BG Overall 1.389 0.102 to 2.677 27.083 
BG Left 1.389 0.102 to 2.677 27.083 
BG Right 1.389 0.102 to 2.677 27.083 
BG: basal ganglia; CI: confident interval; CV: coefficient of variances.  
Table 7.2 Associations between PVS volume and PVS visual rating scores for baseline 
and follow-ups. 




Baseline 100 patients    
BG Overall 0.022 0.012 to 0.031 48.638 
BG Left 0.023 0.013 to 0.032 48.352 
BG Right 0.022 0.013 to 0.032 48.500 
Baseline 46 patients    
BG Overall 0.017 0.005 to 0.030 41.092 
BG Left 0.019 0.007 to 0.031 40.472 
BG Right 0.017 0.005 to 0.030 41.092 
Follow-up 46 patients    
BG Overall 0.017 0.003 to 0.031 34.566 
BG Left 0.017 0.003 to 0.031 34.566 
BG Right 0.017 0.003 to 0.031 34.566 





Chapter 8 Associations between PVS and WMH, 
atrophy, blood markers and BBB permeability 
8.1 Introduction 
Perivascular spaces (PVS) on magnetic resonance imaging (MRI) is an 
imaging marker for cerebral small vessel disease (SVD) (Zhu et al., 2010). 
PVS and other SVD features such as white matter hyperintensities (WMH), 
atrophy, microbleeds, lacunes and recent infarcts are inter-related (described 
in Chapter 1 and 2). Increasing numbers of PVS were also associated with 
blood brain barrier (BBB) permeability and cognitive dysfunction (Wardlaw, 
2010).  
Dynamic contrast enhancing MRI and contrast agent gadodiamide are used 
to detect BBB permeability. Gadodiamide (590 daltons) is a small molecule 
which crossed the abnormal BBB noninvasively (Tofts and Kermode, 1991). 
The dynamic contrast enhancing MRI was based on the assumption that 
greater signal enhancement over time links to higher concentration of 
contrast agent inferring a more severe breakdown of BBB (Armitage et al., 
2011). 
Apart from brain imaging techniques, blood marker levels in the peripheral 
circulatory system could be measured and used as markers to reflect 
endothelial function, inflammation and thrombosis status changes in the 
central nervous system. Blood markers relating to endothelial function, 
inflammation and thrombosis were found to be associated with SVD features 
such as WMH, and lacunar stroke (in Chapter 1). However, there were not 




There were four studies found associations between blood markers and PVS 
levels. Higher levels of PVS in the basal ganglia (BG) regions were 
significantly associated with higher levels of Immunoglobulin G against 
hypochlorite oxidized low-density lipoprotein in the blood after adjustment 
for age, sex, hypertension, large artery disease and patient types (lacunar 
stroke, hypertensive and controls). The results suggested that oxidized low-
density lipoprotein may play a role in the PVS progression through 
endothelial dysfunction and antibody formation (Rouhl et al., 2010). Higher 
levels BG PVS were also significantly associated with higher neopterin after 
correction for age, sex, large vessel disease and patient group. Because 
neopterin is produced by activated monocytes or macrophages, the results 
may suggest a relation between monocyte/macrophage activation and PVS 
(Rouhl et al., 2011). In the 3C-Dijon study, researchers found that after 
adjusted for age, gender, hypertension and intracranial volume PVS severity 
in the basal ganglia regions is associated with increased Interleukin-6 (IL-6) 
level, which suggested role of inflammation in SVD (Satizabal et al., 2013). In 
the Lothian Birth Cohort 1936 study, increased centrium semiovale PVS 
numbers were significantly associated with raised plasma C-reactive protein 
levels after accounting for age, sex, stroke, and vascular risk factors 
(Aribisala et al., 2014). 
In this study we aimed to investigate the associations between BG PVS 
count/volume and other SVD features such as WMH, atrophy and PVS in the 
centrum semiovale regions (CS). We also want to explore the associations 
between BG PVS count/volume and plasma markers of endothelial function, 
inflammation, and thrombosis and BBB permeability in the chronic phase of 




hypertension, smoking, diabetes and stroke types. This would help to 
identify more specific therapeutic targets to reduce the stroke and dementia 
burden caused by SVD. 
8.2 Method 
8.2.1 Patients information and risk factors 
We used the same 100 patients with mild stroke who participated in the BBB 
permeability study (descriptions in Chapter 3). We had measured BG PVS 
count and volume (Chapter 7) in all 100 patients at baseline and in 46 of them 
who also had follow-up scans. We will use both the baseline and follow-up 
results to do the comparisons between BG PVS and SVD features (WMH, 
atrophy and CS PVS), and we will only use the results from baseline 100 
patients to explore the associations between BG PVS count/volume and risk 
factors, blood markers and BBB permeability.  
For risk factors, unlike binary risk factors such as hypertension and diabetes, 
there were originally four smoking categories which were N: non-smoker; R: 
recent smoker, less than a year; S: smoker; H: heavy smoker. In order to 
avoid small numbers in some of the smoking categories, we condensed 
recent smoker, smoker and heavy smoker into one category of current or 
ever smoker versus never smoker. We used this dichotomised smoking 
variable in most of our analysis. We will specify when we use four smoking 
categories in our comparisons. 
8.2.2 WMH, atrophy and CS PVS visual rating scale 
WMH were coded using Fazekas score, for periventricular WMH (PWMH) 
and deep WMH (DWMH) separately in the left and right hemispheres, and 




al., 2011). Brain atrophy were coded using a validated template (Farrell et al., 
2009), with superficial and deep atrophy coded separately, and the whole 
atrophy is the sum of deep and superficial atrophy score. PVS in the CS 
regions were rated as follows: 0=no PVS, 1=<10 PVS, 2=10–20 PVS, 3=21–40 
PVS, and 4>=40 PVS, separately in the left and right hemispheres, and an 
‘overall’ score is the averaged score from both hemispheres using a scale 
previously developed by our group (Maclullich et al., 2004; Potter, 2011). 
8.2.3 Blood marker measurement 
We collected venous blood from each patient approximately two months 
post stroke onset to avoid the influence from the acute stroke phase. For each 
patient, we put the blood samples into two 2.5-mL 
ethylenediaminetetraacetic acid tubes and an 8-mL tube containing clot 
activator and gel. Then samples were all transferred on water ice and 
centrifuged at 3000 revolutions per minute for 10 minutes and stored them at 
-80°C. 
Researchers in the clinical laboratories from the University of Glasgow 
blinded to the patients’ clinical information helped us measure the following 
10 blood markers using high sensitive assays (details for assays related to 
each blood marker were summarized in Table 8.1, all tables in this chapter 
are in section 8.6 Tables). We measured von-Willebrand factor (vWF), 
intracellular adhesion molecule 1 (ICAM-1), interleukin-6 (IL6), tumor 
necrosis factor alpha (TNFα), C-reactive protein (CRP), fibrinogen (Fib), 
prothrombin fragments 1 and 2 (F 1+2), thrombin-antithrombin complex 
(TAT), tissue plasminogen activator (tPA), and D dimer as markers of 
endothelial function, inflammation and thrombosis. We categorized them 




(1) Endothelial function: vWF, ICAM-1   
(2) Inflammation: IL-6, TNF-α, CRP 
(3) Thrombosis: Fib, F 1+2, TAT, tPA, D-dimer 
8.2.4 BBB permeability measurement 
The aim of this study was to assess the background status of the BBB, so it 
was done at least one month after the stroke and measurements were taken 
remotely from the recent stroke lesion to avoid any possible alterations 
caused by the acute effects of the stroke (Wardlaw et al., 2009; Wardlaw et 
al., 2008).We used a 1.5-Tesla MRI scanner (Signa LX; GE, Milwaukee, WI) 
and a fast spoiled gradient echo (FSPGR) sequence was run before and after 
intravenous contrast agent injection to assess BBB permeability in the 100 
stroke patients who participated in the permeability study (details of patient 
recruitment in Chapter 3). The FSPGR sequence was run before contrast 
agent injection with flip angles of 2 degrees and 12 degrees. The sequence 
was repeated sequentially and consecutively after intravenous injection of 40 
ml gadodiamide (Omniscan; GE Healthcare AS, Oslo, Norway) with flip 
angle of 12 degrees repeated 26 times with acquisition time of 69s after 
injection (Armitage et al., 2011; Wardlaw et al., 2009). 
For each patient all permeability images were registered to the structural 
MRI. Small regions of interest (ROI:  9 voxels) were placed on the precontrast 
scan widely in white matter (84 ROIs), cortical gray matter (44 ROIs), deep 
gray matter (12 ROIs), cerebrospinal fluid (10 ROIs) and internal 
carotid/basilar arteries (3 ROIs), and sagittal sinus (2 ROIs) using a standard 
template sample (Armitage et al., 2011; Wardlaw et al., 2009). The signal 




contrast agent injection (example of ROIs in WM, deep GM and SS were in 
Figure 8.5).  The overall mean signal was calculated for each tissue type at 
each time point for each patient.  
8.2.5 Statistical analysis 
(1) Associations with SVD features 
In these 100 patients, we used linear regression to investigate the associations 
between BG PVS count/volume, WMH visual rating scores (periventricular: 
PWMH; deep: DWMH) and volume, atrophy visual rating scores and brain 
volume, and CS visual rating scores. All linear regression analyses were 
performed in R program version 2.15.2 (http://www.r-project.org/). 
(2) Associations with blood markers and risk factors 
In the 100 patients, though all of them had blood drawn, blood marker data 
were missing for seven patients. Smoking status was missing for one patient.  
We calculated:  
(2-1) Mean and standard deviations (SD) for each blood marker. 
(2-2) The influence of age, gender, hypertension, smoking, and diabetes on 
PVS count/volume. 
(2-3) The influence of age, gender, hypertension, smoking, and diabetes on 
each blood marker. 
(2-4) Associations between PVS count/volume and each blood marker 
(univariable linear regression) and associations between PVS count/volume 




(2-5) Associations between PVS count/volume and each blood marker, with 
adjustment for age, gender, hypertension, smoking, and diabetes. 
(2-6) Sensitivity analysis for associations between risk factors and PVS levels: 
We investigated the associations between PVS count/volume and risk factors 
(smoking both two categories and four categories, diabetes, hypertension). 
We also used the dichotomised results for these three vascular risk factors 
and rated the appearance of each risk factor as score 1. We then added scores 
together to make a total risk factor score from 0 to 3 for each patient, and 
investigated the associations between PVS count/volume and total risk factor 
scores. 
(2-7) Sensitivity analysis for associations between blood markers in each 
category and PVS levels: 
We explored the associations between PVS count/volume and total blood 
markers values in three different categories mentioned above (endothelial 
function, inflammation and thrombosis).  
We put the blood markers vWF and ICAM-1 into the endothelial function 
category, but probably they may belong to more than one category, for 
example, researchers considered them as markers of inflammation (Whiteley 
et al., 2011). In addition, we generated a total inflammatory category to 
include blood markers from both endothelium and inflammation categories 
(vWF, ICAM-1, IL-6, TNF-α and CRP). We investigated the associations 
between total values in total inflammatory category and PVS levels. We also 





Initially, we tried to investigate the associations using blood marker 
concentration in each category. Due to differences of scale and units of 
measurement, we standardized the blood marker data. For each blood 
marker we calculated the mean and standard deviation (SD). Each 
measurement was then standardized by subtracting the mean and then 
dividing by the SD. The result of this is: 
 The standardized blood marker data is unitless; 
 The new mean of each blood marker is 0, and the new SD is 1; 
 In a linear regression analysis, the coefficients for each blood marker will be 
directly comparable as they have no units and are on the same scale; 
 The different blood marker variables can be added together with equal 
weighting for each blood marker. 
Seven patients have missing values for some of these blood markers. We 
restricted the analysis to the 93 patients who have complete blood marker 
data. 
(2-8) Influence of age and hypertension on smoking status. 
In these 99 patients who had smoking status, we used two sample T test to 
compare the age difference and used chi-square to compare the hypertension 
difference in smoker and non-smoker groups.  
All analyses were performed within Minitab (Minitab Inc, version 16).  Alpha 
level for significance was p<0.05.   
(3) Associations with BBB permeability 
The data comprised signal enhancement values in each brain tissue 




the analysis because the low temporal resolution did not allow the accurate 
measurement of the first pass kinetics.   
A linear mixed model was used in the signal enhancement analysis in the 
ROIs of white matter (WM), cortical grey matter (cortical GM), deep grey 
matter (deep GM), cerebrospinal fluid (CSF), internal carotid/basilar arteries 
(blood vessels), and sagittal sinus (SS). This mixed model could account for 
repeated measurements taken from the same patient, in this case by 
modelling the initial signal enhancement value (time point 4) of each patient 
as a random intercept to account for differences between patients and 
scanner drift (Armitage et al., 2011).  Also each patient was modelled as a 
random effect to allow for repeated measurements over time being correlated 
within patients. The model also included fixed effects: age, sex, weight, 
stroke type and risk factors (hypertension, smoking and diabetes). Ignoring 
the lack of independence of multiple tissue measurements taken from an 
individual patient would result in a flawed analysis. Signal enhancement 
was the dependent variable, and all other variables were independent.  
The residuals (the difference between the measured value and the model 
predicted value of signal enhancement) from the linear mixed model were 
assumed to be normally distributed with a mean of zero. The fit of the linear 
mixed model was assessed by examining Q-Q plots and histograms of the 
residuals. Analyses were performed separately for each brain tissue type 
(WM, cortical GM, deep GM, CSF, blood vessels and SS) as it was not 




Using linear mixed modelling of the signal-time curves, we assessed the 
associations between PVS and signal change with time in different tissue 
types: WM, cortical GM, deep GM, CSF, blood vessels and SS.  
From previous multivariable linear regression analysis, we found that there 
were strong correlations between PVS count/volume and age, and 
hypertension. We assessed the effect of possible collinearity on the results by 
repeating the analysis excluding PVS as an independent variable. The 
presence of collinearity often causes estimates of coefficients to change with 
the inclusion or exclusion of a variable.  
We further explored the associations between signal enhancement and each 
different factor (age, sex, weight, stroke type and risk factors), adjusted for 
time only. All linear mixed modelling of the data was done by Dr Francesca 







The following results refer to the 100 patients with mild stroke, 51 with 
lacunar stroke and 49 with cortical stroke. The mean age is 69 years old, and 
ages ranged from 37 to 92 years old.  The median score of stroke severity 
with the National Institute for Health Stroke Scale (NIHSS) was 2, and 62% 
had hypertension, 53% had smoking history and 15% had diabetes (see Table 
5.1 in chapter 5) 
8.3.1 Associations between BG PVS and SVD features 
(1) WMH visual rating score/volume 
For the baseline 100 patients, BG PVS computational count was positively 
associated with WMH visual rating (overall PWMH: 2.199, 95%CI 1.215 to 
3.182; overall DWMH: 1.919, 95%CI 0.990 to 2.848). The associations of using 
WMH scores on the left or right hemispheres were similar as (Appendix H, 
Table H1 and H2, Figure H1 and H2). BG PVS count was also weakly 
although positively associated with WMH volume (0.065, 95% CI 0.034 to 
0.096) (Figure 8.1, Table 8.2, all figures and tables in this chapter are in 
section 8.5 Figures and section 8.6 Tables).  
The subgroup of 46 patients with long term follow-up, we found similar 
association as for 100 patients at baseline, both at baseline and follow-up 
(Table 8.2, Figure H1, H2 and H3 in Appendix H).  
Similarly there were positive relationships between PVS computational 
volume and visual rating for both baseline and follow-up scans (Table 8.3) 
and for using WMH scores on the left or right hemispheres (Appendix H:  




(2) Cerebral atrophy visual rating score/brain volume 
In the baseline 100 patients, BG PVS count was positively associated with 
whole brain atrophy visual rating (1.012, 95%CI 0.489 to 1.535). BG PVS 
count increased as brain volume (as % of ICV) decreased (-0.326, 95%CI -
0.526 to -0.127). BG PVS volume showed similar associations (Figure 8.2, 
Table 8.3).  
Similarly, the associations still existed in the subgroup of 46 patients with 
long term follow-up at baseline and follow-up, and using scores from deep 
atrophy or superficial atrophy instead of the whole atrophy (Table H1, H2, 
Figure H6 to H10 in Appendix H). 
(3) CS PVS visual rating score 
In the baseline 100 patients, we did not find significant associations between 
BG PVS count/volume and CS visual rating scores (overall, left and right 
hemispheres). The associations remained insignificant in baseline and follow-
up results in the subgroup of 46 patients with long term follow-up (Table 8.2, 
8.3, H1, H2, Figure H11 and H12). 
8.3.2 Associations between PVS and blood markers and risk 
factors 
(1) Mean and SD for blood markers 
We calculated the mean and standard deviations (SD) from patients for each 
blood marker using their original data (Table 8.4). After data 
standardization, the new mean of each blood marker is 0, and SD is 1.  
(2) Influence of patient demographic features on BG PVS levels 
Age is an important influencing factor for BG PVS levels, showing significant 




(p=0.020).  Hypertension is another crucial factor for BG PVS levels, showing 
a significant positive association with BG PVS count (p=0.013), although the 
association between hypertension and BG PVS volume did not reach 
significance. The association between BG PVS volume and male gender did 
not reach significance, which might be explained by the small number of 
patients (Table 8.5). No associations were seen between BG PVS 
count/volume and smoking or diabetes, which might relate to the small 
sample size.  
(3) Influence of patient demographic features on blood markers 
Both vWF and F 1+2 were associated with age, and the association between 
vWF and age is significant. The inflammatory marker IL-6 and the 
thrombosis markers Fib and tPA showed positive associations with smoking, 
particularly for tPA. No significant associations were seen between any 
blood markers and sex, hypertension and diabetes (Table 8.6). 
(4) Associations between blood markers and BG PVS levels (unadjusted) 
On univariable linear regression, the blood thrombosis marker F 1+2 was 
significantly associated with BG PVS count (p=0.050), and the blood 
thrombosis marker TAT was significantly associated with both BG PVS count 
(p=0.013) and BG PVS volume (p=0.037). There were no associations between 
other blood markers and BG PVS count/volume (Table 8.7). On multivariable 
linear regression of BG PVS count/volume with blood markers only, no 
association was found. 
(5) Associations between blood markers and BG PVS levels (adjusted) 
After adjusting the effect of age, sex, hypertension, smoking and diabetes, the 
association between blood marker TAT, F 1+2 and BG PVS became non-




negatively associated with BG PVS count (p=0.032). However, after 
adjustment, age and hypertension still remained significantly associated with 
BG PVS count/volume with almost all markers (Table 8.8: BG PVS count and 
Table 8.9: BG PVS volume). Male gender shows associations with BG PVS 
volume in the appearance of some blood markers, but none of them reached 
significance level. 
(6) Sensitivity analysis: associations between risk factors and BG PVS 
levels 
Apart from the association between hypertension and PVS levels, there was 
no significant association with diabetes and smoking (both two and four 
categories), though this analysis is probably limited by a small number of 
patients with diabetes and smoking (Table 8.10). Both PVS count and volume 
showed slight positive associations to total summed risk factor scores though 
this was not significant (Figure 8.3, Table 8.10). 
Our result (Table 8.6) showed that IL-6, Fib and tPA are significantly 
associated with smoking. We further investigated whether smoking status is 
a confounding factor for the association between PVS and these blood 
markers. We used both the original four smoking categories and condensed 
them into two smoking categories to investigate the association between 
smoking and PVS and IL-6, Fib and tPA. The relationship between PVS and 
IL-6, Fib and tPA did not change when adjusted for smoking (Table 8.11).  
(7) Sensitivity analysis: associations between blood marker categories and 
BG PVS levels 
In the analysis of 93 patients, no significant associations were found between 
PVS count/volume and total summed blood marker category (Table 8.12), 




and total inflammatory categories showed negative associations with PVS 
and thrombosis factors showed a positive association.   
(8) Influence of age and hypertension on smoking 
Because our result showed age and hypertension were two important factors 
for BG PVS (Table 8.8 and 8.9), so we wanted to know any associations with 
smoking were confounded by age and hypertension. We found that there 
was a difference between smoker and non-smoker, smoker were nearly four 
years younger than non-smoker though not significant (mean age of non-
smoker: 68.7 years old, smoker: 64.9 years old, p=0.094) (Figure 8.4). There 
was no significant difference of hypertension status between smoker and 
non-smoker (Chi-Square=1.212, df=1, p=0.271). The associations between 
smoking and PVS or blood markers were not confounded by age. 
8.3.3 Associations with BBB permeability 
When analysed separately for each brain tissue type, the residuals for a 
model of signal enhancement in the blood vessels of internal carotid/basilar 
arteries showed that the model fit for blood vessel was poor (Figure 8.6), so 
we restricted further analysis to the remaining five tissue types of  WM, 
cortical GM, deep GM, CSF, and SS. 
(1) Univariable analysis: associations between PVS and signal 
enhancement (without adjusting) 
PVS count was significantly associated with signal enhancement in WM, 
cortical GM, and CSF (Table 8.13). PVS volume was significantly associated 
with signal enhancement in cortical GM and borderline-significantly 




(2) Multivariable analysis: associations between different factors and 
signal enhancement (effect adjustment) 
In all tissue types, signal enhancement was related to the PVS count and 
remained negatively associated, though no longer significant, after adjusting 
for time point, age, sex, weight, stroke type and risk factors (Table 8.15). 
Therefore the association between PVS count and signal enhancement in the 
WM might be significant if the sample size was larger (p=0.07). 
Tissue signal enhancement was related to time significantly in all tissue types 
(p<0.001). In WM, GM and SS, signal enhancement decreased with time, but 
in the CSF, signal enhancement increased with time, which might be related 
to the contrast agent entering the CSF slowly. The hypothesis was contrast 
agent crossed the BBB soon after injection and then drained into CSF via PVS 
and direct diffusion from the brain to the ventricles over time (Abbott, 2004) 
(Table 8.15).  
Increasing age was not always associated with increasing brain tissue signal 
enhancement. In contrast, increasing age was significantly associated with 
signal enhancement decreased with time in cortical GM (p=0.025) and CSF 
(p=0.013), and was also associated with signal enhancement decreased with 
time in WM though not significantly. Increasing age was associated with 
increasing signal in deep GM and SS, but these associations were not 
significant. 
Male gender was associated with increasing signal enhancement in WM, CSF 
and SS, and female gender was associated with increasing signal 
enhancement in GM, but none of these associations were significant. The 
association between female gender and signal enhancement in the cortical 




Weight was negatively associated with signal enhancement in all tissue 
types, and associations were significant in WM (p=0.005), deep GM (p=0.002) 
and SS (p=0.005). Negative associations might be influenced by the contrast 
agent concentration: contrast dose was not adjusted for weight, and therefore 
patients of smaller weight had a higher contrast agent concentration. 
Hypertension was related to increasing signal enhancement in WM and SS, 
smoking was related to higher signal enhancement in deep GM, CSF and SS, 
and diabetes related to worse BBB function in deep GM, but these 
associations were not significant. Fifteen patients with diabetes showed 
significant lower signal enhancement in CSF (p=0.032), which might indicate 
drainage dysfunction in the diabetes patients though need to confirm in 
larger sample.  
We changed PVS count into PVS volume, and did the multivariable analysis 
again; the associations between different factors and permeability remained 
similar (Table 8.16). 
Because in previous association analysis between PVS and risk factors, we 
found both age and hypertension were important influencing factors for 
PVS, so we did the collinearity check between PVS and all other factors by 
excluding PVS count/volume in the multivariable linear mixed model. The 
results from this analysis (Table 8.17) were similar as including PVS (Table 
8.15 and 8.16), so we concluded that the possible effect of collinearity, 
because of the association between PVS and age and hypertension, was not 





The significant associations seen for the BG PVS count/volume and WMH 
and cerebral atrophy were consistent with results seen in previous work 
(Doubal et al., 2010b; Potter et al., 2013; Rouhl et al., 2008; Zhu et al., 2010). 
Previous studies showed a positive association between visually rated BG 
and CS PVS scores (Doubal et al., 2010b; Potter, 2011; Potter et al., 2013). 
However, we did not find significant associations between the BG PVS 
count/volume and CS rating scores.  
Apart from being as a SVD feature,  PVS were seen in MS patients (Wuerfel 
et al., 2008) and were considered as a marker of inflammation. PVS were also 
associated with cognitive dysfunction such as in studies of lacunar infarcts 
and WMH (Rouhl et al., 2008), vascular dementia, Alzheimer’s disease and 
mild cognitive impairment (Chen et al., 2011). PVS also appear in MRI scans 
from young and healthy volunteers who participate as controls for studying 
the mechanisms of ageing and brain diseases.  
We drew the blood and performed the contrast enhancement MRI 
approximately two months post stroke onset, and our results may suggest 
the blood marker associations and BBB status in condition of chronic phase 
of stroke instead of acute phase. 
Our results found that most of the blood markers we studied were not 
significantly associated with PVS count/volume. This is an exploratory 
hypothesis generating study, there is a possible relationship between PVS 
count/volume and thrombosis blood marker TAT on univariable analysis, 
and negative associations with endothelial function factor vWF after 




level was considered a sign of endothelial cell dysfunction: studies showed 
that vWF protein is upregulated in the plasma of patients a variety of 
neurological diseases such as with stroke (Folsom et al., 1999), cerebral 
malaria (Hollestelle et al., 2006) and severe head injury (Yokota, 2007). 
However, a recent study demonstrated potential protective effect of vWF on 
BBB permeability using vWF knockout mice model. They showed that vWF 
inhibited the expression of claudin-5 which leaded to increased BBB 
permeability, but in the vWF knockout mice, increased claudin-5 expression 
did not provide protection to the BBB but actually be detrimental (Suidan et 
al., 2013).  
For the associations, we could not be over optimistic about them; all of these 
associations still need to be confirmed by larger sample size, and considering 
the differences between lacunar and cortical stroke types.  
We used standardized results in our comparisons between PVS and 
categorized blood markers. A disadvantage of standardization is a loss of 
ease of interpretation: the concept of a unit change no longer applies. 
However, we added blood marker data together to create new grouped 
variables of “endothelial function”, “inflammation” and “thrombosis”, which 
were not necessarily measured in any one particular unit. Blood markers in 
the endothelial function, inflammatory and total inflammatory categories 
showed negative associations with PVS and thrombosis factors showed a 
positive association.  They might have opposite effects on PVS, and adding 
them together into a total blood marker category could cause the effects to 
cancel each other out. For further blood marker studies, it would be 
reasonable to explore the associations using blood markers in the same 




We found age and hypertension are important influencing factors for BG 
PVS count and volume, which is consistent with previous studies that PVS 
severity is associated with age and hypertension (Martinez-Ramirez et al., 
2013; Potter et al., 2013; Rouhl et al., 2008; Wuerfel et al., 2008; Zhu et al., 
2011; Zhu et al., 2010). Thus it is crucial to adjust for age and hypertension in 
further PVS analysis. 
Smoking is a risk factor for some markers, but it is unclear whether this 
reflects the “poisoning” components in the cigarettes or the life habits related 
to smoking that influence these markers. In the multivariable analysis, we 
found inflammatory blood marker IL-6 and thrombosis blood makers Fib 
and tPA were significantly associated with smoking, however, we did not 
find significant associations between PVS and smoking status neither did 
Zhu in the 3C-Dijon study of 1818 patients, 108 of whom were current 
smoker (Zhu et al., 2010). In our study, we found that there was an age 
difference of four years between smoker and non-smoker which might 
confound the associations between smoking and PVS and blood markers,   a 
larger sample is needed to explore the associations between PVS and 
smoking.  
PVS count/volume were significantly associated with increasing permeability 
in cortical GM, and PVS count was also significantly correlated to higher 
permeability in WM and CSF in the univariable analysis before adjustment of 
other factors. After adjustment, PVS remained negatively associated 
permeability, however, the significance disappeared. 
Body weight was negatively associated with permeability in nearly all 




different contrast agent concentration; because in this study the contrast dose 
was not adjusted by body weight for each individual patient, all patients 
were given the same 40 ml contrast agent injection leading to smaller patients 
had higher contrast agent concentration. For further studies, it would be very 
helpful to adjust contrast agent does by body weight for each patients.  
Further studies with a larger sample size would be useful to investigate the 
associations between PVS count and permeability in the WM, and between 
lacunar stroke and higher permeability in WM. 
The permeability in CSF would be helpful to study the drainage function in 
patients’ brain. The significant decreasing permeability in CSF might be an 
indicator drainage dysfunction in the diabetes patients, it needs further 







Figure 8.1 Associations between baseline 100 BG PVS count/volume and WMH (PWMH, 





Figure 8.2 Associations between baseline 100 BG PVS count/volume and atrophy (brain 
atrophy visual rating scores, and brain tissue volume expressed as a percentage of ICV).  
 





Figure 8.4 Individual value plot of age versus smoking status.  
 
Figure 8.5 Example of the standard template for sampling regions of interest (ROIs: 
yellow circles) in white matter (WM) and deep gray matter (deep GM). One ROI in 





Figure 8.6 Residuals for a model of signal enhancement in blood vessels of internal 






Table 8.1 Assay details for blood markers. 





vWF ELISA (DAKO, High Wycombe, UK) IU/dL 3.3% 4.2% 
ICAM-1 ELISA (R&D Systems, Abingdon, UK) ng/ml 3.6% 7.4% 
Inflammation     
IL-6 ELISA (R&D Systems, Abingdon, UK) pg/ml 7.5% 8.9% 
TNF-α  ELISA (R&D Systems, Abingdon, UK) pg/ml 8.4% 12.5% 
CRP  Immunonephelometry  
(Prospec, Dade Behring Milton 
Keynes, UK)  
mg/l 4.7% 8.3% 
Thrombosis     
Fib  Immunonephelometry  
(Prospec, Dade Behring Milton 
Keynes, UK)  
g/l 7.5% 8.9% 
F 1+2  Immunonephelometry  
(Prospec, Dade Behring Milton 
Keynes, UK) 
pg/ml 6.0% 9.0% 
TAT  Immunonephelometry  
(Prospec, Dade Behring Milton 
Keynes, UK) 
ng/ml 3.6% 4.3% 
tPA  ELISA (Biopool AB, Umea Sweden) ng/mL 6.6% 6.5% 
D dimer  ELISA (Biopool AB, Umea Sweden) ng/ml 4.7% 5.2% 
ELISA: enzyme-linked immunosorbent assay, CV: coefficients of variation, vWF: von-Willebrand 
factor, ICAM-1 intracellular adhesion molecule 1; IL-6interleukin-6, TNF-α: tumor necrosis factor 
alpha, CRP: C-reactive protein; Fib: Fibrinogen, F 1+2: prothrombin fragments 1 and 2, TAT: 






Table 8.2 Associations between BG PVS count and SVD features (WMH, atrophy and CS 
PVS) for baseline and follow-ups. 
Associations Coefficient of linear regression 95% CI CV 
Baseline 100 patients    
PWMH Overall 2.199 1.215 to 3.182 38.038 
DWMH Overall 1.919 0.990 to 2.848 38.507 
WMH volume 0.065 0.034 to 0.096 38.366 
Whole Atrophy 1.012 0.489 to 1.535 38.855 
Brain Volume in ICV -0.326 -0.526 to -0.127 39.606 
CS Overall 0.677 -0.279 to 1.633 41.268 
Baseline 46 patients    
PWMH Overall 1.642 -0.062 to 3.347 40.793 
DWMH Overall 2.626 1.014 to 4.238 38.097 
WMH volume 0.115 0.029 to 0.202 39.404 
Whole Atrophy 1.002 0.010 to 1.995 40.636 
Brain Volume in ICV -0.278 -0.691 to 0.136 41.648 
CS Overall -0.355 -2.002 to 1.292 42.412 
Follow-up 46 patients    
PWMH Overall 0.841 -0.661 to 2.342 28.097 
DWMH Overall 0.936 -0.419 to 2.291 27.893 
WMH volume 0.07 0.011 to 0.129 26.818 
Whole Atrophy 0.522 -0.179 to 1.223 27.797 
Brain Volume in ICV -0.124 -0.430 to 0.182 28.281 
CS Overall 0.533 -0.893 to 1.958 28.315 
CI: confident interval; CV: coefficient of variances; PWMH: periventricular white matter 






Table 8.3 Associations between BG PVS volume and SVD features (WMH, atrophy and 
CS PVS) for baseline and follow-ups. 
Associations Coefficient of linear regression 95% CI CV 
Baseline 100 patients    
PWMH Overall 0.027 0.015 to 0.039 48.677 
DWMH Overall 0.019 0.008 to 0.031 50.746 
WMH volume 0.001 0.001 to 0.001 48.047 
Whole Atrophy 0.009 0.002 to 0.016 51.603 
Brain Volume in ICV -0.003 -0.006 to -0.001 51.79 
CS Overall 0.010 -0.001 to 0.022 52.618 
Baseline 46 patients    
PWMH Overall 0.014 -0.001 to 0.029 43.158 
DWMH Overall 0.020 0.005 to 0.035 41.592 
WMH volume 0.001 0.000 to 0.002 41.788 
Whole Atrophy 0.008 -0.001 to 0.017 43.31 
Brain Volume in ICV -0.002 -0.006 to 0.001 44.028 
CS Overall -0.006 -0.020 to 0.009 44.507 
Follow-up 46 patients    
PWMH Overall 0.017 0.001 to 0.033 35.059 
DWMH Overall 0.014 -0.001 to 0.028 35.552 
WMH volume 0.001 0.001 to 0.002 32.117 
Whole Atrophy 0.006 -0.002 to 0.013 36.101 
Brain Volume in ICV -2E-4 -0.004 to 0.003 36.926 
CS Overall 0.008 -0.008 to 0.023 36.489 
CI: confident interval; CV: coefficient of variances; PWMH: periventricular white matter 






Table 8.4 Mean of original concentrations for each blood marker. 
Blood markers Original concentration mean (SD), unit 
Endothelial function  
vWF (n=99) 127.1 (39.2), IU/dL 
ICAM-1 (n=96) 166.9 (52.3), ng/ml 
Inflammation  
IL-6 (n=98) 3.3 (2.1), pg/ml  
TNF-α (n=99) 1.0 (0.8), pg/ml 
CRP (n=99) 3.8 (9.0), mg/L 
Thrombosis  
Fib (n=97) 3.9 (0.6), g/l  
F 1+2 (n=99) 298.1 (213.9), pg/ml 
TAT (n=99) 6.0 (5.9), ng/ml 
tPA (n=99) 7.8 (3.2), ng/ml 
D dimer (n=99) 160.7 (188.8), ng/ml 
 
Table 8.5 Associations between BG PVS count/volume and age, gender, hypertension, 
smoking, and diabetes. 
Coefficient (95%CI,p) BG PVS count BG PVS volume 
Age  0.117 (0.040 to 0.194, p=0.003*) 0.001 (0.000 to 0.002, p=0.020*) 
Male Sex 1.433 (-0.518 to 3.383, p=0.148) 0.023 (-0.002 to 0.047, p=0.072) 
Hypertension  2.225 (0.476 to 3.973, p=0.013*) 0.022 (-0.001 to 0.044, p=0.056) 
Smoking  -0.648 (-2.315 to 1.019, p=0.442) -0.009 (-0.030 to 0.012, p=0.383) 
Diabetes -0.756 (-3.086 to 1.574, p=0.521) -0.001 (-0.031 to 0.028, p=0.920) 
*p<0.05; BG PVS count: total number of PVS dots in each patient in the selected BG regions; PVS 
volume: total volume of all the PVS dots; Age: age increase per year; Smoking: current or ever 





Table 8.6 Associations between blood markers and age, gender, hypertension, smoking, and diabetes. 
Blood markers Age Male Sex Hypertension Smoking Diabetes 
Endothelial function      
vWF (n=98) 1.565 (0.870 to 2.260, 
p<0.001*) 
-1.815 (-19.897 to 16.266, 
p=0.842) 
-5.428 (-21.275 to 10.419, 
p=0.498) 
5.499 (-9.764 to 20.762, 
p=0.476) 
5.966 (-15.794 to 27.727, 
p=0.587) 
ICAM-1 (n=95) -0.487 (-1.510 to 0.537, 
p=0.347) 
-0.758 (-27.848 to 26.331, 
p=0.956) 
-13.698 (-37.106 to 9.710, 
p=0.248) 
-7.535 (-30.061 to 14.991, 
p=0.508) 
-5.699 (-38.728 to 27.330, 
p=0.733) 
Inflammation      
IL-6 (n=97) 0.021 (-0.020 to 0.062, 
p=0.306) 
0.044 (-1.022 to 1.110, 
p=0.935) 
-0.015 (-0.955 to 0.925, 
p=0.974) 
0.910 (0.010 to 1.811, 
p=0.048*) 
-0.179 (-1.463 to 1.105, 
p=0.782) 
TNF-α (n=98) -0.004 (-0.019 to 0.012, 
p=0.621) 
-0.193 (-0.593 to 0.207, 
p=0.339) 
0.049 (-0.301 to 0.400, 
p=0.781) 
-0.034 (-0.371 to 0.304, 
p=0.844) 
0.022 (-0.460 to 0.503, 
p=0.929) 
CRP (n=98) 0.036 (-0.135 to 0.208, 
p=0.675) 
1.900 (-2.567 to 6.366, 
p=0.400) 
2.240 (-1.674 to 6.154, 
p=0.259) 
3.228 (-0.542 to 6.998, 
p=0.092) 
-2.317 (-7.692 to 3.058, 
p=0.394) 
Thrombosis      
Fib (n=96) 0.008 (-0.003 to 0.018, 
p=0.161) 
0.178 (-0.097 to 0.454, 
p=0.202) 
0.013 (-0.230 to 0.256, 
p=0.913) 
0.287 (0.054 to 0.520, 
p=0.016*) 
-0.126 (-0.457 to 0.205, 
p=0.452) 
F 1+2 (n=98) 3.635 (-0.307 to 7.577, 
p=0.070) 
-2.884 (-105.447 to 99.679, 
p=0.956) 
38.677 (-51.211 to 128.565, 
p=0.395) 
-77.362 (-163.940 to 9.216, 
p=0.079) 
-94.426 (-217.858 to 29.006, 
p=0.132) 
TAT (n=98) 0.064 (-0.048 to 0.176, 
p=0.258) 
0.245 (-2.658 to 3.149, 
p=0.867) 
1.309 (-1.236 to 3.854, 
p=0.310) 
-1.705 (-4.156 to 0.746, 
p=0.170) 
-0.507 (-4.002 to 2.988, 
p=0.774) 
tPA (n=98) -0.005 (-0.063 to 0.052, 
p=0.852) 
1.170 (-0.332 to 2.673, 
p=0.125) 
0.527 (-0.790 to 1.843, 
p=0.429) 
2.165 (0.897 to 3.433, 
p=0.001*) 
-0.036 (-1.844 to 1.772, 
p=0.969) 
D dimer (n=98) 0.855 (-2.821 to 4.531, 
p=0.645) 
27.421 (-68.217 to 123.059, 
p=0.570) 
20.053 (-63.765 to 103.871, 
p=0.636) 
0.546 (-80.186 to 81.278, 
p=0.989) 
-62.350 (-177.447 to 52.747, 
p=0.285) 





Table 8.7 Association between individual blood marker and BG PVS count/volume (univariable). 
Blood markers BG PVS count BG PVS volume 
Endothelial function   
vWF (n=99) -0.005 (-0.028 to 0.018, p=0.660) 3.95E-05 (-23.81E-05 to 31.70E-05, p=0.778) 
ICAM-1 (n=96) -0.009 (-0.026 to 0.008, p=0.311) -1.40E-05 (-22.67E-05 to 19.80E-05, p=0.893) 
Inflammation   
IL-6 (n=98) -0.108 (-0.529 to 0.313, p=0.612) -1.10E-05 (-0.005 to 0.005, p=0.997) 
TNF-α (n=99) -0.702 (-1.825 to 0.422, p=0.218) -0.003 (-0.017 to 0.011, p=0.640) 
CRP (n=99) -0.009 (-0.108 to 0.090, p=0.852) -4.00E-05 (-124.94E-05 to 117.00E-05, p=0.948) 
Thrombosis   
Fib (n=97) -0.160 (-1.732 to 1.411, p=0.840) 0.003 (-0.016 to 0.022, p=0.753) 
F 1+2 (n=99) 0.004 (0.000 to 0.008, p=0.050*) 3.92E-05 (-1.12E-05 to 9.00E-05, p=0.126) 
TAT (n=99) 0.189 (0.041 to 0.336, p=0.013*) 0.002 (0.000 to 0.004, p=0.037*) 
tPA (n=99) -0.065 (-0.343 to 0.214, p=0.647) -0.001 (-0.004 to 0.002, p=0.540) 
D dimer (n=99) 0.002 (-0.003 to 0.007, p=0.386) 2.60E-05 (3.20E-05 to 8.30E-05, p=0.372) 
*p<0.05; vWF: von-Willebrand factor, ICAM-1 intracellular adhesion molecule 1; IL-6interleukin-6, TNF-α: tumor necrosis factor alpha, CRP: C-reactive protein; Fib: 






Table 8.8 Associations between BG PVS count and blood markers after adjusting for age, sex, hypertension, smoking, and diabetes. 
Blood marker Blood marker 
association 
Age Male Sex Hypertension Smoking Diabetes 
Endothelial function       
vWF (n=98) 
 
-0.025 (-0.047 to -
0.002, p=0.032*) 
0.155 (0.072 to 0.239, 
p>0.001*) 
1.364 (-0.605 to 3.333, 
p=0.172) 
2.095 (0.365 to 3.824, 
p=0.018*) 
-0.498 (-2.164 to 1.168, 
p=0.554) 




-0.003 (-0.019 to 0.013, 
p=0.747) 
0.109 (0.031 to 0.187, 
p=0.007*) 
1.259 (-0.798 to 3.316, 
p=0.227) 
2.408 (0.617 to 4.199, 
p=0.009*) 
-0.849 (-2.563 to 0.866, 
p=0.328) 
-0.440 (-2.950 to 2.070, 
p=0.728) 
Inflammation       
IL-6 (n=97) 
 
-0.153 (-0.549 to 0.242, 
p=0.443) 
0.123 (0.044 to 0.201, 
p=0.003*) 
1.377 (-0.646 to 3.401, 
p=0.180) 
2.158 (0.374 to 3.942, 
p=0.018*) 
-0.532 (-2.279 to 1.215, 
p=0.547) 




-0.613 (-1.650 to 0.424, 
p=0.243) 
0.114 (0.037 to 0.192, 
p=0.004*) 
1.290 (-0.724 to 3.304, 
p=0.206) 
2.259 (0.502 to 4.016, 
p=0.012*) 
-0.654 (-2.346 to 1.037, 
p=0.444) 




-0.034 (-0.127 to 0.060, 
p=0.474) 
0.118 (0.041 to 0.196, 
p=0.003*) 
1.473 (-0.548 to 3.494, 
p=0.151) 
2.304 (0.528 to 4.081, 
p=0.012*) 
-0.525 (-2.251 to 1.201, 
p=0.547) 
-0.801 (-3.234 to 1.631, 
p=0.514) 
Thrombosis       
Fib (n=96) 
 
-0.639 (-2.175 to 0.896, 
p=0.410) 
0.123 (0.044 to 0.201, 
p=0.003*) 
1.371 (-0.668 to 3.409, 
p=0.185) 
2.091 (0.309 to 3.872, 
p=0.022*) 
-0.335 (-2.102 to 1.431, 
p=0.707) 
-0.649 (-3.087 to 1.788, 
p=0.598) 
F 1+2 (n=98) 
 
0.002 (-0.002 to 0.006, 
p=0.424) 
0.111 (0.032 to 0.190, 
p=0.006*) 
1.413 (-0.598 to 3.425, 
p=0.166) 
2.165 (0.395 to 3.935, 
p=0.017*) 
-0.507 (-2.234 to 1.220, 
p=0.561) 




0.122 (-0.020 to 0.264, 
p=0.091) 
0.109 (0.032 to 0.186, 
p=0.006*) 
1.379 (-0.609 to 3.366, 
p=0.172) 
2.069 (0.318 to 3.820, 
p=0.021*) 
-0.426 (-2.120 to 1.269, 
p=0.619) 




-0.074 (-0.351 to 0.204, 
p=0.600) 
0.116 (0.039 to 0.194, 
p=0.004*) 
1.495 (-0.547 to 3.536, 
p=0.149) 
2.267 (0.495 to 4.040, 
p=0.013*) 
-0.475 (-2.279 to 1.330, 
p=0.603) 
-0.726 (-3.152 to 1.700, 
p=0.554) 
D dimer (n=98) 
 
0.001 (-0.003 to 0.005, 
p=0.661) 
0.116 (0.038 to 0.194, 
p=0.004*) 
1.382 (-0.638 to 3.402, 
p=0.178) 
2.209 (0.440 to 3.979, 
p=0.015*) 
-0.634 (-2.337 to 1.068, 
p=0.461) 
-0.663 (-3.105 to 1.779, 
p=0.591) 




Table 8.9 Associations between BG PVS volume and blood markers after adjusting for age, sex, hypertension, smoking, and diabetes. 
Blood marker Blood marker 
association 
Age Male Sex Hypertension Smoking Diabetes 
Endothelial function       
vWF (n=98) 
 
1.28E-04 (4.19E-04 to 
1.62E-04, p=0.383) 
0.001 (0.000 to 0.002, 
p=0.014*) 
0.022 (-0.004 to 0.047, 
p=0.095) 
0.021 (-0.001 to 0.043, 
p=0.065) 
-0.008 (-0.030 to 0.013, 
p=0.453) 




0.53E-04 (-1.51E-04 to 
2.57E-04, p=0.606) 
0.001 (0.000 to 0.002, 
p=0.026*) 
0.019 (-0.007 to 0.046, 
p=0.145) 
0.024 (0.001 to 0.047, 
p=0.038*) 
-0.009 (-0.031 to 0.013, 
p=0.400) 
0.004 (-0.028 to 0.036, 
p=0.804) 
Inflammation       
IL-6 (n=97) 
 
-2.27E-04 (-0.005 to 
0.005, p=0.927) 
0.001 (0.000 to 0.002, 
p=0.011*) 
0.020 (-0.005 to 0.045, 
p=0.113) 
0.019 (-0.003 to 0.041, 
p=0.096) 
-0.010 (-0.032 to 0.011, 
p=0.351) 




-0.002 (-0.015 to 0.011, 
p=0.757) 
0.001 (0.000 to 0.002, 
p=0.022*) 
0.021 (-0.004 to 0.047, 
p=0.100) 
0.022 (-0.001 to 0.044, 
p=0.056) 
-0.009 (-0.030 to 0.013, 
p=0.412) 




-2.59E-04 (-0.001 to 
0.001, p=0.664) 
0.001 (0.000 to 0.002, 
p=0.020*) 
0.022 (-0.003 to 0.048, 
p=0.087) 
0.022 (0.000 to 0.045, 
p=0.053) 
-0.008 (-0.030 to 0.014, 
p=0.467) 
-0.001 (-0.032 to 0.030, 
p=0.945) 
Thrombosis       
Fib (n=96) 
 
-0.001 (-0.021 to 0.018, 
p=0.906) 
0.001 (0.000 to 0.002, 
p=0.024*) 
0.021 (-0.005 to 0.047, 
p=0.116) 
0.021 (-0.002 to 0.043, 
p=0.075) 
-0.007 (-0.030 to 0.015, 
p=0.515) 
0.001 (-0.031 to 0.032, 
p=0.971) 
F 1+2 (n=98) 
 
0.16E-04 (-0.35E-04 to 
0.67E-04, p=0.535) 
0.001 (0.000 to 0.002, 
p=0.031*) 
0.022 (-0.004 to 0.047, 
p=0.091) 
0.021 (-0.001 to 0.043, 
p=0.065) 
-0.008 (-0.029 to 0.014, 
p=0.490) 




0.001 (-0.001 to 0.003, 
p=0.163) 
0.001 (0.000 to 0.002, 
p=0.031*) 
0.021 (-0.004 to 0.047, 
p=0.094) 
0.020 (-0.002 to 0.042, 
p=0.078) 
-0.007 (-0.028 to 0.015, 
p=0.538) 




-0.001 (-0.005 to 0.002, 
p=0.451) 
0.001 (0.000 to 0.002, 
p=0.022*) 
0.023 (-0.002 to 0.049, 
p=0.075) 
0.022 (0.000 to 0.045, 
p=0.050*) 
-0.006 (-0.029 to 0.017, 
p=0.604) 
-0.001 (-0.031 to 0.030, 
p=0.974) 
D dimer (n=98) 
 
0.16E-04 (-0.39E-04 to 
0.71E-04, p=0.571) 
0.001 (0.000 to 0.002, 
p=0.023*) 
0.021 (-0.004 to 0.047, 
p=0.099) 
0.021 (-0.001 to 0.044, 
p=0.061) 
-0.009 (-0.030 to 0.013, 
p=0.414) 
0.001 (-0.030 to 0.031, 
p=0.973) 




Table 8.10 Associations between BG PVS count/volume and risk factors (smoking, diabetes, hypertension and total summed risk factors).  
 Smoking:  
4 categories  








Total summed risk 
factors 
(0-3) 
BG PVS count R: -4.884 (-10.058 to 0.290, 
p=0.064) 
S: -1.508 (-3.525 to 0.510, 
p=0.141) 
H: 0.151 (-2.217 to 2.519, 
p=0.900) 
Y:  
-1.104 (-2.872 to 0.664, 
p=0.218) 
Y: 
-0.738 (-3.212 to 1.736, 
p=0.555) 
Y: 
2.725 (0.982 to 4.468, 
p=0.003*) 
1:-1.082 (-3.832 to 1.669,  
p=0.437) 
2: 0.516 (-2.397 to 3.429, 
p=0.726) 
3: 0.000 (-4.351 to 4.351, 
p>0.999) 
BG PVS volume R: -0.046 (-0.109 to 0.018, 
p=0.155) 
S: -0.019 (-0.043 to 0.006, 
p=0.139) 
H: 0.002 (-0.027 to 0.031, 
p=0.907) 
Y: 
-0.013 (-0.034 to 0.009, 
p=0.239) 
Y:  
-0.001 (-0.031 to 0.029, 
p=0.954) 
Y: 
0.027 (0.005 to 0.048, 
p=0.016*) 
1: -0.021 (-0.054 to 0.012, 
p=0.215) 
2: -0.001 (-0.036 to 0.035, 
p=0.971) 
3: 0.000 (-0.053 to 0.053, 
p=0.994) 





Table 8.11 Association between smoking, BG PVS and blood markers IL-6, Fib, tPA. 
 BG PVS count BG PVS volume 
IL-6 (n=97)   
smoking (4 categories) R:-4.949 (-10.168 to 0.269, p=0.063) 
S:-1.528 (-3.600 to 0.545, p=0.147) 
H:0.536 (-1.973 to 3.045, p=0.672) 
IL-6:-0.139 (-0.570 to 0.292, p=0.523) 
R: -0.046 (-0.109 to 0.017, p=0.150) 
S: -0.022 (-0.047 to 0.003, p=0.080) 
H: 0.005 (-0.026 to 0.035, p=0.766) 
IL-6: -1.7E-04 (-0.005 to 0.005, p=0.948) 
smoking (2 categories) Y: -1.070 (-2.914 to 0.773, p=0.252) 
IL-6: -0.057 (-0.488 to 0.374, p=0.792) 
Y: -0.015 (-0.037 to 0.007, p=0.183) 
IL-60.001 (-0.004 to 0.006, p=0.790) 
Fib (n=96)   
smoking (4 categories) R: -4.709 (-9.885 to 0.467, p=0.074) 
S: -1.381 (-3.485 to 0.722, p=0.195) 
H: 0.544 (-1.936 to 3.024, p=0.664) 
Fib: -0.099 (-1.719 to 1.521, p=0.904) 
R: -0.044 (-0.108 to 0.020, p=0.172) 
S: -0.019 (-0.045 to 0.007, p=0.152) 
H: 0.004 (-0.026 to 0.035, p=0.777) 
Fib: 0.004 (-0.016 to 0.025, p=0.659) 
smoking (2 categories) Y: -0.938 (-2.801 to 0.925, p=0.320) 
Fib: 0.038 (-1.596 to 1.673, p=0.963) 
Y: -0.013 (-0.035 to 0.010, p=0.278) 
Fib: 0.006 (-0.014 to 0.026, p=0.574) 
tPA (n=98)   
smoking (4 categories) R: -4.837 (-10.074 to 0.400, p=0.070) 
S: -1.446 (-3.583 to 0.692, p=0.183) 
H: 0.409 (-2.137 to 2.955, p=0.751) 
tPA:-0.028 (-0.325 to 0.269, p=0.853) 
R: -0.045 (-0.109 to 0.020, p=0.170) 
S: -0.017 (-0.043 to 0.009, p=0.199) 
H: 0.006 (-0.025 to 0.037, p=0.701) 
tPA: -0.001 (-0.004 to 0.003, p=0.706) 
smoking (2 categories) Y: -1.036 (-2.957 to 0.885, p=0.287)  
tPA: -0.012 (-0.312 to 0.288, p=0.938) 
Y: -0.011 (-0.035 to 0.012, p=0.351)  
tPA: -0.001 (-0.004 to 0.003, p=0.777) 





Table 8.12 Associations results between BG PVS count/volume and categorized blood markers (standardized).  












BG PVS count -0.243  
(-0.850 to 0.364, p=0.428) 
-0.145  
(-0.540 to 0.251, p=0.469) 
0.163  
(-0.157 to 0.483, p=0.315) 
-0.138  
(-0.432 to 0.157, p=0.355) 
1.34 E-04  
(-0.184 to 0.183, p=0.998) 
BG PVS volume 0.001  
(-0.007 to 0.008, p=0.864) 
-0.001 
 (-0.005 to 0.004, p=0.833) 
0.002  
(-0.002 to 0.006, p=0.329) 
-2.00 E-04  
(-0.004 to 0.003, p=0.941) 
0.001  
(-0.002 to 0.003, p=0.611) 
 
Table 8.13 Estimates of the change in signal enhancement per unit change in PVS count adjusted for time.  
Tissue Signal enhancement  P value 
White matter -0.0005 (-0.001,-0.00006) 0.026* 
Cortical grey matter -0.0016 (-0.0028,-0.0003) 0.016* 
Deep grey matter -0.0004 (-0.0018,0.00098) 0.57 
Cerebrospinal fluid -0.005 (-0.0098,-0.0002) 0.043* 
Sagittal sinus -0.0016 (-0.021,0.01785) 0.89 
 
Table 8.14 Estimates of the change in signal enhancement per unit change in PVS volume adjusted for time. 
Tissue Signal enhancement P value 
White matter -0.040 (-0.081,0.0002) 0.051 
Cortical grey matter -0.131 (-0.238,-0.024) 0.017* 
Deep grey matter -0.038 (-0.153,0.078) 0.52 
Cerebrospinal fluid -0.302 (-0.710,0.105) 0.15 





Table 8.15 Estimates of the effect of PVS count, time, age, sex (male versus female), weight, stroke type (lacunar versus cortical) and risk factors 
(hypertension, smoking and diabetes: present versus absent) on signal enhancement in WM, cortical GM, deep GM, CSF and SS.  
Coefficient (95%CI,p) 
 
WM cortical GM deep GM CSF SS 
PVS count -4.9E-4 (-10.1E-4 to 0.4E-
4, p=0.070) 
-7.0E-4 (-20.7E-4 to 6.7E-
4, p=0.317) 
-1.0E-4 (-15.9E-4 to 13.9E-
4, p=0.898) 
-0.001 (-0.007 to 0.004, 
p=0.608) 
-0.005 (-0.027 to 0.016, 
p=0.631) 
Time -4.6E-4 (-5.1E-4 to -4.1E-4, 
p<0.001*) 
-7.9E-4 (-8.5E-4 to -7.4E-4, 
p<0.001*) 
-8.2E-4 (-9.0E-4 to -7.4E-4, 
p<0.001*) 
4.1E-3 (3.7E-3 to 4.4E-3, 
p<0.001*) 
-0.016 (-0.016 to -0.015, 
p<0.001*) 
Age -1.0E-4 (-3.2E-4 to 1.2E-4, 
p=0.370) 
-6.6E-4 (-12.4E-4 to -0.8E-
4, p=0.025*) 
0.2E-4 (-6.1E-4 to 6.5E-4, 
p=0.957) 
-0.003 (-0.005 to -0.001, 
p=0.013*) 
0.003 (-0.006 to 0.012, 
p=0.485) 
Sex 0.003 (-0.002 to 0.009, 
p=0.259) 
-0.014 (-0.029 to 0.001, 
p=0.076) 
-0.002 (-0.019 to 0.014, 
p=0.786) 
0.006 (-0.051 to 0.064, 
p=0.826) 
0.069 (-0.168 to 0.306, 
p=0.570) 
Weight -2.4E-4 (-4.0E-4 to -0.7E-4, 
p=0.005*) 
-3.3E-4 (-7.6E-4 to 1.0E-4, 
p=0.128) 
-7.3E-4 (-12.0E-4 to -2.6E-
4, p=0.002*) 
-2.5E-4 (18.8E-4 to 13.9E-
4, p=0.765) 
-0.010 (-0.017 to -0.003, 
p=0.004*) 
Stroke type 0.004 (-0.001 to 0.009, 
p=0.082) 
0.004 (-0.008 to 0.016, 
p=0.496) 
-0.005 (-0.017 to 0.008, 
p=0.479) 
-0.005 (-0.049 to 0.040, 
p=0.838) 
0.086 (-0.097 to 0.269, 
p=0.356) 
Hypertension 0.003 (-0.002 to 0.007, 
p=0.279) 
-0.002 (-0.014 to 0.010, 
p=0.770) 
-0.001 (-0.014 to 0.012, 
p=0.932) 
-0.024 (-0.069 to 0.022, 
p=0.308) 
0.094 (-0.093 to 0.281, 
p=0.325) 
Smoking -0.002 (-0.006 to 0.002, 
p=0.416) 
-0.005 (-0.016 to 0.006, 
p=0.335) 
0.008 (-0.004 to 0.020, 
p=0.181) 
0.029 (-0.013 to 0.071, 
p=0.175) 
0.057 (-0.114 to 0.229, 
p=0.512) 
Diabetes -0.004 (-0.010 to 0.002, 
p=0.206) 
-0.003 (-0.019 to 0.012, 
p=0.694) 
0.011 (-0.006 to 0.028, 
p=0.197) 
-0.065 (-0.124 to -0.006, 
p=0.032*) 






Table 8.16 Estimates of the effect of PVS volume, time, age, sex (male versus female), weight, stroke type (lacunar versus cortical) and risk factors 
(hypertension, smoking and diabetes: present versus absent) on signal enhancement WM, cortical GM, deep GM, CSF and SS. 
Coefficient (95%CI,p) WM cortical GM deep GM CSF SS 
PVS volume -0.040 (-0.083 to 0.003, 
p=0.068) 
-0.069 (-0.181 to 0.043, 
p=0.229) 
-0.015 (-0.137 to 0.107, 
p=0.810) 
-0.024 (-0.451 to 0.403, 
p=0.911) 
-0.453 (-2.207 to 1.301, 
p=0.612) 
Time -4.6E-4 (-5.1E-4 to -4.1E-4, 
p<0.001*) 
-7.9E-4 (-8.5E-4 to -7.4E-4, 
p<0.001*) 
-8.2E-4 (-9.0E-4 to -7.4E-4, 
p<0.001*) 
4.1E-3 (3.7E-3 to 4.4E-3, 
p<0.001*) 
-0.016 (-0.016 to -0.015, 
p<0.001*) 
Age -1.1E-4 (-3.3E-4 to 1.1E-4, 
p=0.331) 
-6.5E-4 (-12.2E-4 to -0.9E-
4, p=0.024*) 
0.3E-4 (-6.0E-4 to 6.5E-4, 
p=0.935) 
-0.003 (-0.005 to -0.001, 
p=0.008*) 
0.003 (-0.006 to 0.012, 
p=0.486) 
Sex 0.004 (-0.002 to 0.010, 
p=0.195) 
-0.013 (-0.028 to 0.003, 
p=0.104) 
-0.002 (-0.019 to 0.015, 
p=0.812) 
0.006 (-0.052 to 0.064, 
p=0.840) 
0.075 (-0.165 to 0.315, 
p=0.540) 
Weight -2.5E-4 (-4.1E-4 to -0.8E-4, 
p=0.004*) 
-3.5E-4 (-7.7E-4 to 0.8E-4, 
p=0.112) 
-7.3E-4 (-12.0E-4 to -2.6E-
4, p=0.002*) 
-2.9E-4 (-19.2E-4 to 13.4E-
4, p=0.730) 
-0.010 (-0.017 to -0.003, 
p=0.004*) 
Stroke type 0.005 (0.000 to 0.009, 
p=0.050*) 
0.005 (-0.007 to 0.017, 
p=0.406) 
-0.004 (-0.017 to 0.008, 
p=0.501) 
-0.004 (-0.049 to 0.041, 
p=0.853) 
0.092 (-0.092 to 0.277, 
p=0.326) 
Hypertension 0.002 (-0.002 to 0.007, 
p=0.306) 
-0.002 (-0.014 to 0.010, 
p=0.766) 
-4.7E-4 (-0.013 to 0.012, 
p=0.943) 
-0.026 (-0.071 to 0.020, 
p=0.267) 
0.093 (-0.093 to 0.278, 
p=0.328) 
Smoking -0.002 (-0.006 to 0.002, 
p=0.414) 
-0.005 (-0.016 to 0.005, 
p=0.325) 
0.008 (-0.004 to 0.020, 
p=0.184) 
0.030 (-0.012 to 0.071, 
p=0.166) 
0.057 (-0.114 to 0.229, 
p=0.513) 
Diabetes -0.004 (-0.010 to 0.002, 
p=0.207) 
-0.003 (-0.019 to 0.012, 
p=0.682) 
0.011 (-0.006 to 0.028, 
p=0.200) 
-0.064 (-0.123 to -0.005, 
p=0.035*) 





Table 8.17 Estimates of the effect time, age, sex (male versus female), weight, stroke type (lacunar versus cortical) and risk factors (hypertension, 
smoking and diabetes: present versus absent) on signal enhancement in WM, cortical GM, deep GM, CSF and SS. 
Coefficient (95%CI,p) WM cortical GM deep GM CSF SS 
Time -4.6E-4 (-5.1E-4 to -4.0E-4, 
p<0.001*) 
-7.9E-4 (-8.5E-4 to -7.4E-4, 
p<0.001*) 
-8.2E-4 (-9.0E-4 to -7.4E-4, 
p<0.001*) 
4.1E-3 (3.7E-3 to 4.4E-3, 
p<0.001*) 
-0.016 (-0.016 to -0.015, 
p<0.001*) 
Age -1.7E-4 (-3.8E-4 to -0.4E-4, 
p=0.121) 
-7.6E-4 (-13.0E-4 to -2.1E-
4, p=0.007*) 
0.4E-5 (-59.0E-5 to 59.5E-
5, p=0.990) 
-0.003 (-0.005 to -0.001, 
p=0.005*) 
0.002 (-0.006 to 0.011, 
p=0.564) 
Sex 0.003 (-0.003 to 0.009, 
p=0.319) 
-0.014 (-0.029 to 0.001, 
p=0.065) 
-0.002 (-0.019 to 0.014, 
p=0.778) 
0.005 (-0.052 to 0.063, 
p=0.851) 
0.065 (-0.171 to 0.300, 
p=0.590) 
Weight -2.5E-4 (-4.2E-4 to -0.8E-4, 
p=0.003*) 
-3.5E-4 (-7.8E-4 to 0.7E-4, 
p=0.104) 
-7.3E-4 (-11.9E-4 to -2.0E-
4, p=0.002*) 
-2.5E-4 (-18.8E-4 to 13.9E-
4, p=0.726) 
-0.010 (-0.017 to -0.003, 
p=0.003*) 
Stroke type 0.004 (-0.001 to 0.009, 
p=0.085) 
0.004 (-0.008 to 0.016, 
p=0.494) 
-0.005 (-0.017 to 0.000, 
p=0.476) 
-0.005 (-0.049 to 0.040, 
p=0.839) 
0.086 (-0.096 to 0.269, 
p=0.353) 
Hypertension 0.002 (-0.003 to 0.006, 
p=0.474) 
-0.003 (-0.015 to 0.009, 
p=0.611) 
-0.001 (-0.013 to 0.012, 
p=0.909) 
-0.026 (-0.070 to 0.018, 
p=0.249) 
0.084 (-0.098 to 0.266, 
p=0.363) 
Smoking -0.001 (-0.006 to 0.003, 
p=0.505) 
-0.005 (-0.016 to 0.006, 
p=0.374) 
0.008 (-0.004 to 0.020, 
p=0.174) 
0.030 (-0.012 to 0.071, 
p=0.159) 
0.061 (-0.110 to 0.231, 
p=0.485) 
Diabetes -0.003 (-0.009 to 0.003, 
p=0.276) 
-0.002 (-0.018 to 0.013, 
p=0.762) 
0.011 (-0.006 to 0.028, 
p=0.188) 
-0.063 (-0.122 to -0.005, 
p=0.034*) 






Chapter 9 Discussion 
9.1 Main results 
9.1.1 Blood brain barrier (BBB) literature review 
We summarized the blood brain barrier (BBB) normal structures from the 
level of neurovascular unit (NVU), perivascular spaces (PVS, one of the 
components NVU), and junctional proteins located in the endothelium. PVS 
function importantly in cereral fluid drainage and inflammation, which are 
also associated with various cerebral diseases, and enlarged PVS are 
important imaging markers for cerebral small vessel disease. The PVS 
abnormalities link the microscopic changes of BBB with hyperintensities on 
T2-weighted magnetic resonance imaging, which are a more macroscopic 
view and more visualized way to observe (Figure 9.1).  
 
Figure 9.1 The abnormalities of PVS link the BBB microscopic structures with 




Under ischemic stimulus, cytokines such as matrix metalloproteinases, 
vascular endothelial growth factor and tissue plasminogen activator 
exacerbate the disruption of BBB. 
9.1.2 Accurate white matter hyperintensities (WMH) 
measurement 
We used the colour fusion MCMxxxVI method (Hernandez et al., 2010) in the 
white matter hyperintensities (WMH) measurement. This colour fusion 
method enabled a wider colour range, offering more threshold levels (65536 
levels) than a single sequence grey scale image such as fluid attenuated 
inversion recovery (FLAIR) sequence (256 levels) for tissue identification.  
We also excluded WMH artefacts and stroke lesions. In order to know the 
frequent WMH artefacts on FLAIR image (which is commonly used for 
WMH identification), I reviewed existing articles relating to WMH artefacts 
on FLAIR, and used the information to make a WMH artefacts frequency 
training guide and applied this information in our WMH segmentation 
training. I also summarized the WMH frequencies in 46 patients, and our 
WMH artefact results were consistent with the published literatures: 
cerebrospinal fluid (CSF) flow artefacts and patient movements were two of 
the most frequent artefacts influencing large areas in the brain image. In both 
cross-sectional and longitudinal studies of WMH, we found that failed to 
exclude stroke lesions from WMH could lead to misleading estimates of 
WMH volumes and progression, and would double the sample size needed 
for clinical trials which use WMH as a measure.  
These aspects give valuable information for large clinical trials and 
observational studies relating to WMH mechanism and cognition, and in 




in a large randomized clinical trial of anti-hyperintensive drug perindopril 
PROGRESS (Perindopril Protection Against Recurrent Stroke Study) (Dufouil 
et al., 2005), the WMH progression was used as an outcome measure in 192 
hypertensive patients who had both baseline and follow-up magnetic 
resonance imaging (MRI) scans. They carefully controlled the image 
registration, image signal histogram equalization and display to ensure 
comparable image characteristics in terms of anatomical feature and signal 
intensity. They used a semi-automatic method to measure the WMH volume 
on T2W image and carefully excluded the hypointense lesions on T1-
weighted (T1W) sequence which they considered as stroke lesions.  
However, T1W image is not sensitive for acute or old stroke lesion detection, 
and T2W is not the best sequence for WMH, so their conclusion about the 
effect of the drug treatment on WMH could be distorted by its effect on 
stroke.   
9.1.3 Basal ganglia (BG) PVS measurement and associations 
PVS visual rating scores are widely used in previous studies, this is the first 
time analysis were taken to assess the associations between volumetric PVS 
(BG PVS computational count/volume) and SVD markers, blood markers and 
BBB permeability. 
In order to develop a computational PVS method, we reviewed current 
studies that described any computational methods suitable for PVS 
quantification. Our final optimized method was suitable for PVS count and 
volume measurement in the basal ganglia (BG) regions. We also suggested 




from this computational method showed good agreement within and 
between observers and with a validated visual rating scale.  
In the BG PVS associations investigations, we found that  there were 
significant associations between the BG PVS count/volume and WMH and 
cerebral atrophy, which were consistent with previous studies (Doubal et al., 
2010b; Potter et al., 2013; Rouhl et al., 2008; Zhu et al., 2010). We also found 
that age and hypertension were two important influencing factors for BG 
PVS. On univariable linear regression analysis we found that the blood 
thrombosis marker thrombin-antithrombin complex (TAT) and fragments 1 
and 2 of prothrombin (F 1+2) were significantly associated with BG PVS. 
After adjusting for age, sex, hypertension, smoking and diabetes, the 
association between thrombosis blood markers F 1+2, TAT and BG PVS 
became non-significant, but the blood endothelial function marker von-
Willebrand factor (vWF) had become negatively associated with increasing 
BG PVS count, which suggested more vWF release may provide desired BBB 
flexibility during certain disease states and could be potentially (Suidan et al., 
2013).  
On the BBB permeability imaging univariable analysis, BG PVS count was 
significantly associated with signal enhancement in white matter (WM), 
cortical gray matter (GM), and CSF. BG PVS volume was significantly 
associated with signal enhancement in cortical GM and borderline-
significantly associated with WM. After adjusting for time point, age, sex, 
weight, stroke type and risk factors, the associations became insignificant. 
The results may be influenced by sample size, scanner drift, subtle signal 
changes in BBB and encourage further studies in the associations between 





9.2.1 BBB literature 
We summarized the literature relating to PVS systematically, including the 
aspects of PVS ultrastructure, functions such as immune cell accumulation, 
transmigration, and drainage, associations with inflammatory disease and 
cerebral small vessel disease (SVD). We systematically summarized ischemic 
triggers for BBB change.  
I generated figures illustrating the combined information from most updated 
literature. The visulasation work enlightens my thoughts and makes it 
easrier for me to see what are lacking in a broad view. 
9.2.2 Good study design in primary data source- the Mild Stroke 
Study 
I used data from 100 patients which was previously recruited in the Mild 
Stroke Study. 
(1) Control and Careful blinding  
In this study of lacunar stroke and SVD mechanism, we recruited age-
matched mild cortical ischemic stroke as controls to adjust for risk factors. 
Normal ageing subjects without stroke lesions would not be appropriate to 
be used as controls as any associations found between lacunar strokes could 
just be with any other types of stroke, not with lacunar stroke specifically. 
We analysed imaging features blindly to all patients’ clinical characteristics 
and follow-up scans were analysed separately and blindly to the results from 





(2) Prospective study 
The recruitment for this study was prospective and as consecutive as 
possible. The patients with clinical features of acute lacunar stroke and mild 
cortical stroke (as controls) who were seen at a large academic teaching 
hospital between January 2005 and July 2007 were included in this study 
(Wardlaw et al., 2009). 
All patients underwent investigations for stroke causes such as carotid 
Doppler ultrasound, electrocardiogram, blood tests and brain imaging. All 
patients underwent standard structural MRI brain imaging on the same 
scanner using the same protocol, which included sagittal T1W, axial T2-
weighted, diffusion-weighted imaging, FLAIR, and gradient-recalled echo 
sequences (GRE). 
A trained stroke physician assessed all patients and defined the clinical 
stroke subtypes according to the Oxfordshire Community Stroke Project 
classification (Bamford et al., 1991). Lacunar stroke was defined as pure 
motor disorder and/or sensory loss, or ataxic hemiparesis; mild cortical 
stroke was defined as being equivalent to a partial anterior circulation stroke, 
the definition did not take account of risk factors. Following initial clinical 
classification, a standardized radiological classification system was used for 
recoding the presence, site, and size of the recent infarct using diagnostic 
MRI (high signal on diffusion imaging, low signal on apparent diffusion 
coefficient map) by an experienced neuroradiologist (Wardlaw et al., 2009). 
The radiological stroke subtype was based on the acute lesion, and the 
presence and characteristics of any old stroke lesions were recorded 
(Wardlaw et al., 2009). When the clinical and radiological classifications 




stroke were clinically misdiagnosed as lacunar stroke and vice versa (Potter 
et al., 2010a). Because about one third of the patients with mild stroke have 
negative MRI of recent infarct, if no visible stroke lesions on the scan, the 
clinical classification was used (Doubal et al., 2010a). Both the clinical and 
radiological classifications were used to decide a final stroke subtype 
classification after systematically reviewed and discussed by stroke expert 
panel on a weekly basis.  
A variety of patients’ characteristics were recorded, such as patients’ 
demography (age, gender, weight, and race), vascular risk factors of stroke 
and SVD (history of hypertension, smoking, diabetes, alcohol use and so 
forth), severity of stroke (National Institutes of Health Stroke Scale), 
cardiovascular diseases (ischemic heart disease, peripheral vascular disease, 
or transient ischemic attack) and drug treatment before the stroke.  
Because the patients’ information was collected and recoded prospectively 
and systematically, so we had a fairly large and complete dataset of both MR 
imaging and patients’ characteristics which can be used to explore potential 
associations and confounders of SVD features and BBB permeability. 
(3) Longitudinal and cross-sectional studies 
Using the imaging and clinical data from 100 patients and 46 of whom had 
long term follow-ups; we were able to assess cross-sectional comparisons 
between SVD features and risk factors, blood markers and BBB permeability. 
We could also investigate the longitudinal progression of WMH, atrophy 





(4) Data management and expert support  
In this study, all the clinical and imaging relating data had been put into a 
master database, which had been verified, and was handy to find and do 
comparisons. The stroke subtype definition had been classified using 
standardised classification systems and discussed by a stroke expert panel.  
Image segmentation of radiological features such as WMH, atrophy, PVS, 
and stroke lesions had been guided and checked by an experienced 
neuroradiologist. Statistical analysis and modelling were supported from a 
medical statistician.  
9.2.3 Accurate WMH measurement 
In the WMH measurement, we used MCMxxxVI method (Hernandez et al., 
2010), which used fused pairs of FLAIR and GRE sequences. Each image 
pixel of the fused pairs was projected into the Red and Green (RG) colour 
space, and the WMH volumes were calculated using minimum variance 
quantisation (Hernandez et al., 2010). This colour fusion method enabled a 
wider colour range, offering more threshold levels (65536 levels) than a 
single FLAIR sequence (256 levels) for tissue identification. Comparison 
results with other multispectral methods showed that the MCMxxxVI 
method can provide fast and accurate WMH measurement (Hernandez et al., 
2012). WMH segmentation was done blindly to patients’ clinical 
characteristics and follow-up image segmentation was done blind to the 
results at baseline. We also carefully excluded WMH artefacts and stroke 
lesions which mimic the WMH and influence its accurate measurement at 






9.3.1 Literature review 
We tried to do a review of the cellular and other components of the BBB as 
systematically as possible; however, it is an enormous topic and it was not 
possible to assess all aspects within PhD time limit, so we focused on the BBB 
structure of endothelial junction proteins and PVS, and ischemic and 
inflammatory triggers as they are pathologically and anatomically relevant to 
imaging findings and SVD mechnism. We searched PVS, ischemic trigger for 
BBB and WMH artefact systematically and also checked reference lists from 
review papers. We tried to make it as complete as possible, however limited 
by searching tools, we were unable to include all relating papers exclusively 
and may have missed some papers which mentioned these topics in their 
introduction or discussion part, but not as their main topic.  
9.3.2 More refinements needed in further WMH method 
We used eight patients in the pilot study to test refinements of the WMH 
segmentation method, as the segmentation which should be accurate and not 
laborious and suitable for later WMH cross-sectional and longitudinal 
analysis. We were able to find that the colour fusion method (MCMxxxVI) 
method was more superior to single sequence thresholding methods in terms 
of tissue identification and less time consuming as adjusted by an visual 
inspection of the different methods. 
The number of patients in the pilot study was not enough to do a formal 
statistical analysis to find out which method was the most efficient. In order 
to do such comparisons, we need a larger dataset and should include all 
available methods (far more than the seven experiments), which was not the 




Moreover, any current semi-automatic and automatic WMH segmentation 
method cannot avoid visual inspection and manual editing especially when 
condensing the distorting effect of WMH artefacts and stroke lesions 
frequently shown on the images.  
9.3.3 Patient recruitment and data collection 
The data I used from 100 patients who were prospectively and consecutively 
recruited in the Mild Stroke Study BBB permeability study and 46 of them 
returned for follow-up scans. The sample size, though reasonable for the 
cross-sectional and longitudinal comparisons of SVD features such as white 
matter hyperintensities, atrophy, perivascular spaces and BBB permeability,  
was too small for analysing lacunes  (only seven patients had lacunes) and 
not large enough to do comparisons. Though diabetes was one of the risk 
factors for SVD and related to BBB permeability in other studies, we were 
unable to find potential associations between diabetes possibly due to its 
small number of patients who had diabetes (15 patients). We tried to have a 
complete dataset for all the patients, however, due to radiographer error and 
unsuccessful contrast agent injections, there were permeability data 
unavailable in three patients; smoking status was missing in one patient, and 
some of the blood marker were missing in seven patients. Some of the 
insignificant results might be confirmed by larger sample sizes. 
There were more male than female, and patients who had lacunar stroke 
were slightly younger than patients with cortical stroke in our study which 
has probably not influenced the generalizability of our results although 
further studies are required. We managed to recruit every consecutive 




unavailability, staff absences, and patient refusals and our sample was not 
biased by exclusions (Wardlaw et al., 2009). 
9.3.4 PVS measurements limited to BG regions 
In the beginning, we chose both BG and centrum semiovale (CS) as regions 
of interest to develop the semi-automatic PVS quantification method. 
However, we found that PVS in the CS were harder to quantify than the BG 
PVS because CS PVS were frequently running through the scan slice and 
sometimes obscured by confluent WMH. This was the same as the problem 
found in the development of a validated PVS rating scale where BG PVS 
showed higher observer agreement than in the BG regions (Potter, 2011). 
Therefore in later method optimization steps we limited PVS in the BG ovoid 
regions to increase measurement consistency.   
Similar to the findings in this study, in a study of the associations between 
visual PVS scores and SVD features, Doubal et.al (Doubal et al., 2010b) using 
the same dataset found the same associations between BG PVS scores and 
WMH scores, Potter et.al (Potter et al., 2013) using a different dataset found 
that BG PVS were significantly associated with advancing age, CS PVS, 
atrophy and lacunar stroke, and CS PVS were mainly associated with BG 
PVS. Because BG PVS and CS PVS are inter-related, the associations we 
found between BG PVS and WMH, atrophy, blood markers and BBB 
permeability are likely to be generalized but require testing in larger dataset.  
9.3.5 MRI technique development 
Recent development of MRI scanner and new algorithms [1] produce high 
contrast resolution images, which is helpful for subtle lesions detection. In 




compromised by various limitations, including total scanning time, large 
slice thickness and uncontrolled patient movement. Fast slice acquisition 
techniques reduce image acquisition time to a fraction of a second, which 
minimise artefact caused by patients' movements (Gholipour et al., 2010). 
The increased signal at higher field strength (3.0 T) in recent MRI scanners 
also produces better overall image quality than these captured by 1.5 T 
(Bachmann et al., 2006). The new development in MRI devices and 
algorithms enables 3D reconstruction from volumetric images, which helps 
to assess anatomical structures and disease progression (Gholipour et al., 
2010; Yang et al., 2011) and this trend will facilitate further researches in SVD 
and BBB. 
9.4 Implications for further studies 
9.4.1 BBB studies 
In our human BBB structure literature search, in both the junctional proteins 
and PVS (Figure 9.2), we found that there was a lack of human anatomical 
and pathological studies and systematic description in regard to the different 
parts of the vascular tree in the brain. Our general concept of BBB structures 
and functions were mostly based on experimental evidence fragments from 
various animal and disease models under different triggers or 
microenvironment, which made it hard to compare studies, account for 
differences between animal models or even summarize them systematically. 
For example, we hypothesized that human general structure of PVS in the 
brain using combined information limited human untrastructural studies. 
There is a need for systematic reviews of BBB structure along the vascular 




Apart from junction proteins and PVS (Figure 9.2), researchers have 
increased interest in the interactions between endothelium and pericyte or 
glial cells. Besides their structural support for endothelium, pericytes have 
bidirectional contractile function in controlling capillary size and so play a 
major role in controlling cerebral blood flows (Peppiatt et al., 2006). Glial 
cells are involved in signal transport through a various factors they produced 
and removal of metabolic by-products (Alvarez et al., 2013; Xie et al., 2013). 
Systematic literature reviews of these two components in NVU are essential 
for further BBB studies.  
 
Figure 9.2 Increasing interests of pericyte and glias cells. 
9.4.2 Unsolved questions for WMH artefacts 
In the WMH artefacts chapter, there were three types of ‘artefacts’ we 
considered but we did not find relevant experiment and standards to deal 
with them in the previous literature: the “bright skull circle”, “dirty WM” 




4.3). “Dirty WM” may not be an artefact; better ways of dealing with them 
consistently would be beneficial for further studies.  
 
Figure 9.3 Three unsolved questions for WMH artefacts: “bright skull circle”, “dirty WM” 
and “bright dots above the lateral ventricles” 
9.4.3 Stimuli for BBB dysfunctions 
Besides the triggers relating to the ischemic and inflammatory stimuli of the 
BBB permeability mentioned in Chapter 2, other factors such as salt intake, 
smoking, sleeping problem (Xie et al., 2013), alcohol intake and 
hyperglycemia could potentially affect BBB function.  
Increasing evidence showed that a high salt diet from food and drinks (more 
than 6 grams per day: (He et al., 2010)) have increasing risk of hypertension, 
cardiovascular disease, renal disease, osteoporosis, stomach cancer and 




epidemiological studies showed that a high salt diet had an effect on stroke, 
independent of and in addition to hypertension (He and MacGregor, 2009). 
High-salt intake also influenced nitric oxide (NO) metabolism. NO is a small 
molecule produced by endothelial nitric oxide synthases in response to shear 
from increased blood flow in arteries and has very important function as a 
vasodilator of the blood vessels. Levels of NO metabolites in plasma and 
urine, and endothelial-dependent vasodilation have been used to assess NO 
bioactivity in humans and showed that decreased NO-metabolite excretion 
and increased blood pressure were observed after high-salt intake 
(Hoffmann et al., 2007; Knottnerus et al., 2009). Inhibition of NO production 
may play a role in mediating endothelial dysfunction in high salt 
microenvironment. 
Cigarette smoking was a risk factor for SVD (Khan et al., 2007) and was 
significantly related to stroke after adjusting age and hypertension (Wolf et 
al., 1988).  Blood marker results from both smokers and non-smokers showed 
that smokers contained higher levels of vWF and more cytotoxic to 
endothelial cells in vitro (Blann and McCollum, 1993). Smoking was 
significantly associated with systemic inflammation in men because smokers 
had higher values for white blood cell count, fibrinogen, plasma viscosity, 
and C-reactive protein when compared to non-smokers (Frohlich et al., 2003). 
Smoking influenced proliferation, maturity state, activity and immune 
responses of immune cells in cultured cells and experimental animals. One 
molecular mechanism behind the association between smoking and 
inflammation involved the nuclear factor kappa B which is a gene 
transcription factor mediates gene transcription and cytokine expression. 




smokers smoking patients when compared with non-smokers (Goncalves et 
al., 2011). Smoking may possibly trigger BBB permeability through its effect 
on endothelium and inflammation through tissue plasminogen activator, 
Interleukin-6 or fibrinogen. 
Worsening or disturbance of sleep was progressively associated with many 
neurological disorders such as dementia, stroke and death in humans 
(Montagna et al., 2003; Underwood, 2013). The brain is fragile to neurotoxic 
waste but it lacks a conventional lymphatic system which removes high 
metabolic products through lymphatic vessels. The PVS plays a crucial role 
in removing waste and fluid from the brain. The convective changes between 
cerebrospinal fluid (CSF) influx along the arteries and interstitial fluid (ISF) 
around the veins functioned homologous to peripheral lymphatic system 
and were named as the “glymphatic” system based on their dependence on 
aquaporin-4 water channels on astrocytic endfeet (Xie et al., 2013). Recently 
researchers found that cortical interstitial space increases by more than two 
thirds during sleep compared with awake state, and sleeping facilitated the 
efficient clear out of amyloid-β (Xie et al., 2013). Sleeping also assisted the 
removal of other neurotoxic compounds (e.g. adenosine) or supressed their 
production (e.g. noradrenaline) (Herculano-Houzel, 2013; Underwood, 2013; 
Xie et al., 2013). Therefore, sleeping is probably even more important than 
presumably thought for balanced cerebral metabolism and its disturbance 
could be a trigger for neurotoxic waste accumulation, exacerbate BBB 
malfunction and further lead to neurological disorders. 
Alcohol abuse is related to cerebral atrophy and WMH (den Heijer et al., 
2004; Mann et al., 2001). Alcohol abuse maybe another trigger for BBB 




oxidative stress induced by ethanol metabolism lead to myosin light chain 
kinase activation and tight junction phosphorylation. The cytoskeletal 
alterations resulted in BBB impairment which was assessed by 
transendothelial electrical resistance (Haorah et al., 2005a; Haorah et al., 
2005b; Haorah et al., 2007).  
Diabetic patients had increased BBB permeability suggested on contrast 
enhancement MRI (Starr et al., 2003). Expression and activity of MMPs  is 
increased in diabetic patients and MMPs also enhance blood coagulability, 
and they contribute to acute thrombotic occlusion of vessels (Kadoglou et al., 
2005). MMP was associated with junction protein degradation and was a 
known mediator of BBB impairment. In the diabetic rat models, both 
hyperglycaemia and increased plasma MMP activity contributed to increased 
BBB permeability through decreased tight junction proteins (occludin and 
ZO-1) production and disruption (Hawkins et al., 2007).  Targeting to 
decrease plasma MMP activity may benefit BBB protection in diabetic 
patients.  
9.4.4 Further risk factors studies 
In our studies of risk factor association and BBB stimuli, we found the risk 
factors smoking, hypertension and alcohol could be refined in the analysis 
and salt intake and sleeping difficulties should be considered as risk factors.  
For smoking, dichotomous categories (never versus ever smoked) was better 
than four smoking categories which separated ever smoked into recent 
smoker, smoker and heavy smoker; could the fewer categories increased 
statistical power by having larger numbers of patients in the same category. 




study reported that relative risk of stroke in heavy smokers (greater than 40 
cigarettes per day) was doubled than that of light smokers (fewer than ten 
cigarettes per day) (Wolf et al., 1988), that results probably influenced by the 
age difference which they did not adjust for. Our results between blood 
markers and smoking still need to be confirmed by a larger sample size. 
In recent cancer studies, researchers suggested that there was no safe 
threshold for alcohol and high consumption increased cancer risk (Nelson et 
al., 2013). Should the behaviour of alcohol drinking as a risk factor such as 
smoking, hypertension and diabetes, instead of just measuring the alcohol 
excess intake in the future? However, if we need to use the amount of alcohol 
intake as a risk factor, there is need to set a standard of converting different 
types of alcohol intake into ethanol intake, which is very hard to apply in 
reality (Vasdev et al., 2006).  
For the current study, we measured patients’ blood pressures at the time of 
scanning; however, this was probably not very representative of the patient’s 
usual blood pressure. For future studies, we suggest a more detailed blood 
pressure measurement, for example, by monitoring patients’ 24-hour blood 
pressure to identify patients’ usual blood pressure and other parameters 
such as blood pressure variability. 
Apart from refinements of traditional risk factors listed above, we suggest 
adding salt intake and sleeping problems as risk factors in further studies. 
9.4.5 Optimization in PVS rating scale 
The PVS visual rating score categories needs further modifications. The PVS 
category intervals are equal in size from score 0 to 2 (0=no PVS, 1=<10 PVS, 




PVS. Score 3 could possibly be narrowed down and possible separated into 
two scores, for example 3=21-30 PVS and 4=31-40, to make the spread of 
scores better. There is a need for more standardized ways to deal with high 
background signal instead of giving it score 4.  
9.4.6 Further optimization in PVS method  
The volumetric PVS measurement method (Descombes et al., 2004) could be 
considered in further use if one could remove intense programming and be 
modified as user friendly. The multiple thresholds step in our method could 
be applied in further PVS studies and the time-consuming problem of 
finding thresholds could be solved by making the multiple threshold 
selection and combination part automatic, probably through a program that 
one only needs to input values of the first and last threshold. Both 
optimizations would possibly be complementary methods in CS PVS 
measurement.  
9.4.7 More ways to improve pathological brain segmentation 
and analysis 
Future studies of SVD should avoid using bias field corrected images in 
stroke and WMH segmentation with better methods of removing bias field 
artefacts without distorting the true lesions. It is essential to adjust statistical 
analysis for age and hypertension, especially for PVS studies, because they 
are two important influencing factors for PVS. 
9.4.8 Peripheral blood marker studies   
Apart from blood markers of endothelial function, inflammation and 
thrombosis measured in the current study, further studies investing 
associations between blood markers and PVS could consider measuring 




9.5 Recent publications relating to novel imaging 
markers  
Besides the contrast agent gadodiamide we used in the dynamic contrast 
enhancing MRI to detect BBB permeability, other imaging marker such as 
11C-[R]-PK11195 used in positron emission tomography (PET) (Radlinska et 
al., 2009) and targeted MRI contrast agent (Hoyte et al., 2010) enabled 
sensitive detection of inflammatory processes in human and mice. 11C-[R]-
PK11195 used in human PET imaging is a radioligand which binds to the 
mitochondrial membrane of cerebral activated microglia cells (Radlinska et 
al., 2009). Targeted MRI contrast agent based on iron oxide microparticles 
enabled visualization of vascular cell adhesion molecule 1 (VCAM-1) 
through their specific binding at the acute stage of ischemia (Hoyte et al., 
2010). Based on the same mechanism, other junctional proteins located in the 
cerebral endothelium could be potentially selected as targets and be 
visualized in vivo. These two types of imaging markers showed promising 
potentials for imaging studies, however, more metabolic and drainage 
kinetic experiments are needed to prove their safeties before use in clinical 
studies.  
9.6 Conclusions 
In conclusion, neuroimaging is essential for cerebral SVD and BBB 
dysfunction investigation, and PVS is an important imaging feature of SVD 
which related to BBB permeability. In this work, we highlighted the 
importance of BBB and PVS pathophysiology, and highlighted the 
importance of WMH accurate measurement by excluding artefacts and 
stroke lesions. We developed a BG PVS computational method and this is the 




count/volume and SVD markers, blood markers and BBB permeability, 
which will hopefully be helpful in future investigations of SVD diagnostic 
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Appendix (A) Appendix table for BBB literature  
Table A1. Effects of cytokines, enzymes, drugs and other stimuli which 
increase or decrease BBB permeability after the ischemic stimulus. 
Effectors Type Increase or decrease BBB 
permeability 
Reference 
VEGF Cytokine Increase Paul, 2001 
Src Enzyme Increase (VEGF)  
Src Inhibitor Antibody Decrease  
Src deficiency Gene knockout Decrease  
VEGF Cytokine Increase Wang, 2005 
Capsazepine Drug Decrease Gauden, 2007 
tPA Cytokine Increase Kelly, 2009 
NOX2 Enzyme Increase (ROS)  
Apocynin 
(NOX2 inhibitor) 
Drug Increase (aged)  
Apocynin 
(NOX2 inhibitor) 
Drug               Decrease (young)  
MMP-9 Cytokine Increase Wang, 2009 
MMP-9 deficiency Gene knockout Decrease  
Rho-kinase inhibitors Antibody Decrease Satoh, 2010 
MMP-9 Cytokine Increase (TJ: occludin, ZO-1) Bauer, 2010 
VEGF Cytokine Increase (TJ, MMP-9)  
MMP-9 inhibitor Antibody Decrease  
VEGF inhibitor Antibody Decrease  
tPA Cytokine Increase Abu Fanne, 
2010 
P-selectin Surface protein Increase Jin, 2010 
P-selectin deficiency Gene knockout  Decrease  
Atorvastatin Drug        Decrease (TJ) Cui, 2010 
NK1 tachykinin 
receptor antagonist 








VEGF: Vascular endothelial growth factor; MMP: Matrix metalloproteinase; tPA: Tissue 
plasminogen activator; NOX2: NADPH oxidase; ROS: reactive oxygen species; TJ: tight 




Appendix (B) Image segmentation manuals 
Appendix (B1) Intracranial volume (ICV) segmentation Manual 
Edit brain mask to create intracranial volume (ICV) mask 
After extracting the brain mask using Object Extractor module, we use the region 
definition tools in the Region of Interest module to edit the brain mask into 
intracranial volume (ICV) mask within a 3-D volume image. The Sample Options in 
Region of Interest model allow measuring the volume of ICV.  
The brain mask extraction process can be divided as follows: 
 Load image and brain mask 
 Change the name to ICV (and change colour to red)  
 Edit and save the ICV mask 
 Calculate the ICV 
 Save and change ICV in the AnalyzeImage(7.5) format 
1. Load the GRE image from directory. Click on Load to load the image, and click on 
image icon to highlight that image.  
2. Open the Region of Interest module  (Measure > Region of 
Interest).  Choose File > Load Object Map and load the brain mask object map from 
the directory (in this example BM225.obj). Open the Objects window (View > 
Objects), change Object from Original to Object_2 (Figure 1 [A]). Change Name 
from Object_2 to ICV (Figure 1 [B]), and Color to red (default color for the second 
object). Click Done to dismiss the Objects.  
3. The first slice of the volume is automatically displayed when the ROI module is 
opened. You can move to a different slice using the Show Next and Show Previous 




size and Halve current size  to adjust the displaying image size. The 
buttons below the image display allow you to modify the defined objects: Edit and 
Delete objects. If after defining the region it is unsatisfactory, click the Undo button 
(Figure 2). The fused FLAIR and GRE images are used as reference images through 
the editing. 
When one slice contains no suitable objects, click Clear Regions on the 
left side of the window to clear all regions defined on this slice. 
Figure 3 and 4 are examples of deleting and editing ICV mask by ROI. 
4. When we need to separate one object into more than two objects in order to do 
further editing, we use the Manual Trace tool . We first need to change the 
Object To Define button below the image into Original, and then click and hold the 
mouse to begin drawing the trace, release the mouse button to end the trace. The 
one object will be divided into more than two objects (in the example of Figure 5, 
one object is separated into two objects). 
5. After finishing editing the whole ICV mask, check the whole mask before further 
steps. Save the ICV object map though File > Save Object Map, name it as ICV. 
6. In the Sample Options window set the following (Figure 6): 
 Sample Type: Object(s), check the ICV 
 Summing: On 
 Sample: All Slices 
 Log Stats: On  
After setting as above, click Sample Images. The module will now sample the 
defined object (‘ICV’). The ROI Stat Log will automatically be returned, displaying 




7. AnalyzeImage(7.5) format is useful for cerebrospinal fluid (CSF) segmentation 
using MCMxxxVI method, so we also save the ICV mask in the AnalyzeImage(7.5) 
format. Open the Objects window (View > Objects), click the Save Binary, the save 
options will automatically be returned and change the Name into ICV, then click 
Save (Figure 7). The binary mask is saved and highlighted in the Analyze 
workspace, then click File > Save and navigate to the directory where you would 
like to save the data set and specify a name (ICV in this example). Use the Format 
drop-down menu to specify the AnalyzeImage(7.5) format to save, then click Save 
(Figure 8). 
8. Because the default image direction are different between Matlab and Analyze 
software, the ICV mask generated in Analyze software need to be flipped direction 
for the further use. File > Save as > Flip/Shift, select X, Y and Z directions.  
When finished, save the ICV_XYZ in both objectmap format and AnalyzeImage(7.5) 







Figure 1. Set object and name for ICV mask. 
 





Figure 3. Object deleting using ROI. The yellow arrow points to the object needs 
deleting. The left image is before deleting, and the right image is after deleting.  
Figure 4. Object editing using ROI. The yellow arrows point to the objects need 
deleting and the blue arrows points to the places need editing. The left image is the 




Figure 5. Manual trace tool. Before drawing the manual trace (Left), setting and 
drawing for manual trace (Middle), and after drawing the manual trace and editing 
(Right).  
 
Figure 6. Sample Options for ICV. After changing the settings in rectangles, press 





Figure 7. Save binary mask for ICV. 
 
Figure 8. Save ICV mask in AnalyzeImage(7.5) format. 
 




Appendix (B2) Image Registration Manual 
We registered Fluid a enuated inversion recovery (FLAIR) , gradient-recalled echo 
(GRE) and T2-weighted (T2W) images to the permeability fspgr_12 image by using 
ANALYZE 10.0 3-D Voxel Registration module, which allows us to spatially 
register two volume images, based on the  Normalized Mutual Information 
algorithm. The volume registration process can be divided as follows:  
 Load images  
 Intensity adjustment 
 3D-voxel registration 
 Save transformed image 
 Manual registry for unsuccessful automated registration  
We took the registration of T2W image into permeability image to demonstrate the 
registration process: 
1. Load both permeability and T2W images from directory. Click on Load to load 
the images. Select the permeability image first, and then while holding down the 
<Ctrl> key, select the T2W image (resulting in both being selected, Base image: 
permeability image; Match image: T2W image). 
2. Open the 3-D Voxel Registration module (Register > 3-D Voxel).  
Open the Blend window  (Generate > Blend). Different colour combinations 
under the Blend window assist evaluate the registration visually. Different blend 
options are in Figure 1. In this case, we set the Blend Type to Green-Red, the ‘Red-
Green’ blend option will help evaluate the registration. Click Done to dismiss the 
window. 
3. Open the Intensity option (View > Intensity), use the slider bar to change the 
Maximum intensity level. Intensity display change also help evaluate the 




4. Press the Register PowerBar button or choose Generate > Register. 
5. Examine the center ‘Fused’ column. Save the transformed image when the 
registration is acceptable. Select File > Save Transformed and save the transformed 
T2W image in AnalyzeImage(7.5) format (Figure 3, red arrow). Change the name 
and save directory. 
6. When the automatic registration done above is not acceptable, manually adjust 
the registration scale. Open the Manual Registration (Tools > Manual menu). Click 
Reset Matrix in the Manual tool (Figure 4, red arrow), this will reset the match 
volume to the original starting position. Choose the extent from ‘coarse’ to ‘very 
fine’, then click on the direction arrows to adjust the registration scale (Figure 4, red 







Figure 1. Different colour options in the Blend. 
 
Figure 2. Intensity adjustment and registration in the 3D-Voxel registration 





Figure 3. Save transformed image. 
 
 






Appendix (C) WMH artifacts training guide 
(http://www.sbirc.ed.ac.uk/research/imageanalysis.html) 



















(4) Dirty white matters 
 
 



















Appendix (D) Chapter 5 non-parametric results 
adjusted for head size. 
Table D1. Results from non-parametric tests (Wilcoxon Signed Rank Test) for 
differences in white matter hyperintensities (WMH) according to 
inclusion/exclusion of lacunes or stroke lesions (SL), adjusted for inter-subject 
differences in head size using the intracranial volume (ICV). 
Total 46 patients: 
median (IQR) as a 
percentage of ICV (%) 
Baseline Follow-up Difference (change from 
Baseline to Follow-up) 
WMH excluding 



















































13 patients with only 
WMH: 
median (IQR) as a 
percentage of ICV (%) 
Baseline Follow-up Difference (change from 
Baseline to Follow-up) 






26 patients with WMH 
and SL: 
median (IQR) as a 
percentage of ICV (%) 
Baseline Follow-up Difference (change from 
Baseline to Follow-up) 




















7 patients with lacunes: 
median (IQR) as a 
percentage of ICV (%) 
Baseline Follow-up Difference (change from 
Baseline to Follow-up) 























































33 patients with index 
stroke: 
median (IQR) as a 
percentage of ICV (%) 
Baseline Follow-up Difference(change from 
Baseline to Follow-up) 

























































Appendix (E) Detailed perivascular space (PVS) 
segmentation steps and manuals 
E1-Detailed eight PVS segmentation steps in Figure 6.1 
Step 1-Choice of standard slices in the basal ganglia (BG) and centrum 
semiovale (CS) 
Based on the PVS visual rating scale user guide, all the slices through the BG and CS 
regions would be reviewed. In the BG region, one slice which shows the highest 
number or area of PVS, and also contains at least one characteristic structure in the 
BG as shown in Figure E1 was selected to be the standard slice in the BG region. In 
the CS region, one slice between the slice containing the vertex and the slice 
containing the lateral ventricles was chosen as standard slice (Figure E2). 
 
Figure E1 Typical anatomical structures in the basal ganglia region. C: Caudate nucleus ; IC: 
Internal Capsule; T: Thalamus; L: Lentiform nucleus; E: External Capsule; I: Insular cortex 





 (a)   (b) 
Figure E2 An illustration of the structures which helps choice of the standard slice in the CS. 
(a) Slice containing the vertex; (b) Slice containing the lateral ventricles (Figure adopted from 
the Potter et al. PVS visual rating scale and user guide 
http://www.bric.ed.ac.uk/documents/epvs-rating-scale-user-guide.pdf). 
 
Step 2-Multiple thresholds: in the BG and CS regions. 
In order to reduce the intensity influence of the non-brain tissue on the T2-weighted 
(T2W) image, the T2W was combined with the intracranial (ICV) mask, which 
removed the extracranial tissues (Figure E3). Both the T2W image and the ICV mask 
were loaded into AnalyzeTM software Workspace, and were combined using a 





Figure E3 Combination of T2W image and ICV mask reduced the influence of extracranial 
tissues on the T2W image (in the BG region). 
The combined image was then used as input image to segment the PVS by the 
‘Object Counter’ function. In the ‘Object Counter’ module, we set the ‘Max. Size’ to 
‘12’ and ‘Min. Size’ to ‘2’ (the maximum/minimum area size of each object). The 
minimum was set to 2 voxels instead of 1 to avoid image background noise. By 
definition, the PVS diameter is less than 3 mm (Kwee and Kwee, 2007), so the area 
of one PVS dot is less than 9 mm2. The image information (Figure E4, parameters 
related to voxel size were highlighted by the yellow rectangle) showed that both the 
height and width of one voxel are 1mm, thus the 2-D area of 9 voxels are equal to 9 
mm2.  And we increased 3 voxels in the maximum size setting to include linear 





Figure E4 Image information from the combined image of T2W image and ICV mask. 
The setting of threshold (t) began when the PVS dots appeared on the binary image. 
Then the threshold was increased in 3% increments until there were no obvious PVS 
dots appearing in the binary image. The segmented volumes from individual 
thresholds were saved in the AnalyzeTM software workspace, and all of these 
segmented volumes were combined as the final PVS mask. This was then used to 






Figure E5 PVS mask generated from multiple thresholds (highlighted in yellow) in the BG 
and CS regions. 
Both observers performed the above segmentation steps twice. For both times, Ob1 
used the same slice. Ob2 performed one set of measurements blinded to the slice 
number used by Ob1, and for the second set of measurements Ob2 used the same 
slice as Ob1. The results were documented as: first measurement from Ob1 (Ob1_1); 
second measurement from Ob1 (Ob1_2); first measurement from Ob2 when blinded 
to the slice number (Ob2_1); and second measurement from Ob2 unblinded to the 




Step 3-Multiple thresholds: specifically in the BG ovoid regions.  
In this step, we aimed to increase the measurement consistency. The results from the 
previous step suggested that restricting the measurements within the two ovoid 
regions in the BG might give higher consistency and lower observer variability than 
other parts of the BG and CS regions. Thus, in this step, we set the regions of interest 
(ROI) specifically to the two ovoid regions in the BG instead of the whole brain 
(ICV). 
We consistently used the anatomical structures: vertical ramus of the lateral fissure 
and posterior segment of lateral fissure to set the boundaries for the mask of ovoid 
regions in the BG (BG ROI). The BG ROI mask was generated for each case (Figure 
E6). The PVS segmentation steps were the same as described in Step 2 except 
changing the ICV mask into BG ROI mask.  
 
Figure E6 Anatomical boundaries for the mask of ovoid regions in the BG (BG ROI) and the 





Step 4. Generation of the T2W intensity adjusted image. 
The different amount of threshold applied was considered to be related to the image 
intensity. In this step, we adjusted the intensity of images adjustment used was 
based on the theory of ‘histogram equalization’ (Seul et al., 2000). It involved 
mapping the values of the input intensity image to new values when 1% of the 
highest intensities and 1% of the lowest intensities were saturated. The intensity 
adjustment changed the areas of lower local contrast to a higher contrast and 
allowed the most frequent intensity values to spread out effectively (Figure E7).  
  





Step 5-Applying one threshold to the BG ROI of intensity adjusted T2W 
image.  
In this step, we aimed to apply a single threshold on the intensity adjusted images 
for the PVS segmentation. We then tested whether using the same threshold for all 
cases would be effective in picking up most of the PVS dots in BG ROI using the 
T2W intensity adjusted image. 
For the first aim, for each case, we applied three thresholds separately to the 
intensity adjusted T2W image combined with BG ROI mask. These three thresholds 
should include the most of the PVS dots, and we recorded the PVS volume and 
count for each threshold (Figure E8).  
 
Figure E8 PVS masks generated from three different thresholds. 
To solve the question of using the same threshold for all cases, an experienced 
neuroradiologist picked one PVS mask which included the most cavitied PVS and 
did not include artifacts from the three PVS masks generated from the previous 
step. This process was done when the neuroradiologist was blinded to the patients’ 
information, the threshold values and the PVS results.  We used the threshold 
values refer to the best fitting PVS masks been picked and calculated the average of 
these thresholds. We also tested the efficiency of this averaged threshold in 




Step 6-Applying the lacune mask to the BG ROI of the intensity adjusted 
T2W image. 
Because the intensity of PVS is similar to the lacunes on MR images, and because 
there is an overlapping in size between PVS and lacunes (3-5mm) (Hernandez et al., 
2013), we wanted to know whether the appearance of the lacunes would influence 
the PVS segmentation and whether applying the lacune mask before the PVS 
segmentation would improve the segmentation efficiency. Within the 16 cases, four 
of them had lacunes. We manually generated the lacune mask on the FLAIR image  , 
based on a region-growing algorithm in Analyze 10.0 software (Robb and Hanson, 
1995). Then we applied the lacune masks to the BG ROI in the intensity adjusted 
T2W images (Figure E9). 
 






Step 7. Applying one threshold to the BG ROI of a combined image of 
intensity adjusted T1-weighted (T1W) and intensity adjusted T2W.   
Previous optimization results in the Step 5 and 6 showed that the use of an intensity 
adjusted T2W image itself failed to find a common threshold for all cases. Applying 
a lacune mask was not successful either. Therefore, combining intensity adjusted 
T2W images with other MRI sequences was considered for further optimization.  
T2W images were found to be the best images to identify PVS (Kwee and Kwee, 
2007). T1-weighted images (T1W) had also been used in PVS visualization 
(Groeschel et al., 2006; Zhu et al., 2010). PVS were visualized as hyperintense 
regions on T2W image and as hypointense regions on T1W. Their combination use 
was applied to detect PVS visually in several computational methods (Sachdev et 
al., 1999; Uchiyama et al., 2008; Wuerfel et al., 2008). Thus in this step, three cases 
with severe and confluent lesions were selected for testing the efficiency of T2W 
intensity adjusted image and T1W intensity adjusted image. 
In this step we wanted to know whether applying one threshold to the BG ROI of 
the combined image (T2W and T1W images after intensity adjustment) could be 
successful in identifying the PVS. The combination of images was achieved by the 
dot product function in the ‘Image Calculator’ in the AnalyzeTM software (same 
operations as described in the Step 2).  
Step 8. Applying one threshold to the BG ROI of the combined image of 
two intensity adjusted T2W images.  
In this step we used the same set cases and combination method described in 
Step 7 to test the PVS segmentation efficiency of applying one threshold to 






E2-Manual of multiple thresholds using Object Counter in 
AnalyzeTM 10.0 software (Step 2) 
(1) Loading files 
(1.1) Open AnalyzeTM 10.0 by double clicking in the icon. The main window will 
appear. 
 
(1.2) Select File | Load  
 
(1.3) Load the T2-weighted image (T2W) and intracranial volume (ICV) mask in 
Analyze format in the explorer’s Load window that appear in the screen. The image 





(2) Multiple ICV mask by T2W image 
(2.1) Choose ICV mask, then select Process| Image Calculator 
 






(2.3) Press , choose “Change a Copy of the Loaded Volume”. 
 
The combined image would appear in both Image Calculator Workspace and the 






(2.4) Close Image Calculator; choose the combined image in the Analyze 
Workspace, select File| Save As, named as LBC36xxxx_ICVT2, in 
AnalyzeImage(7.5) format. 
 
(3) Settings and Segmenting for PVS by Object Counter 
Take the segmenting of PVS in the Basal Ganglia as an example, the segmenting of 
PVS in the Centrum Semiovale follows the same procedure.  
(3.1)  Load LBC36xxxx_ICVT2 image, then select Measure | Object Counter. 
 
(3.2) Basic setting. 
The image would appear in the “Connect” tab (2D; Neighbors: 8) as default. Click 




Basal Ganglia in “Standard slices Choosing” step (in this case, slice 48). Set Max. 
Size 12 and Min. Size as 2. 
 
The Max. Size means the number of voxels, which depends on the voxel sizes, in the 
LBC study, the voxel sizes are , the height  is 1 mm, and the 
width is 1 mm. The area of one voxel in this 2D image is 1mm2.The maximum area 
of an PVS dot should be 9 mm2 (less than 3 mm maximum diameter); however, it 
was set to 12 to include linear structured PVS. 
For all the cases, the Min. Size was set to 2 to avoid the noise from the background 




(3.3) Threshold setting and segmenting. 
When the threshold is low, it is useful to include the PVS which are not so hyper 
intensive; but it cannot distinguish the hyperintensive PVS from CSF in the 
ventricles and white matter hyperintensities (WMH). When the threshold is high, all 
the objects are more separated, it is useful to include the hyper intensive PVS, but 
may fail to include the non-hyperintensive PVS.  
o Always start from 600 (intensity displayed in the Analyze software): if for 
some cases, when set the threshold t=600, there is no obvious PVS dots, but 
all merged backgrounds, then try to start from higher threshold, e.g. 700 or 
800. 
o Then add 100 more to the previous threshold until there is no obvious PVS 
appear in the binary image. Save all the Segmented Volume in the Analyze 
Workspace.   
o Use the same set of intervals of a hundred thresholds for all the cases (range 
from 600 to 1500) to include all potential PVS in the images. 





Then press the “Limit” tab, set the Z Min and Z Max into the same Basal Ganglia 





Then select File | Save Segmented Volume, named “t600” (t means threshold and 





In this case, there is no obvious PVS appear in the binary image when 
threshold=1000. Save all the Segmented Volume in the Analyze Workspace.   
 
(4) Create PVS mask 
(4.1) Combine all these segmented volumes in the Image Calculator. 
Select Process | Image Calculator, press  to combine all the segmented volumes 





(4.2)  Close Image Calculator and choose the combined image in the Analyze 
Workspace, select File| Save As, named as LBC36xxxx_BG, in OBJMAP format. 




(4.3)  Combine all the objects into the same object in the Region Of Interest. 
Click on the LBC36xxxx_ICVT2 image in Analyze Workspace, and then select 
Measure | Region Of Interest (ROI).  





Open the View | Objects window. Once you're in the Objects window, select the 
"Reassign Object(s)" button. The Reassign Object(s) window will be returned and 
you can select all the objects except Object 1 (because Object 1 is the default object 
for background) and reassign them to a single object (always select Object_2, you 
could also reassign them to any other objects, the only difference would be the 






Then in the objects window, change the Name (PVS) and Color (red) of the object. If 
you have already choose Object_2 in the "Reassign Object(s)" step, then do not need 





(4.4)  Use  to remove false positive near surface of the brain, ventricles, sulci 
and WMH. Go through the slices before and after the slice we chose, and use 






(4.5)  Before close the Region of Interests module, save the object map, named as 
LBC36xxxx_BG. This object map also needs to be saved in the AnalyzeImage(7.5) 
format for further use.  
In order to save this object map in AnalyzeImage(7.5) format, open View | Objects 
window, select the object as PVS, then click "Save Binary" button, named as 






The saved binary object image would appear in the main Analyze Workspace and 
highlighted in the Analyze window. Then select File| Save As, named as 






(5) Calculate the Counts and Areas of PVS 
(5.1) Calculate the Counts and Areas in Object Counter. 
Load the T2W image in Analyze Working space, and then open the Object Counter, 
then select File | Load Volume, load LBC36xxxx_BG which is in AnalyzeImage(7.5) 
format. 
Then choose slice of BG, change the Min.Size as 2, click Apply. 
 






(5.3) A window with the final report (summarised and/or detailed). From the 
summarised report, you could get the average area of the PVS and total number; 
from the detailed report, you could get the area of each individual PVS. Right-click 
when the mouse is over this window to save the report. Write down the results 








E3-Manual of intensity adjustment (Step 4) 
 
(1) Convert the T2-weighted images from nifti format to Analyze 7.5 
format using Analyze software. 
(1.1) Open Analyze 10.0 by double clicking in the icon. The main window will 
appear. 
(1.2) Select File | Load  
(1.3) Load the original T2-weighted image in nifti format to the explorer’s Load 
window that appear in the screen. The image volume selected will appear loaded 
and highlighted in the Analyze window. 
 
 





2. In the MATLAB, call the intensity adjustment function. 
(2.1) Open the ‘V:\EPVS_segmentation folder’, double click the 
‘intensity_adjustment_EPVS. MATLAB M-file’. 
 






In the command window would appear an error 
 










Appendix (F) Observer agreement in the PVS method 
development and validation 
Two observers measured PVS twice in Step 2, 3 and 5 (refer to Figure 6.1 in Chapter 
6 and Appendix E) on two separate occasions. Observer 1 used the same standard 
slices both times. Observer 2 was blinded to the standard slice number chosen by 
me for the first measurement, and was unblinded for the second measurement. We 
calculated the mean and standard deviation (SD) of the intra- and inter-observer 
variability of PVS volume and count summarized them in the Table F1 and F2.  
Table F1 Summary of intra- and inter-observer variability for PVS volume (voxels) 
measurements from different steps.  
Location Image Variability Type Mean SD 
Step 2- Multiple thresholds in the CS region 
CS T2W Intra (Ob1) 307.81 146.37 
  Intra (Ob2) 336.59 99.19 
  Inter (b) 31.50 82.30 
   29.00 84.83 
  Inter(u) 28.56 84.33 
   26.06 90.89 
Step 2- Multiple thresholds in the BG region 
BG T2W Intra (Ob1) 321.66 136.47 
  Intra (Ob2) 249.22 53.90 
  Inter (b) -74.69 114.04 
   -83.63 124.03 
  Inter(u) -61.25 103.82 
   -70.19 113.13 
Step 3- Multiple thresholds specifically in the BG ovoid region (BG ROI) 
BG ovoid region T2W Intra (Ob1) 232.31 75.90 
  Intra (Ob2) 226.75 53.57 
  Inter (b) -7.56 60.96 
   -12.19 60.74 
  Inter(u) 1.06 53.13 
   -3.56 47.84 
Step 5- Applying one threshold to the BG ROI of intensity adjusted T2W 
BG ovoid region T2W-ia Intra (Ob1) 321.66 136.47 
  Intra (Ob2) 249.22 53.90 
  Inter (b) -74.69 114.04 
   -83.63 124.03 
  Inter(u) -61.25 103.82 
   -70.19 113.13 
SD: standard deviation; T2W: T2-weighted; ia: image after intensity adjustment; BG: basal ganglia; 






Table F2 Summary of intra- and inter-observer variability for PVS count (number of dots) 
measurements from different steps.  
Location Image Variability Type Mean SD 
Step 2- Multiple thresholds in the CS region 
CS T2W Intra (Ob1) 73.66 32.92 
  Intra (Ob2) 79.19 20.17 
  Inter (b) 6.12 27.66 
   4.81 23.40 
  Inter(u) 6.25 25.14 
   4.94 21.02 
Step 2- Multiple thresholds in the BG region 
BG T2W Intra (Ob1) 72.50 28.65 
  Intra (Ob2) 56.69 10.55 
  Inter (b) -15.88 24.47 
   -18.12 25.89 
  Inter(u) -13.5 24.58 
   -15.75 25.26 
Step 3- Multiple thresholds specifically in the BG ovoid region (BG ROI) 
BG ovoid region T2W Intra (Ob1) 49.88 15.88 
  Intra (Ob2) 51.06 10.27 
  Inter (b) 1.12 13.12 
   -0.50 13.36 
  Inter(u) 2.87 12.55 
   1.25 12.15 
Step 5- Applying one threshold to the BG ROI of intensity adjusted T2W 
BG ovoid region T2W-ia Intra (Ob1) 18.97 5.67 
  Intra (Ob2) 19.37 4.95 
  Inter (b) 0.12 6.45 
   0.31 7.14 
  Inter(u) 0.50 4.87 
   0.69 6.94 
SD: standard deviation; T2W: T2-weighted; ia: image after intensity adjustment; BG: basal ganglia; 






Bland-Altman plots (Bland and Altman, 1986) were used to estimate the agreement 
within or between observers in Step 2, 3 and 5. Step 2 used multiple thresholds in 
the both the basal ganglia (BG) and centrum semiovale (CS) regions to assess PVS 
on the original T2-weighted (T2W) images. Step 3 used multiple thresholds in the 
restricted two ovoid BG regions to assess PVS on the original T2W images. Step 5 
used one threshold in the restricted two ovoid BG regions to assess PVS on the 
intensity adjusted T2W images.   The results were documented as: first 
measurement from Ob1 (Ob1_1); second measurement from Ob1 (Ob1_2); first 
measurement from Ob2 when blinded to the slice number (Ob2_1); and second 
measurement from Ob2 unblinded to the slice number used by Ob1 (Ob2_2).  
1. Observer variability in Step 2 
Both observers had high intra-observer variability on the PVS volume and count 
measurements in the BG and CS regions (Figure F1). For PVS volume intra-observer 
variability, most dots were located between -40 and 40 voxels (voxel: the unit of 
volume measurement). For the PVS count intra-observer variability, most dots 
located between -10 and 10 (number of dots).  Ob2 tended to measure less than Ob1 
in the BG regions, and more in the CS regions for PVS volume and Count 
measurements. The results from both observers showed that both volume and count 
obtained in the CS regions had larger SD than in the BG regions (Table F1, F2).
 
Figure F1 Intra-observer variability in PVS measurements (Step 2). Left: intra-observer 





PVS volume and count measurements in both regions showed high inter-observer 
variability (Figure F2, Table F1, F2). The discrepancy of the inter-observer difference 
in PVS volume and number in the CS regions was more scattered than the 
discrepancy in the BG regions. The situation was the same as observed in the intra-
observer variability: there was a systematic bias between observers in differentiating 
PVS in both the BG and CS regions, and Ob2 tended to measure less than Ob1 in the 
BG regions, and measure more in the CS regions (Table F1, F2).  
 
Figure F2 Inter-observer variability in PVS measurements (Step 2). Upper left: inter-observer 
variability of PVS volume when Ob2 was blinded to the standard slice number chosen by 
Ob1. Lower left: inter-observer variability of PVS volume when Ob2 was unblinded to the 
standard slice number chosen by Ob1. Upper right: inter-observer variability of PVS count 
when Ob2 was blinded to the standard slice number chosen by Ob1. Lower right: inter-
observer variability of PVS count when Ob2 was unblinded to the standard slice number 
chosen by Ob1. 
The intra- and inter-observer variability figure (Figure 6.3 in chapter 6) 
demonstrated that though this method was not effective in picking up the linear-




of the BG. In order to diminish the observer variability and increase the consistency, 
the regions of interest (ROI) were suggested to set specifically to the two BG ovoid 
regions in later method optimization. 
2. Observer variability in Step 3 
After restricting the ROI specifically to the two BG ovoid regions, both observers 
obtained smaller SD and smaller ranges of discrepancy on the measurements of PVS 
volume and count when compared with measuring the whole BG slice (Figure F3, 
Table F1, F2). For the PVS volume measurement, after setting the ROI into the two 
specific ovoid BG regions, the number of cases which had larger differences (>40 
voxels or <-40 voxels) was reduced from four to one for Ob1 but stayed the same for 
Ob2 (five cases). For the PVS count measurement, the number of cases (>10 or <-10) 
was reduced from five to zero for Ob1 and reduced from three to two for Ob2. The 
restricted BG ROI helped increase the intra-observer consistency. The discrepancy of 
measurements from Ob2 was more scattered than Ob1 and might be caused by a 
learning effect, as Ob1 was more experienced in the PVS measurements than Ob2.  
 
Figure F3 Intra-observer variability of PVS volume and count measurements showing the 
efficiency of setting ROI into the BG ovoid regions (orange) when compared with the results 
from Step 2 (pink). 
The variability between the two observers was reduced by restricting the 
measurements to BG ROI, as shown in the aspects of SD and discrepancy of dots 
(Figure F4 and Table F1, F2). The systematic bias still existed between the two 




PVS was small in terms of volume or count, but measured less when the volume 
was bigger.  
 
Figure F4 Intra-observer variability of PVS volume and count measurements showing the 
efficiency of setting ROI into the BG ovoid regions (yellow) when compared with the results 
from Step 2 (blue). Upper left: inter-observer variability of PVS volume when Ob2 was 
blinded to the standard slice number chosen by Ob1. Lower left: inter-observer variability of 
PVS volume when Ob2 was unblinded to the standard slice number chosen by Ob1. Upper 
right: inter-observer variability of PVS count when Ob2 was blinded to the standard slice 
number chosen by Ob1. Lower right: inter-observer variability of PVS count when Ob2 was 
unblinded to the standard slice number chosen by Ob1. 
The intra- and inter-observer variability decreased after we restricted ROI, and there 





Figure F5 Location of intra- and inter-observer variability in two ovoid regions in the BG 
regions.  
3. Observer variability in Step 5 
Both observers obtained much smaller PVS volume and count after applying a 
single threshold to intensity-adjusted T2W images when compared to applying 
multiple thresholds to the original T2W images in step 2, and the SD was also 
smaller (Table F1, F2). The discrepancies of PVS were fan-shaped, suggesting there 
was no systematic bias in this method, and also suggesting that step 5 was less 






Figure F6 Intra-observer variability comparison of PVS volume and count measurements 
(step 2: pink; step 3: orange; step 5: yellow).  
The inter-observer variability of PVS volume and count was much smaller after 
applying a single threshold to intensity-adjusted images in step 5 than applying 
multiple thresholds to the original images in step 2 (Table F1, F2). There was no 
systematic bias shown by the two fan-shaped discrepancies on the Bland-Altman 
plots (Figure F7, orange dots).  
  
 
Figure F7 Inter-observer variability comparison of PVS volume and count measurements 




When restricting ROI to BG ovoid regions, applying one threshold to the intensity-
adjusted images (Figure F8) increased the observer variability when compared to 
using multiple thresholds to the original images (Figure F5). The accuracy and 
consistency of measurements was sacrificed by reducing the amount of thresholds. 
The intra- and inter-observer variability and location of variability suggested that 
the intensity-adjusted images alone were not enough to reduce the number of 
thresholds as well as keep the observer consistency. Applying lesion masks and 
combination with other MR images was considered for further investigation. 
 
Figure F8 Location of intra- and inter-observer variability in two BG ovoid regions after 






Appendix (G) Results from unsuccessful steps in the 
PVS method development and optimization 
Step 5-Single threshold in intensity adjusted image 
In order to find a best fitting threshold on the intensity adjusted T2W image within 
BG ROI, for each case, we applied three thresholds. These thresholds ranged from 
25% to 54% of maximum intensity value. Then the experienced neuroradiologist 
chose the best-fitting threshold according to visual comparisons.  According to the 
best-fitting threshold applied and the image characters, we categorized these 16 
testing cases into four subgroups into four groups and with an overlapping of the 
groups (Figure G1): 
(a) For nine cases, applying one threshold picked up most of the appearing PVS. 
Within those cases, a threshold of t=25% was suitable for three cases, t=27.5% was 
suitable for two cases, t=29.5% was suitable for three cases, and t=33% was suitable 
for one case. 
(b) For six cases (threshold range 35.5% to 53%), applying only one threshold missed 
a large number of PVS when compared with reference, an intensity adjusted T2W 
image. The missing PVS may be due to the high background signal of the image, 
which made it difficult for the program to distinguish the PVS from other patchy 
lesions such as WMH. In addition, PVS that were close to each other were 
considered as a big ‘whole lesion’ and excluded by the program because it exceeded 
the maximum size limit (maximum=12). 
(c) Applying only one threshold was not successful in picking up PVS in three cases 
which had high background signal. 
(d) Applying only one threshold was not successful in picking up PVS in two cases 





Figure G1 Four groups of cases applying one threshold within in BG ROI in the intensity-
adjusted T2W images. (a) Using one threshold was effective in picking up most of the PVS; 
(b) Using one threshold missed a large amount of PVS; (c) Image with high background 
signal; (d) Poor MR scan quality image. 
Because the range of best fitting threshold varied a lot, for example in group (a) the 
threshold range was from 25% to 33% and in group (b) it was from 35.5% to 53%, it 
was take the averaged threshold and applied it for all 16 cases. We selected group 
(a) to test whether applying the threshold was effective in picking up most of the 
PVS in the BG ROI in the intensity adjusted T2W images. We applied the averaged 
threshold in group (a), 29% of the maximum intensity, to all 9 cases in group (a). 
However, it was not effective and suitable to pick up PVS dots in all 9 cases.  
The results suggested applying a single threshold on the intensity adjusted T2W 
image alone was not enough to find a gold standard threshold or threshold range 
suitable for all cases. We needed to test the effect of lesion masks and combination 




Step 6- Applying lacune masks 
Within the 4 cases had lacunes, there was little overlapping on the location or size 
between lacunar lesions and PVS (Figure G2). Lacune removement did not help 
improve PVS segmentation. It might possibly be useful for the cases having more 
overlapping of the location and size between lacunar lesions and PVS.  
 
Figure G2 PVS and lacune masks on the four cases had lacunes. PVS mask: yellow; lacune 
mask: blue. 
Step 7-Combination of T2W intensity adjusted image and T1W intensity 
adjusted image 
We tested the effect of combined T2W intensity adjusted image and T1W intensity 
adjusted image in identifying the PVS computationally. The results showed, 
compared with T2W image after intensity adjustment, the combined image in the 
non-colour and colour blend conditions blurred the edges of the PVS lesions, and 
was not suitable to test the effect of reducing thresholds in the PVS segmentation 






       (1)                  (2)                  (3)                   (4)                    (5)                 (6) 
Figure G3 T2W intensity adjusted image and its combinations with T1W intensity adjusted 
image in non-colour blend or colour blend conditions. (1) T2W intensity adjusted image; (2) 
T2W intensity adjusted image combined with T1W intensity adjusted image (non-color 





Appendix (H) PVS associations  
Table H1 Associations between BG PVS count and SVD features visual rating scales (WMH, 
atrophy and CS PVS) for baseline and follow-ups. 
Associations Coefficient of linear regression 95% CI CV 
Baseline 100 patients    
PWMH Left 2.175 1.176 to 3.174 38.197 
PWMH Right 2.128 1.123 to 3.133 38.366 
DWMH Left 1.997 1.093 to 2.900 38.103 
DWMH Right 1.894 0.973 to 2.816 38.535 
Deep Atrophy 1.614 0.732 to 2.495 39.127 
Superficial Atrophy 1.774 0.701 to 2.846 39.559 
CS Left 0.688 -0.254 to 1.629 41.239 
CS Right 0.677 -0.279 to 1.633 41.268 
Baseline 46 patients    
PWMH Left 1.642 -0.062 to 3.347 40.793 
PWMH Right 1.642 -0.062 to 3.347 40.793 
DWMH Left 2.626 1.014 to 4.238 38.097 
DWMH Right 2.626 1.014 to 4.238 38.097 
Deep Atrophy 2.111 0.315 to 3.908 40.029 
Superficial Atrophy 1.241 -0.604 to 3.086 41.648 
CS Left -0.355 -2.002 to 1.292 42.412 
CS Right -0.355 -2.002 to 1.292 42.412 
Follow-up 46 patients    
PWMH Left 0.847 -0.700 to 2.394 28.110 
PWMH Right 0.841 -0.661 to 2.342 28.097 
DWMH Left 1.208 -0.063 to 2.479 27.382 
DWMH Right 0.936 -0.386 to 2.258 27.859 
Deep Atrophy 0.927 -0.322 to 2.176 27.797 
Superficial Atrophy 1.025 -0.462 to 2.512 27.893 
CS Left 0.533 -0.893 to 1.958 28.315 
CS Right 0.416 -1.027 to 1.860 28.389 
CI: confident interval; CV: coefficient of variances; PWMH: periventricular white matter 







Table H2 Associations between BG PVS volume and SVD features visual rating scales 
(WMH, atrophy and CS PVS) for baseline and follow-ups. 
Associations Coefficient of linear regression 95% CI CV 
Baseline 100 patients    
PWMH Left 0.027 0.015 to 0.039 48.904 
PWMH Right 0.027 0.014 to 0.039 48.973 
DWMH Left 0.021 0.009 to 0.032 50.234 
DWMH Right 0.019 0.007 to 0.030 50.815 
Deep Atrophy 0.016 0.005 to 0.027 51.367 
Superficial Atrophy 0.013 0.000 to 0.027 52.450 
CS Left 0.010 -0.002 to 0.021 52.677 
CS Right 0.010 -0.001 to 0.022 52.618 
Baseline 46 patients    
PWMH Left 0.014 -0.001 to 0.029 43.158 
PWMH Right 0.014 -0.001 to 0.029 43.158 
DWMH Left 0.020 0.005 to 0.035 41.592 
DWMH Right 0.020 0.005 to 0.035 41.592 
Deep Atrophy 0.018 0.002 to 0.034 42.516 
Superficial Atrophy 0.008 -0.008 to 0.025 44.278 
CS Left -0.006 -0.020 to 0.009 44.507 
CS Right -0.006 -0.020 to 0.009 44.507 
Follow-up 46 patients    
PWMH Left 0.017 0.001 to 0.034 35.172 
PWMH Right 0.017 0.001 to 0.033 35.059 
DWMH Left 0.015 0.001 to 0.026 35.091 
DWMH Right 0.014 0.000 to 0.028 35.318 
Deep Atrophy 0.009 -0.005 to 0.023 36.231 
Superficial Atrophy 0.012 -0.004 to 0.028 36.061 
CS Left 0.008 -0.008 to 0.023 36.489 
CS Right 0.008 -0.008 to 0.023 36.538 
CI: confident interval; CV: coefficient of variances; PWMH: periventricular white matter 







Figure H1 Associations between BG PVS count and PWMH visual rating scores (overall, left 





Figure H2 Associations between BG PVS count and DWMH visual rating scores (overall, left 
and right hemispheres) at baseline and follow-ups. 
 
 







Figure H4 Associations between BG PVS volume and PWMH visual rating scores (overall, 





Figure H5 Associations between BG PVS volume and DWMH visual rating scores (overall, 
left and right hemispheres) at baseline and follow-ups. 
 
 






Figure H7 Associations between BG PVS count and atrophy visual rating scores (deep, 
superficial and whole) at baseline and follow-ups. 
 
Figure H8 Associations between BG PVS count and brain tissue volume expressed as a 





Figure H9 Associations between BG PVS volume and atrophy visual rating scores (deep, 
superficial and whole) at baseline and follow-ups. 
 
Figure H10 Associations between BG PVS volume and brain tissue volume expressed as a 





Figure H11 Associations between BG PVS count and CS PVS visual rating scores (overall, 





Figure H12 Associations between BG PVS count and CS PVS visual rating scores (overall, 
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